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Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease in man and is complicated by dementia in up to 83% of people with PD. 
The risk of dementia is increased in people with PD who lose weight. Stable 
body weight relies on maintaining a balance of energy intake and energy output; 
a process coordinated by a number of circulating hormones of energy 
homeostasis. There is evidence that some of these; ghrelin, insulin and leptin 
may have pro-cognitive and neuroprotective effects in animal models of PD. 
Ghrelin secretion may be disordered in PD as levels are lower than in healthy 
controls. It is not known whether hormones of energy homeostasis are 
disrupted in people with PD and cognitive impairment (PD-CI). We conducted a 
cross-sectional quasi-experimental pilot study of 16 people with PD-CI,19 
people with PD and normal cognition and 20 healthy controls. Fasting and post-
prandial acyl-ghrelin, total ghrelin, growth hormone, insulin-like growth factor-1, 
insulin and leptin levels were measured. Fasting values and area under the 
curve for each value was analysed using ANOVA and post-hoc testing using the 
least-significant difference test. Post-hoc testing demonstrated lower acyl-
ghrelin in the PD-CI group (p=0.02). Moreover, there was a correlation between 
acyl-ghrelin and cognition across the cohort (p=0.01) and acyl ghrelin 
significantly predicted cognition in multiple linear regression, accounting for 15% 
of the variance. Insulin and leptin were not different between groups and did not 
predict cognition. Hunger and fullness were measured using visual analogue 
scales. Energy intake at lunch was also recorded. Groups were compared using 
ANOVA. There were no significant differences in hunger, fullness or energy 
intake between groups. The data show reduced acyl-ghrelin in PD-CI. Acyl-
ghrelin is a potential biomarker for cognitive decline in PD and further 
longitudinal studies should be carried out to further investigate this. 
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Chapter 1. Brief background, aims and outline 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder after Alzheimer’s disease (Hirsch and Hunot, 2009). PD is associated 
with a nearly 6 fold increased risk of dementia compared with healthy ageing 
(Aarsland et al., 2001). Identifying people with PD who are at greater risk of 
developing dementia may enable treatment in the pre-clinical phase when 
disease modifying medications become available. Weight loss is common in PD 
due to altered energy balance and has been linked with increased risk of 
dementia. Weight loss and dementia in PD may be linked by dysregulation of 
pleiotropic hormones of energy homeostasis such as ghrelin, insulin-like growth 
factor (IGF-1), insulin and leptin which have also been implicated in learning 
and memory and may be neuroprotective. This thesis aims to explore the 
relationship between appetite, dysregulation of hormones involved in body 
weight regulation and cognitive impairment in PD and to determine if hormones 
of energy homeostasis merit further investigation as potential biomarkers of 
cognitive decline in PD. This will be achieved through the following objectives; 
To explore whether perceived and objective measures of appetite and food 
intake differ between patients with PD, PD-CI and controls. 
To explore whether fasting and post-prandial changes in ghrelin, insulin-like 
growth factor-1 (IGF-1), insulin, glucagon-like peptide 1 (GLP-1) and leptin 
concentrations differ between patients with PD, PD-CI and controls. 
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Chapter 2. Introduction and Literature Review 
2.1 Parkinson’s disease 
2.1.1 Clinical features of Parkinson’s disease 
Parkinson’s disease (PD) is a systemic neurodegenerative disorder 
characterised by bradykinesia, tremor, rigidity and postural instability (Hughes 
et al., 1992) . It was first described by James Parkinson in 1817 in his “Essay on 
the Shaking Palsy” (Parkinson, 1817) and 200 years later, a cure remains 
elusive. PD is the second most common neurodegenerative disorder in the UK 
after Alzheimer’s disease (AD) (Ben-Shlomo, 1997) and has an age-adjusted 
prevalence of  83.9-202.7/100,000 in the UK (Newman et al., 2009, Walker et 
al., 2010). PD is estimated to cost the UK economy £449 million to £3.3 billion 
each year (Findley, 2007). Although many treatments provide symptomatic 
relief, no disease modifying medications are available and the progression of 
PD is unrelenting (Evans et al., 2011, Hely et al., 2008). Dopamine replacement 
and augmentation are the mainstay of treatment for the motor symptoms of PD 
(National Institute for Health and Clinical Excellence, 2006). 
PD does not solely affect motor function but rather causes a constellation of 
other symptoms over a wide range of systems. These are termed non-motor 
symptoms (NMS) and include constipation, incontinence, orthostatic 
hypotension, cognitive impairment, apathy, hallucinations and frank dementia 
amongst others (Barone et al., 2009). Figure 1 outlines common NMS in PD.  
The PRIAMO study found that 98.6% of patients with Parkinson’s disease had 
NMS (Barone et al., 2009). Moreover, they can be as devastating as they are 
diverse, causing significant impact on patients’ and carers’ quality of life 
(Aarsland et al., 2009b, Martinez-Martin, 2011). Neuropsychiatric NMS such as 
dementia, apathy, depression and psychosis are especially burdensome, 
increasing caregiver stress, negatively impacting quality of life and increasing 
the likelihood of transfer to residential or nursing care (Aarsland et al., 2009b, 
Barone et al., 2009, Leroi et al., 2012, Schrag et al., 2000, Aarsland et al., 
2007). As with motor symptoms there are no curative treatments and therapy is 
therefore symptomatic.  
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Figure 1. Non-motor features of Parkinson’s disease (Todorova et al., 2014, 
Martinez-Martin, 2011, Chaudhuri et al., 2006, Chaudhuri and Schapira, 2009) 
2.1.2 Pathophysiology of Parkinson’s disease 
The biological basis of PD is a progressive loss of neurones throughout the 
brain, but particularly dopaminergic cells in the substantia nigra pars compacta 
(SNpc) of the midbrain. This cell death is associated with the presence of Lewy 
bodies; these are pathological inclusions in the neuronal cytoplasm made up of 
misfolded α-synuclein, ubiquitin and neurofilaments (Spillantini et al., 1997). 
Alpha-synuclein is usually soluble in cytosol but becomes insoluble when 
misfolded (Goedert, 2001).  It then precipitates out in the cell causing Lewy 
body formation and, ultimately, cell death (Moore et al., 2005). The underlying 
cause of synuclein misfolding is unknown and the cause of cell death is poorly 
understood. Mitochondrial dysfunction, leading to increased reactive oxygen 
species and apoptosis (programmed cell death) has been implicated (Figure 2). 
The cause of mitochondrial dysfunction is unclear and may be the cause rather 
than the effect of α-synuclein aggregation (Moore et al., 2005). Cell death may 
also result from a failure of usual cell maintenance by the ubiquitin proteasome 
system and autophagy lysozyme pathway. These processes prevent the 
accumulation of toxic proteins in order to preserve cell function (Pan et al., 
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2008). Finally, neuroinflammation has been implicated in the pathogenesis of 
PD, though again it is unclear whether this is a reaction to the degenerative 
process or the cause (Hirsch and Hunot, 2009). Recent research has 
demonstrated that higher pro-inflammatory markers are associated with disease 
progression and cognitive impairment in PD (Williams‐Gray et al., 2016)  
 
Figure 2. Simplified pathway for neuronal apoptosis. Damaged mitochondria 
release cytochrome C and initiate apoptotic cascade. Other pro-apoptotic 
proteins include bax protein. B-cell lymphoma protein 2 (Bcl-2) prevent this 
cascade and is therefore anti-apoptotic. A cell may be pushed towards apoptosis 
or survival by the ratio of pro- and anti-apoptotic factors within it (Underwood 
and Cross, 2009, Brunet et al., 2001). 
If the mechanism by which cells are damaged is unclear, so is the underlying 
trigger for the disease. Some theories implicate toxin exposure, for example 
with pesticides, other unknown environmental agents (Hubble et al., 1993, 
Koller et al., 1990), or prion-like disease process with so-called “permissive 
templating” (Olanow and Prusiner, 2009, de Lau and Breteler, 2006). Braak and 
colleagues postulate that an unknown environmental agent enters the body 
through the gut or respiratory tract and spreads to the brain via the enteric 
nervous system or olfactory bulb in a retrograde fashion. This is based on their 
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observation that Lewy bodies form sequentially in different areas of the brain. 
They describe Lewy bodies appearing first in the dorsal motor nucleus of the 
vagus nerve (DMNV) and olfactory bulb then the brainstem and midbrain 
(including the SNpc) and eventually the cortex (Braak et al., 2003a, Braak et al., 
2003b). This cannot explain the pathological process in patients with the early 
widespread cortical Lewy bodies seen in patients with early cognitive 
impairment. Furthermore, pathological stage may not correlate with clinical 
features and progression from one stage to another is not inevitable (Burke et 
al., 2008). Despite this the Braak hypothesis does appear to apply to a 
subgroup of young PD patients (Halliday et al., 2008). This is important as it 
suggests that neuronal loss precedes the onset of motor features in at least 
some patients. It has been proposed that there are three stages of PD; pre-
clinical, pre-motor and motor (Todorova et al., 2014). Preclinical and premotor 
disease could represent opportunities for future disease modifying therapies to 
prevent PD. Prevention will only be possible if patients at risk can be identified, 
for example, using clinical or biochemical biomarkers. 
The pathophysiology of NMS is less well understood but may be due to 
dopaminergic and non-dopaminergic neuronal loss throughout the brain and 
body (Todorova et al., 2014). NMS may precede motor symptoms by up to 10 
years (Chaudhuri et al., 2006, Braak et al., 2003a, Braak et al., 2003b) and are 
very common. Their treatment can be difficult and evidence for efficacy of  
some treatments is lacking (Seppi et al., 2011). Dopaminergic medications used 
to treat motor symptoms may be ineffective for NMS and can actually 
exacerbate symptoms such as dementia, psychosis and orthostatic hypotension 
(Chaudhuri and Schapira, 2009, Chaudhuri et al., 2006). There is a great deal 
of ongoing research into effective treatments for NMS in PD, with some 
promising new medicines and new indications for old medicines on the horizon. 
Despite this, treatment remains symptomatic(Schrag et al., 2015). 
2.1.3 Cognitive impairment in Parkinson’s disease 
Up to 83% of people with PD who survive more than 20 years from diagnosis 
will develop Parkinson’s disease dementia (PDD) (Hely et al., 2008). Advanced 
age, mild cognitive impairment (MCI), non-tremor dominant phenotype, greater 
disease severity and weight loss all predispose to PDD (Emre, 2003, Aarsland 
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and Kurz, 2010, Kim et al., 2012, Burn et al., 2006, Selikhova et al., 2009, 
Williams-Gray et al., 2007). Clinically, PDD manifests as cognitive impairment 
within several domains; attention, executive function, visuo-constructive ability 
and memory (Emre et al., 2007, Docherty and Burn, 2010, Emre, 2003, 
Aarsland and Kurz, 2010). The Movement Disorder Society (MDS) Task Force 
diagnostic criteria state that PDD may be diagnosed in patients with a greater 
than 12 month history of parkinsonism if there is evidence of impairment in 
more than one of the above cognitive domains. The deficit must be severe 
enough to impact on activities of daily living and there should be no depression, 
delirium or other confounding factors (Dubois et al., 2007) (Table 1). PDD has 
been shown to adversely impact patients’ and carers’ quality of life (Aarsland et 
al., 2009b, Barone et al., 2009, Leroi et al., 2012, Schrag et al., 2000, Aarsland 
et al., 2007) and is associated with increased mortality and dependency (Hely et 
al., 2008, Hely et al., 2005). As with PD there are no disease modifying 
therapies for PDD. Treatment, for example with cholinesterase inhibitors, is 
therefore symptomatic (van Laar et al., 2011, Emre, 2004). 
Table 1.  Movement disorder society task force level 1 criteria for the diagnosis of 
Parkinson’s disease dementia (Dubois et al., 2007) 
MDS task force criteria for the diagnosis of PDD (Level 1) 
1. A diagnosis of PD based on Queen’s Square (UK) Brain Bank criteria for PD 
2. PD developed prior to the onset of dementia 
3. Mini mental state examination (MMSE) below 26/30 
4. Cognitive deficits severe enough to impact daily living 
5. Impairment in at least two of; 
a. Months reversed or seven backwards 
b. Lexical fluency or clock drawing 
c. MMSE pentagons 
d. 3 word recall 
 
PDD is biologically characterised by widespread Lewy body pathology and 
neuronal loss throughout the brain (Aarsland et al., 2005). It is felt to be a 
pathological continuum with dementia with Lewy bodies (DLB) but differs 
clinically from DLB in that the onset of cognitive impairment occurs more than 
one year after the motor deficit develops (McKeith et al., 1996). The pattern of 
neuronal loss in PDD varies according to the patient’s symptoms. Hippocampal 
atrophy is seen in people with PDD who have hallucinations and difficulties with 
verbal learning, for example, whereas those with impaired visual memory have 
more orbitofrontal neuronal loss (Kehagia et al., 2010). Degeneration of 
dopaminergic (ventral tegmental area), cholinergic (nucleus basalis of Meynert), 
    
 7 
noradrenergic (locus coeruleus) and serotonergic (dorsal raphe nucleus) 
pathways all occur to varying degrees and, again, may relate to phenotype 
(Kalaitzakis and Pearce, 2009). Alpha-synuclein is not the only important 
pathological protein in PDD. Beta-amyloid (Aβ) plaques in cortical and limbic 
areas have been shown to correlate with the presence of Lewy body formation. 
Beta-amyloid plaques are usually associated with AD (Lashley et al., 2008). 
This observation could be explained by increased fibrillisation of α-synuclein in 
the presence of Aβ (Masliah et al., 2001). In other words, Aβ plaque formation 
may accelerate neurodegeneration associated with Lewy body formation in 
PDD. This hypothesis is supported by the Sydney Multicentre Study finding that 
PDD patients had more Lewy bodies and amyloid plaques in the neocortex than 
non-demented PD patients with the same disease duration (Halliday et al., 
2008). Furthermore, studies by Compta et al. and Irwin et al have both 
demonstrated that a greater burden of Aβ at reduces the time from the 
development of motor symptoms to the emergence of dementia in PD (Compta 
et al., 2011, Irwin et al., 2017). 
Almost all of the available research regarding Aβ deposition has been carried 
out in humans with AD and in animal models of AD. The burden of Aβ in AD 
depends on the rates of Aβ synthesis and clearance from the brain 
parenchyma. Amyloid precursor protein (APP) is produced by all cells in the 
body and is cleaved by γ- and β- secretase to form Aβ species, some of which 
(such as Aβ1-42) are thought to be more toxic than others (Aβ1-40) (Hardy and 
Selkoe, 2002). Beta-amyloid clearance from the brain occurs in four main ways; 
through binding of Aβ to carrier proteins such as albumin and transthyretin, 
through degradation by proteases such as insulin degrading enzyme (IDE), 
endocytosis of Aβ resulting in breakdown by lysosomes (possibly involving 
APOE-4), and increased transport across the blood brain barrier (Adamis et al., 
2009, Bates et al., 2009, Bu, 2009, Mawuenyega et al., 2010) (Figure 3). The 
finer details of the molecular processes underlying Aβ clearance are still not 
fully understood. 
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Figure 3. Simplified model of Aβ production and clearance 
Mild cognitive impairment (MCI) has been proposed as a pre-dementia state in 
Parkinson’s disease (PD-MCI) (Litvan et al., 2012). This is defined as “cognitive 
decline that is not normal for age but with essentially normal functional 
activities”. PD-MCI comprises a diverse range of cognitive deficits. Diagnosis is 
made using the MDS task force criteria based on testing of five cognitive 
domains; attention and working memory, executive function, language, memory 
and visuospatial function (Litvan et al., 2011) (Figure 3). PD-MCI is even more 
common than PDD, with studies reporting frequencies of up to 42.5% of PD 
patients at presentation (Yarnall et al., 2014). Although PD-MCI does not, by 
definition, impact on activities of daily living it has been shown to negatively 
impact quality of life for patients and their carers (Leroi et al., 2012). There are 
no current treatments available for PD-MCI. 
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Table 2. Movement disorder society task force criteria for the diagnosis of mild 
cognitive impairment in Parkinson’s disease (Litvan et al., 2012) 
MDS task force criteria for the diagnosis of PD-MCI (Level 1) 
Inclusion Criteria 
 Diagnosis of PD as based on UK PD brain Bank Criteria 
 Gradual decline, in the context of established PD, in cognitive ability reported by either the patient or 
 informant, or observed by the clinician 
 Cognitive deficits on either formal neuropsychological testing or a scale of global cognition 
 Cognitive deficits are not sufficient to interfere significantly with functional independence, although 
 subtle difficulties on complex functional tasks may be present 
Exclusion criteria 
 Diagnosis of PDD based on MDS task force criteria 
 Other primary explanations for cognitive impairment (e.g. delirium, stroke, major depression, 
 metabolic abnormalities, adverse effects of medication, or head trauma) 
 Other PD-associated comorbid conditions (e.g. motor impairment or severe anxiety, depression, 
 excessive daytime sleepiness, or psychosis) that, in the opinion of the clinician, significantly 
 influence cognitive testing 
Specific guidelines for PD-MCI level I categories 
 Impairment on a scale of global cognitive abilities validated for use in PD or 
 Impairment on at least 2 tests, when a limited battery of neuropsychological tests is performed (i.e. 
 the battery includes less than 2 tests within each of the 5 cognitive domains assessed) 
 
The pathophysiology of PD-MCI has not yet been fully elucidated. PD-MCI is 
presumed to occur due to the same pathological processes responsible for PDD 
(Aarsland et al., 2011). Post-mortem examination of the brains of eight people 
with PD-MCI found a heterogeneous pattern of neurodegeneration associated 
with both α-synuclein and Aβ (Adler et al., 2010). As with PDD a number of 
brain regions have been implicated. Two recent studies have used magnetic 
resonance imaging (MRI) to assess the brains of patients with PD and normal 
cognition, PD-MCI and healthy controls. Both studies found cortical thinning in 
PD-MCI patients compared with PD and controls (Pereira et al., 2014, Danti et 
al., 2015). The areas involved appeared to be related to the observed deficit but 
with considerable overlap. Danti et al. found reduced temporal thickness 
associated with reduced verbal fluency (Danti et al., 2015). Pereira et al. 
demonstrated parietal and temporal thinning associated with visuospatial 
deficits, executive function and attentional deficits associated with cortical 
thinning in temporal, parietal and frontal cortex and amnestic deficits associated 
with temporal thinning (Pereira et al., 2014). 
Parkinson’s disease MCI is associated with an increased risk of PDD but 
progression from PD-MCI to PDD is not inevitable (Aarsland et al., 2009a, 
Janvin et al., 2006, Pedersen et al., 2013). Identifying those most at risk of 
progression will be necessary when disease modifying agents for PDD become 
available. Early clinical and biochemical predictors of PDD will be needed for 
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this. Identifying biomarkers may also give clues to pathogenesis thereby paving 
the way for novel therapeutic agents. The pathological overlap between PDD 
and AD increases the available pool of scientific research to enable us to 
achieve this. 
2.1.4 Weight loss and cognitive decline in Parkinson’s disease 
Unintended weight-loss has been proposed as a potential biomarker for 
cognitive decline in PD. It is linked with poorer cognitive function (Kim et al., 
2012, Lorefalt et al., 2004, Uc et al., 2006) and may predict PDD (Kim et al., 
2012). To date, no studies have investigated the aetiology of weight loss in PDD 
though body weight does fluctuate as Parkinson’s disease progresses 
(Bachmann and Trenkwalder, 2006, Beyer et al., 1995, Sharma and Turton, 
2012). Weight loss in PD is common. Despite this, weight loss has been shown 
to increase the risk of cognitive impairment and accelerate the rate of cognitive 
decline in PD without dementia at baseline (Kim et al., 2012). Moreover, 
cognitive impairment and neuropsychiatric complications such as hallucinations 
are risk factors for weight loss in PD (Lorefalt et al., 2004, Uc et al., 2006). 
Weight loss has also been shown to be important in other dementias, and has 
been reported to precede cognitive impairment in AD patients (Stewart et al., 
2005, Ogunniyi et al., 2011, Johnson et al., 2006). Weight loss in AD continues 
throughout the disease course and is associated with increased mortality (White 
et al., 1998). Furthermore, a large multicentre study carried out in eight 
countries showed that the severity of all cause dementia correlated with the 
degree of weight loss in 16,538 adults over 65 (Albanese et al., 2013). As 
expected given that weight loss preceded AD, weight loss was also seen in 
MCI. Besser et al. carried out a longitudinal study of 2268 people with MCI and 
1506 people with AD. They demonstrated that symptom progression in 
amnestic MCI was faster in participants with weight loss and lower baseline 
body mass index (BMI) than in weight stable participants and those with a 
higher baseline BMI (Besser et al., 2014). More recently, a number of studies 
support the hypothesis that weight loss increases the risk of dementia. A 2016 
prospective study found that weight loss predicted progression from MCI to all 
cause dementia and AD in 125 people with MCI followed over 4 years. 
Moreover, the onset of AD was earlier in patients with weight loss (Cova et al., 
2016). A 20 year study of 289 women found that weight loss of just 0.5kg/year 
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increased the risk of MCI or dementia by 30%(LeBlanc et al., 2016). Finally, 
these results were very closely replicated by a UK-based retrospective cohort 
study of nearly 2 million people which demonstrated that those with a BMI 
<20kg/m2 had a 34% increased risk of dementia over 20 years (Qizilbash et al., 
2015). Weight loss therefore appears to be associated with increased risk of 
dementia, earlier dementia onset and greater disease severity, at least in the 
context of AD. Interestingly, there may be a U-shaped relationship between 
adiposity and the risk of AD over the life course as mid-life obesity has also 
been linked to an increased risk of developing the disease (Fitzpatrick et al., 
2009, Kivipelto et al., 2005). This has been proposed to reflect deleterious 
metabolic processes occurring in midlife contributing to disease and associated 
weight loss over time. The study by Qizilbash et al described above did not 
support this, however, and so a relationship between midlife obesity and 
dementia remains unclear.  
The neural control of energy balance is complex and finely balanced. Myriad 
feedback signals from the body need to be integrated by several brain areas to 
ensure that intake is adequate for metabolic needs (Morton et al., 2006, Woods 
et al., 1998). This neural control includes hormones of energy homeostasis, 
some of which have been implicated in cognition and neuroprotection. It is 
possible that neurodegeneration, even at a pre-clinical stage, could disrupt this 
delicate balance. This thesis will focus on hormones of energy homeostasis as 
a putative link between cognitive decline and weight loss in Parkinson’s 
disease.  
2.2 Parkinson’s disease, adiposity and energy homeostasis over the life 
course 
2.2.1 Overview 
Meta-analysis has demonstrated that patients with PD have lower BMIs than 
controls and that lower BMI correlates with severity of disease but not disease 
duration. They propose that the lack of association between disease duration 
and weight loss may be due to different rates of progression amongst 
individuals (van der Marck et al., 2012). This would fit with the proposal by 
Sharma and Turton that there are two phenotypes of PD with weight change. 
Phenotype A is characterised by anosmia, higher weight at baseline, weight 
    
 12 
loss throughout the disease course, dyskinesia, more severe 
neurodegeneration and a longer premotor phase. Meanwhile, phenotype B is 
characterised by lower weight at baseline, stable weight or weight gain 
throughout the disease course, slower neurodegeneration and a shorter 
premotor phase (Sauerbier et al., 2016, Sharma and Turton, 2012). As well as 
more severe motor symptoms weight loss may increase the risk of NMS, 
including neuropsychiatric symptoms, and has been associated with poorer 
quality of life (Akbar et al., 2015, Kim et al., 2012, Lorefalt et al., 2004). People 
with PD are up to 4 times more likely to be malnourished than their age 
matched counterparts and those with greater disease severity are most likely to 
be malnourished (Beyer et al., 1995, Sheard et al.). Perhaps unsurprisingly, in 
view of this, weight loss is associated with increased mortality in men with PD. It 
is proposed that women are protected from this effect by increased adipose 
reserve (Walker et al., 2012). It is worth noting that it is unintended weight loss 
that may be deleterious in PD. There is some evidence from animal studies that 
calorie restriction may be protective in PD (Maswood et al., 2004), through anti-
inflammatory, anti-apoptotic or hormonal means (Bayliss and Andrews, 2016, 
Bayliss et al., 2016b, Fontana, 2009). Weight loss referred to in this thesis may 
be assumed to be unintended unless otherwise stated. The mechanisms by 
which weight loss occurs in PD is likely to be multifactorial. Overall in order for 
weight loss to occur more energy must be expended than consumed resulting in 
negative energy balance. 
There has been much research into the effects of deep brain stimulation (DBS) 
on weight in Parkinson’s disease, and it appears that DBS leads to weight gain 
(Aiello et al., 2015). The mechanism underpinning this is an area of debate and 
outwith the scope of this thesis. 
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2.2.2 Energy balance in Parkinson’s disease 
Oral intake 
It has been proposed that PD patients with weight loss have reduced oral intake 
due to anosmia, drug side effects, poor swallow and the time taken to complete 
a meal (Bachmann and Trenkwalder, 2006, Barichella et al., 2009, Beyer et al., 
1995). This is intuitive given the high prevalence of GI symptoms and anosmia 
in PD (Pfeiffer, 2003). Several studies have therefore investigated a possible 
link between NMS and energy intake in PD. Sharma and Turton assessed 
olfaction and intake in PD patients with and without weight loss. They found that 
patients with weight loss were more likely to have more severe anosmia than 
those with a stable weight. There was a trend towards lower energy intake in 
anosmic patients though this did not reach statistical significance (Sharma and 
Turton, 2012). Previously, Lorefalt et al assessed 26 PD patients over two 
consecutive years for problems with eating, swallowing and activities of daily 
living. Nineteen patients lost weight (0.5-8kg) during follow up. The authors 
found that patients with weight loss had more dysphagia than controls and 
patients with stable weights (p <0.05 at baseline and < 0.01 the following year). 
In keeping with this, the PD patients with weight loss ate less solid food than 
controls. There was no significant difference in food choices or dysphagia 
between controls and PD patients with a stable weight. The authors speculate 
that eating and swallowing difficulties may lead to reduced intake in PD patients 
with weight loss (Lorefalt et al., 2004). Elsewhere, Barichella et al. investigated 
nutritional risk in the presence of dysphagia, excessive salivation and 
constipation (dysautonomia symptoms). They found that nutritional risk as 
measured by the Malnutrition Universal Screening Tool increased in patients 
with advancing Hoehn and Yahr stage, levodopa dose and the number of 
dysautonomia symptoms present (Barichella et al., 2013b). Finally, Aden et al 
assessed energy intake, olfaction, swallowing, food cutting ability and salivation 
in 87 cognitively intact people with incident PD. They found that protein intake, 
though not total energy intake, was reduced in PD patients with anosmia (Aden 
et al., 2011). Their cohort was followed up at 3 years and the relationship 
between these variables and cognition was examined. There was no 
association between anosmia, energy intake or eating difficulties at baseline 
and cognitive decline. Energy intake was not re-assessed at follow up (Vikdahl 
et al., 2015). 
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Despite this apparent increased nutritional risk, there is as yet no clear evidence 
that energy intake is reduced in PD patients compared to healthy older adults. 
In fact, several studies have demonstrated increased energy intake in PD. A 
small study by Davies et al. found that PD patients ate around 400kcal/day 
more than controls (p=0.02) when dietary intake was assessed by a seven day 
food diary. Participants received training on food portion sizes but portions were 
not weighed (Davies et al., 1994). The authors concluded that reduced energy 
intake did not account for weight loss in PD. Their assertion is supported by 
Lograscino et al. who found that energy intake was 350kcal/day more in PD 
patients than controls (p=0.001) when assessed using a semi-quantitative food 
questionnaire. Importantly, the authors did not analyse data from patients who 
had lost weight. It is therefore difficult to draw conclusions about the eating 
habits of weight losing PD patients from this study (Logroscino et al., 1996). 
This may be important as people with PD who lose weight may be 
phenotypically different as detailed above (Sauerbier et al., 2016, Sharma and 
Turton, 2012). In support of this, a further paper published on the same cohort 
as the Lorefalt paper described above reports increased energy intake in PD 
patients compared with those with stable weights. Energy intake was 
significantly increased in weight-losing people with PD when expressed as a 
function of body weight (kcal/kg/day). It is worth noting that PD patients with 
weight loss had a significantly lower BMI than the weight stable group, making 
the validity of a weight corrected measurement questionable (Lorefalt et al., 
2004). A subsequent small study of PD patients with and without weight loss by 
Delikanaki-Skaribas et al. revealed very similar results. The authors reported 
that energy intake was increased in the weight loss group when expressed as a 
function of body weight. Once again, the weight loss group had significantly 
lower BMIs than the weight stable groups so that the significance of results is 
uncertain. (Delikanaki-Skaribas et al., 2009). 
There is evidence that both weight loss and increased energy intake may occur 
early in the disease process, even in the pre-clinical phase. In a large 
prospective study of more than 170,000 individuals, 468 (267 men and 201 
women) developed PD during follow up (14 and 18 years respectively). Weight 
was self-reported biennially and dietary intake was measured using a food 
frequency questionnaire. The team found that patients lost weight prior to 
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diagnosis and that weight loss was significantly more than for controls (p for 
trend <0.0001). Weight loss started 2-4 years prior to PD diagnosis and energy 
intake increased during this period. Patients had an average increase of 347 
kcal/day compared to controls (p <0.002 from 2-4 years prior to diagnosis). 
However; it is worth noting that confidence levels for energy intake in PD were 
large and overlapped with those for energy intake in controls at several time 
points (Chen et al., 2003).  
The most compelling evidence that energy intake is increased in PD comes 
from a large, cross-sectional case controlled study of 600 people with 
Parkinson’s disease and 600 age, physical activity, education and gender 
matched healthy controls. People with weight loss were not excluded but those 
requiring prescribed nutritional supplementation were. A trained dietician 
completed a semi-quantitative food frequency questionnaire with each 
participant. The authors found that BMI was lower in the PD groups and 
worsened with increasing disease severity. Despite this, energy intake was 
higher by around 200 kcal/day in those with PD and continued to increase with 
disease progression. This was significant both as a function of body weight 
(p<0.001) and in absolute numbers (p<0.001). People with cognitive impairment 
were excluded from this study (Barichella et al., 2017). 
Evidence for increased energy intake in PD compared with healthy adults has 
not been entirely consistent, however. An earlier study by Barichella et al. found 
no significant difference in intake between PD patients and controls (Barichella 
et al., 2013a). Furthermore, an earlier study by Toth et al. investigating energy 
intake in 16 PD patients and 46 controls found that energy intake was no 
different between groups. Importantly, this study excluded patients with recent 
weight loss (Toth et al., 1997), which may have biased their results.  
On balance, it does appear likely that energy intake is higher in PD than in 
controls. It is difficult to reconcile this with increased nutritional risk in the 
presence of non-motor symptoms. Accurately measuring energy intake is 
fraught with difficulties. Food diaries are prone to errors due to inaccurate 
estimation of portion sizes by respondents. None of the above studies used 
weighed portions. Similarly, food frequency questionnaires are useful to record 
trends in food consumption in populations but are unable to record intake at an 
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individual day to day level (Gibson, 1990). The available studies do not 
adequately account for potential differences between weight stable and weight 
losing people with PD. It is possible that energy intake is increased in PD but 
that energy requirements are increased resulting in weight loss overall. 
Energy expenditure 
It has been proposed that weight losing PD patients have increased energy 
expenditure due to increased muscle rigidity and the emergence of dyskinesia. 
Total energy expenditure (TEE) may be separated into resting energy 
expenditure (REE) and physical activity. Early studies looked at REE alone to 
determine whether or not energy expenditure is increased in PD. A small study 
by Levi et al. found that REE significantly decreased when patients had a 
reduction in motor symptoms or “switched on” following PD medication (Levi et 
al., 1990). Similarly, Markus et al. studied REE in 12 PD patients and eight 
controls. REE was increased in patients with PD compared to controls. Four 
patients had increased REE in the “off” state but 7 showed no difference 
(Markus et al., 1992). More recently, Capecci et al. measured REE in 58 PD 
patients when the patients were fasted and “off” and then again 60 minutes after 
PD medication. They found an 8% reduction in REE in the “on”-state. Despite 
this, the participants REE was similar to that expected for gender, age and BMI. 
The clinical significance of increased REE is therefore uncertain (Capecci et al., 
2013). Conversely, Lorefalt et al. found reduced REE per Kg body weight and 
reduced physical activity in PD patients compared to controls. The reduction in 
REE was seen in PD patients with and without weight loss. There was no 
difference in REE between PD patients who lost weight and those whose weight 
remained stable (Lorefalt et al., 2004). Taking these studies together it is 
unclear to what extent REE is increased in PD, if at all.  
Two well conducted studies have gone on to investigate TEE in PD with a view 
to obtaining a more complete picture of energy expenditure. Both studies used 
the doubly labelled water technique to measure TEE. This technique uses water 
labelled with naturally occurring isotopes of hydrogen and oxygen (H2 and O18). 
Energy expenditure can then be calculated using the proportion of labelled 
hydrogen and oxygen excreted in urine, rather than exhaled as carbon dioxide 
(Schoeller, 1988). Indirect calorimetry, in which expired CO2 is measured at rest 
using a ventilation hood, was used to measure REE (Schoeller, 1988). Toth et 
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al. measured TEE and REE in 16 men with PD and 46 healthy male controls. 
TEE was found to be reduced in patients with PD compared to controls due to 
reduced physical activity, proposed to be due to poor mobility and increased 
dependency (Toth et al., 1997). More recently, Delikanaki-Skaribas et al. 
investigated 10 PD patients with stable weight and 10 PD patients with weight 
loss. They found that neither TEE nor REE were significantly different between 
weight loss and weight stable groups (Delikanaki-Skaribas et al., 2009). 
There is further evidence in support of the idea that energy expenditure is 
reduced, rather than increased in PD. Data from a study using accelerometers 
to measure physical activity in free-living people with PD demonstrated that 
people with PD are significantly less active than controls, even in early disease 
(Lord et al., 2013). Moreover, the recent Barichella paper discussed above 
collected data on daily sleep, hobbies, housework and other daily activities to 
calculate TEE and physical activity. They also calculated REE based on height, 
weight and age. They found that physical activity was lower in people with PD 
and reduced further as disease progressed (Barichella et al., 2017). There is, 
therefore, relative agreement in the literature that people with PD lose weight in 
the face of apparent positive energy balance, which is to say increased energy 
intake and reduced energy expenditure. Let us consider other potential ways in 
which this excess energy might be “lost” in PD. 
Malabsorption 
As discussed above, gastrointestinal symptoms such as dysphagia, 
constipation and abdominal bloating are common in PD. Many of these 
symptoms have been attributed to disruption in gut motility (Pfeiffer, 2003). This 
has led some authors to speculate that weight loss in PD may have an enteric 
cause. Small intestinal bacterial overgrowth (SIBO) has been shown to 
contribute to occult weight loss in older adults (McEvoy et al., 1983). Intestinal 
dysmotility is thought to be an important aetiological factor in the development 
of SIBO (Gasbarrini et al., 2007) so it follows that SIBO should be more 
common in PD patients. As expected, the prevalence of SIBO is higher in 
patients with PD than in the healthy population. However; this has not been 
shown to correlate with weight loss in PD (Fasano et al., 2013, Gabrielli et al., 
2011, Tan et al., 2014). An important role for malabsorption in causing weight 
loss therefore appears unlikely.  
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Medication 
Dopaminergic medications have been implicated in the aetiology of weight loss 
in people with PD (Kashihara, 2006). These drugs have side effects including 
nausea and vomiting which may impair appetite. However, even when present, 
nausea and vomiting do not appear to reduce oral intake (Lorefalt et al., 2004, 
Palhagen et al., 2005). It was previously proposed that levodopa may contribute 
to weight loss by enhancing lipolysis (Vardi et al., 1976). This is in keeping with 
the finding that weight loss in PD tends to be fat loss-based rather than due to 
sarcopaenia (Lorefalt et al., 2009, Markus et al., 1993). However; direct 
measurement using microdialysis failed to demonstrate increased lipolysis with 
levodopa administration (Adams et al., 2008). Prolonged levodopa treatment 
and higher doses are often accompanied by the emergence of motor 
fluctuations and dyskinesia in PD. The Barichella study discussed above 
demonstrated that positive energy balance in PD correlated positively with 
motor fluctuations, including involuntary dyskinesia (Barichella et al., 2017). 
Sharma and Turton also found that more severe motor fluctuations and 
dyskinesia were associated with weight loss in PD (Sharma and Turton, 2012). 
These data suggest that complications of long term levodopa treatment may 
increase energy requirements, which is difficult to measure under laboratory 
conditions.  
The principal argument against a significant role for medications directly 
causing weight loss in PD is that weight loss appears to precede drug therapy 
and motor symptoms (Chen et al., 2003, Cheshire Jr and Wszolek, 2005). The 
onset of weight loss prior to motor symptoms and in early disease also makes 
increased energy expenditure an unlikely sole cause of weight loss.  
It seems likely that the cause of weight loss in PD is multifactorial, with 
increased requirements due to as yet unidentified reasons and inadequate 
nutrition to maintain homeostasis despite overall increased energy intake. It 
appears that there is failure of the usual homeostatic mechanisms in PD. As 
detailed above, weight loss in PD is associated with an increased risk of 
cognitive decline but the nature of this relationship, whether or not weight loss 
causes cognitive decline, is unclear (Kim et al., 2012). No studies to date have 
assessed energy intake in people with PD-CI. Extensive neurodegeneration by 
α-synuclein and Aβ may cause both weight loss and cognitive impairment 
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through damage to limbic and cortical areas of the brain. There are plausible 
mechanisms by which weight loss in PD may precipitate or accelerate cognitive 
decline. A number of hormones of energy homeostasis have been proposed to 
be neuroprotective in PD and in AD. Disruption of these systems may result in 
loss of neuroprotection and increased neuronal loss. This will be discussed in 
detail in the chapters below. 
2.3 Energy Homeostasis 
2.3.1 Overview 
Energy homeostasis refers to the active maintenance of total body energy 
stores at a level appropriate to the environment over time. Our bodies store 
energy derived from food in muscle, liver and adipose tissue. If more energy is 
consumed than is expended then more adipose tissue is laid down and body 
weight increases. Conversely, if energy intake is less than energy spent then 
body weight decreases. This may be lost from muscle or adipose mass (Woods 
and D'Alessio). 
Energy homeostasis requires signals about body energy stores to be 
communicated from the peripheral tissues to the central nervous system. These 
signals must then be integrated and result in appropriate changes in feeding 
behaviour and energy expenditure. Most humans and several species of animal 
consume energy in discrete meals. It is thought that satiation, or a feeling of 
“fullness”, resulting in the limitation of energy consumption at meal times is 
more important in energy homeostasis than satiety, which is to say meal 
initiation (Valassi et al., 2008). This makes sense in the social and cultural 
context of feeding behaviour in humans in which meals are often initiated due to 
habit, mood and circumstances rather than in response to a lack of circulating 
nutrients. Regulation of energy homeostasis through satiation (meal 
termination) rather than satiety (meal initiation) also makes sense in the context 
of human evolution where scarce food resources meant that food was eaten 
whenever it was available (Woods and D'Alessio). In order to ensure that 
homeostasis is maintained, information from the body regarding the amount and 
type of nutrients ingested at each meal must be conveyed to the central 
nervous system (CNS) along with information about total background energy 
stores (Woods and D'Alessio, 2008) 
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The hypothalamus is the main “hunger centre” of the brain. The arcuate nucleus 
(ARC) of the hypothalamus contains both appetite suppressant (anorexigenic) 
and appetite stimulant (orexigenic) neurones. Anorexigenic neurones secrete 
pro-opiomelanocortin (POMC), which is cleaved into α- melanocyte stimulating 
hormone (αMSH). Alpha-MSH acts at Melanocortin 3 (MC3R) and Melanocortin 
4 receptors (MC4R) to reduce food intake (Cowley et al., 2001, Fan et al., 
1997). Orexigenic neurones secrete the neurotansmitters neuropeptide Y (NPY) 
and agouti-related peptide (AgRP). AgRP antagonises αMSH, whilst NPY acts 
directly on Y receptors, both resulting in increased food intake. The control of 
intake depends on the balance between these two sets of neurones, which are 
stimulated in response to a myriad of peripheral and central factors (Valassi et 
al., 2008). The downstream effect is likely to be mediated by adenosine 5’ 
monophosphate-activated protein kinase (AMPK) and mammalian target of 
rapamycin (mTOR) (Cota et al., 2006, Minokoshi et al., 2004). The blood brain 
barrier (BBB) at the ARC is more permeable than in other areas of the brain and 
consequently may be able to sense peripheral hormones and circulating 
nutrient levels (Peruzzo et al., 2000). Glucose, free fatty acids and the amino 
acid leucine have been proposed to inhibit appetite centrally (Woods and 
D'Alessio, Lam et al., 2005, Obici et al., 2002, Cota et al., 2007). The ARC also 
receives and integrates input from other areas of the hypothalamus and 
throughout the CNS resulting in shifts in balance between the stimulation of 
orexigenic and anorexigenic neurones and hence energy intake (Cone, 2005, 
Cota et al., 2007, Elmquist et al., 2005, Morton et al., 2006, Small and Bloom, 
2004, Woods and D'Alessio, 2008) (Figure 4). 
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Figure 4. First order neural pathways involved in appetite 
Feeding is a complex behaviour requiring the organism to be able to find food, 
correctly identify it as food and ingest it in appropriate amounts according to 
their metabolic needs. It is not surprising then that numerous areas of the brain 
are involved in energy homeostasis (Figure 5). In the brainstem, the nucleus 
tractus solitarius (NTS) receives sensory input from the tongue regarding the 
taste and texture of foods and from the vagus nerve under hormonal control and 
in response to stomach stretching. In the diencephalon, the lateral hypothalamic 
area (LHA), ventral tegmental area (VTA) and nucleus accumbens (NAc) make 
up the cholinergic-dopaminergic reward circuit (Morton et al., 2006, Woods, 
2013). The NTS and cholinergic-dopaminergic reward circuit work together to 
assign food reward and communicate with the ARC to regulate intake (Morton 
et al., 2006). The LHA (part of the cholinergic-dopaminergic reward circuit) 
receives input from the oribitofrontal cortex, regarding the look, smell, taste and 
texture of foods (Rolls, 2005). It has a direct neural connection with the ARC 
and contains orexigenic neurones itself (Broberger et al., 1998). It is thought to 
be important in initiating food seeking behaviour (Morton et al., 2006).  In 
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contrast, the paraventricular nucleus (PVN) is thought to augment anorexigenic 
signals by producing corticotropin-releasing hormone and oxytocin, both of 
which suppress appetite(Woods and D'Alessio, 2008). Peripheral signals 
regarding adiposity and nutrient status are transmitted to the CNS through the 
blood brain barrier and via the vagus nerve. There are a number of hormones of 
energy homeostasis involved in this process (Table 3). This thesis will focus on 
the actions of ghrelin, insulin, leptin and glucagon-like peptide 1 as these are 
the compounds most relevent to neurodegenerative disease.





Table 3. Hormones of energy homeostasis (Cholerton et al., 2013, Norton et al., 2014, Rizza et al., 1982, Smith and Thorner, 2012, Woods and 
D'Alessio, 2008) 
Hormone Receptor Production Site of action Appetite Other actions 
Active Ghrelin GHSR1a X/A like cells in Oxyntic glands of 
stomach 
Requires intact vagal nerve 







 Increases motility , gastric emptying and stomach acid 
secretion 
Metabolic 
Increases blood glucose during starvation, reduces insulin 
release, increases adiposity (reduces utilisation of fat) 
Central nervous system 
Increases GHRH,GH, prolactin and ACTH , increases reward 
Other 
↑ cardiac output, ↓ blood pressure, Anti-inflammatory 
Insulin Insulin 
receptor (IR) 
Β-cells in the pancreas in response to 
circulating glucose. Augmented by 
GLP-1, suppressed by growth 





Anorexigenic Enables storage of energy, lowers blood glucose 
Regulates Ach and noradrenaline 
Decreases ghrelin 




Anorexigenic Augments CCK response  
May increase insulin sensitivity  
Resistance occurs 
Inhibits bone formation 
May have a role in fertility 









I cells duodenum and jejunum Hypothalamus 




Anorexigenic Inhibits ghrelin 
Augments response to leptin 
Reduces gastric emptying 
Increases exocrine pancreatic secretions 
Increases PYY secretion 
Stimulates gall bladder contraction 
Glucagon-like 
peptide 1  
(GLP-1) 






Anorexigenic Augments insulin secretion 
Reduces glucagon 
Increases β cell proliferation 




Y2 L-Cells in GI tract in response to 
nutrients  
Hypothalamus Anorexigenic Reduce motility in stomach and GI tract 
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Figure 5. Areas of the brain involved in appetite regulation 
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2.3.2 Ghrelin  
Ghrelin is a 28 amino acid peptide which was discovered by Kojima et al. in 
1999 and identified as endogenous ligand for an orphan G-coupled receptor 
called growth hormone secretagogue receptor (GHSR1a) (Kojima et al., 1999). 
Ghrelin is a powerful orexigenic hormone produced as des-acyl or unacylated-
ghrelin (UAG) in oxyntic X/a-like cells in the stomach in response to fasting 
(Wren et al., 2001, Date et al., 2000a, Nakazato et al., 2001). Once secreted, 
ghrelin passes into the blood stream where it is acylated into its active form, 
acyl-ghrelin (AG) by ghrelin-O-acyltransferase (GOAT) (Yang et al., 2008). Acyl-
ghrelin stimulates the DMNV and crosses the blood brain barrier into the brain. 
Once across the BBB AG binds with growth hormone secretagogue receptor 1 
a (GHSR1a) receptors in the hypothalamus and DMNV, resulting in inhibition of 
anorexigenic POMC neurones and stimulation of orexigenic NPY 
neurones(Cowley et al., 2003, Horvath et al., 2001, Currie et al., 2005, 
Nakazato et al., 2001). The net result is increased hunger and food intake 
(Andrews, 2011, Markaki et al., 2012, Yang et al., 2008, Cummings, 2006). 
Acyl-ghrelin also acts at the NTS via the vagus nerve where input is integrated 
with information about food taste and texture. Finally AG acts at the cholinergic-
dopaminergic reward circuit to increase reward assigned to palatable foods 
(Jerlhag et al., 2012a). 
Ghrelin has both short term or “phasic” and long term or “tonic” secretion 
(Figure 6). Phasic ghrelin levels peak before meals and decline thereafter 
(Davis et al., 2011, Cummings et al., 2001). There is also diurnal variation, with 
a night-time peak in the early hours of the morning (Nass et al., 2013). The 
control of ghrelin release is not yet well understood but appears to require an 
intact vagus nerve (Date et al., 2002, Huda et al., 2010) and to be at least partly 
under higher cortical control (Seoane et al., 2007, Williams et al., 2003a, 
Williams et al., 2003b). Suppression after meals occurs when nutrients enter the 
duodenum after stomach emptying, or after tease feeding (Seoane et al., 2007, 
Tschöp et al., 2001a). Control appears to be, at least partially, mediated by 
acetylcholine. Oral pyridostigmine, a cholinergic agonist, was shown to increase 
ghrelin levels whilst pirenzepine, an anti-cholinergic, decreased ghrelin 
secretion in 6 healthy humans (Broglio et al., 2004).  
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Tonic ghrelin and AG levels increase with declining BMI; increasing hunger and 
promoting food intake in times of negative energy balance as part of a negative 
feedback loop (Tschöp et al., 2001b, Beberashvili et al., 2017). The tonic level 
of ghrelin can also be described as the area under the curve of ghrelin over the 
course of the pre-prandial, post- prandial and recovery phases of secretion. 
Ghrelin is effective in increasing weight and muscle mass in cachectic patients 
with severe heart failure and COPD and increases intake in patients with 
metastatic cancer and anorexia. Exogenous administration of ghrelin results in 
increased energy intake in humans with heart failure, COPD, end-stage renal 
failure and cancer (Wynne et al., 2005, Neary et al., 2004, Nagaya et al., 2004, 
Nagaya et al., 2006, Nagaya and Kangawa, 2006). (Akamizu and Kangawa, 
2011, Neary et al., 2004) 
 
Figure 6. Schematic of ghrelin release 
Ghrelin levels have been proposed to decline with age, a phenomenon that has 
been linked with somatopause (relative growth hormone deficiency in older age) 
and hypothalamic degeneration (Akamizu et al., 2006, Nass et al., 2013, 
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Rigamonti et al., 2002). In 2002 Rigamonti et al. measured fasting total ghrelin 
in young people with anorexia nervosa (n= 6, aged 17.5±0.5), obesity (n=7, 
aged 26.9±2.7) and normal weight (n=12, aged 33.4 ±1.0) and older people with 
normal weight (n=7, 79.8±2.1). They found that ghrelin levels were high in 
young people with anorexia and low in those with obesity relative to young 
people with normal weight. This was in keeping with the expected pattern of 
ghrelin according to BMI. They found that older adults with normal weight had 
lower ghrelin levels despite a similar BMI and that their ghrelin levels were 
similar to young people with obesity (Rigamonti et al., 2002). This was quickly 
followed by a 2003 study examining the dynamic total ghrelin response to 
ingesting ice-cream in 8 well-nourished older adults (aged 77±0.9) 8 
undernourished older adults (aged 80.4±2.6) and 8 well-nourished young adults 
(aged 22 ± 1.3). The authors report that total ghrelin levels were 20% lower in 
the well-nourished older adults compared with well-nourished younger adults. 
This effect failed to achieve significance, however (p=0.2), making their results 
inconclusive. The authors felt this may be due to the study being underpowered 
(Sturm et al., 2003). A Japanese study of 105 older people (aged 73.4 ±6.3) 
and 39 younger people (aged 33.5 ±9) found that fasting AG was lower in older 
women than younger women but no difference was observed for men (Akamizu 
et al., 2006). More recently, Nass et al. found significantly lower 24 hour AG 
profile in 6 older adults (aged 65.2±4.9) compared with eight healthy young men 
(aged 25.8 ±3.1). Blood tests were taken every 10 minutes over the 24 hour 
period and a loss of a nighttime peak of ghrelin was seen in the older subjects 
(Nass et al., 2013).  
There is some evidence that the relationship between ageing and ghrelin is not 
as straightforward as deterioration over time. A recent study by Serra-Prat et al. 
looked at 55 people over 70 and 33 people aged 25-65. The older group were 
determined to be either sarcopaenic (i.e. had clinical evidence of muscle 
wasting) or non-sarcopaenic. Of the 55 older participants 23 were sarcopaenic. 
Ghrelin levels were not significantly different between the young adult group 
and the non-sarcopaenic older participants. Sarcopaenic participants had lower 
ghrelin levels than non-sarcopaenic older adults but this effect was lost when 
analysed by gender, possibly due to small sample size. The authors propose 
that ghrelin may not decline in healthy ageing but rather may reflect a loss of 
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homeostasis in unhealthy ageing, perhaps reflecting a pre-frail state (Serra-Prat 
et al., 2015). This is supported by their previous work showing that lower ghrelin 
levels at baseline were associated with weight loss and functional decline in 
elderly people over 2 years (Serra‐Prat et al., 2010). Further evidence comes 
from a small study by Schneider et al. who looked at total ghrelin and AG pre-
prandially and for 4 hours post-prandially in healthy people and malnourished 
people requiring dietician input for nutrition. They found that AG levels were 
higher in undernourished young people (age 26 ± 6, n=10) compared with well-
nourished young people (aged 34±8, n=10) but undernourished older people 
(aged 80±6, n=11) did not have significantly elevated AG compared to healthy 
older adults (76 ±9, n=9). There was no significant difference in AG between 
healthy older adults and healthy younger adults. This study is limited by its 
small numbers and also because the reason for malnourishment was different 
between younger and older groups. More young people were suffering from 
anorexia nervosa and older people were suffering with depression, infection or 
recent surgery (Schneider et al., 2008). This is important as ghrelin is proposed 
to be an acute phase reactant (Maruna et al., 2008). Levels do not change in 
depression (Kluge et al., 2009) but may be elevated in anorexia nervosa 
(Soriano-Guillén et al., 2004), making interpretation difficult. Although flawed, 
this study does support the idea that ageing per se. may not affect ghrelin 
secretion but that there may be a failure of homeostasis in ill health in older age. 
The studies by Rigamonti, Sturm and Akamizu’s groups cannot clarify this 
relationship as their inclusion criteria were broad and measures of frailty and 
sarcopaenia were not included. It has been suggested that the efficacy of 
ghrelin may decrease with ageing, due to reduced GHSR1a signaling (Nass et 
al., 2013, Yin and Zhang, 2015). Further research is needed to determine if 
decline in ghrelin is part of healthy ageing or a reflection of an increased 
prevalence of frailty in older age.  
Pleiotropic ghrelin 
Ghrelin is a pleiotropic hormone, which is to say that it has differing effects in 
parts of the body. Its receptor, GHSR1a is expressed throughout the body in a 
number of different tissues (Gnanapavan et al., 2002). Along with its orexigenic 
effects ghrelin acts as a stimulating hormone for growth hormone (GH) (Arvat et 
al., 2000). It is thought to have anti-inflammatory properties, to reduce blood 
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pressure (Wynne et al., 2005) and to improve left ventricular function (Nagaya 
et al., 2004). Ghrelin has also been implicated in learning and memory and may 
have a role in neuroprotection. Figure 7 gives an overview of the main actions 
of ghrelin known to date. We will look at some of these in more detail. 
  
Figure 7. The pleiotropic effects of ghrelin 
Ghrelin and the gut 
Animal studies have shown ghrelin to increase gut motility, the rate of gastric 
emptying and stomach acid secretion (Depoortere et al., 2005, Edholm et al., 
2004, Fukuda et al., 2004, Levin et al., 2005, Masuda et al., 2000, Trudel et al., 
2002). The prokinetic effects of ghrelin have also been demonstrated in humans 
in two double-blind randomized controlled crossover studies. Levin et al. gave 
intravenous ghrelin to eight healthy adults and six patients with GH deficiency 
using scintigraphy (radiolabeled foods that can be imaged radiographically). 
Ghrelin increased gastric motility whether or not GH was administered, 
suggesting that ghrelin’s prokinetic effects are independent of GH (Levin et al., 
2006).Tack et al. studied nine healthy volunteers and measured their gastric 
motility using manometry. They administered ghrelin or saline intravenously. 
They found that gastric motility was increased and that there was sustained 
stomach contraction after ghrelin infusion (Tack et al., 2006).  
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Ghrelin has also been investigated as a treatment for gastroparesis. Six people 
with idiopathic gastroparesis were administered ghrelin or saline in a 
randomized controlled crossover trial. Gastric emptying was measured using 
C13 breath testing. Gastric emptying was faster following ghrelin treatment than 
following saline and symptoms of gastroparesis were improved (Tack et al., 
2005). Another double blind placebo controlled cross over study looked at ten 
people with diabetic gastroparesis. They were administered ghrelin or saline IV. 
Intravenous ghrelin increased gastric emptying as measured using ultrasound. 
Interestingly this persisted even with vagal neuropathy, suggesting that the 
effects were independent of the vagus nerve (Murray et al., 2005). The finding 
that an intact vagal nerve is not required for ghrelin’s prokinetic effects is 
corroborated by another small randomized controlled crossover study in six 
women with impaired vagal innervation of the stomach; five with autonomic 
neuropathy due to diabetes and one with gastroparesis following vagotomy. The 
authors demonstrated that gastric emptying was increased following ghrelin 
treatment compared with saline infusion (Binn et al., 2006). This is important as 
it suggests that ghrelin could improve gastric emptying even in the face of 
neurodegeneration of the vagus nerve. Gastroparesis is a common non motor 
symptom of PD, for which there are few treatment options at present (Marrinan 
et al., 2013). Ghrelin treatment could be of potential therapeutic benefit for 
gastroparesis in PD and human studies examining this are ongoing (Schrag et 
al., 2015). 
Ghrelin and the immune system 
There is compelling evidence that ghrelin is an immune modulator. In 2001, 
Hattori et al. found that GHSR1a and ghrelin were present in human T-calls, B 
cells and neutrophils  (Hattori et al., 2001). It has since been demonstrated that 
GHSR1a is expressed on human T-cells and that expression increases with t-
cell activation. In vitro ghrelin administration to T-cells inhibits pro-inflammatory 
cytokines (IL-1α, IL-1β TNFα and IL-6). In vivo, bacterial lipopolysaccharide 
(LPS), also known as endotoxin, mimics septic shock. Exogenous ghrelin 
reduced the inflammatory response to LPS at 4 and 24 hours in mice (Dixit et 
al., 2004). It has been proposed that ghrelin is important for the maintenance of 
the thymus; an organ which produces T-cells and is important for immunity. 
With age, thymic cells are gradually replaced with fatty tissue and the diversity 
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and number of T-cells produced declines. Dixit et al. found that thymic ghrelin 
expression and GHSR1a expression decline with age in mice, that ghrelin 
knock-out mice have a greater rate of thymic involution than wild-types and that 
exogenous ghrelin can reverse this process (Dixit et al., 2007). Similar results 
are seen in GHSR1a knock out mice (Youm et al., 2009).  
Exogenous ghrelin has been shown to reduce inflammation and to improve 
phenotype in animal models of sepsis (Li et al., 2004), traumatic brain injury 
(Bansal et al., 2012), myocardial ischaemia (Cao et al., 2013), chronic kidney 
disease (Deboer et al., 2008), stroke (Cheyuo et al., 2011), inflammatory 
arthritis (Granado et al., 2005), lung contusion (Guven et al., 2013), acute lung 
injury (Imazu et al., 2011, Li et al., 2015a), non-alcoholic fatty liver disease (Li et 
al., 2013b), multiple sclerosis (Souza-Moreira et al., 2013, Theil et al., 2009) 
and gut ischaemia (Wu et al., 2008) amongst others. All of these studies found 
reduced pro-inflammatory cytokine expression in response to treatment with 
ghrelin.  
In addition to direct action on the thymus and T-cells, ghrelin may reduce 
inflammation via vagal stimulation. Kevin Tracey described the “cholinergic anti-
inflammatory pathway” or “inflammatory reflex” in 2002. He proposed that the 
CNS is able to sense tissue inflammation and rapidly produce an anti-
inflammatory response via the autonomic nervous system, specifically sensory 
vagal afferent and motor vagal efferent neurons. This prevents excessive 
immune responses, which may be harmful in systemic inflammatory response 
syndrome or autoimmune disease, for example (Tracey, 2002).This theory was 
based on previous work demonstrating that acetylcholine (Ach) deactivated 
macrophages in vitro via specific Ach receptors (α-bungarotoxin-sensitive 
nicotinic receptors) on macrophages. Furthermore, the production of the 
inflammatory cytokine TNFα was attenuated both at rest and in response to 
LPS with vagal efferent stimulation (Borovikova et al., 2000). Studies in animal 
models support the idea that ghrelin exerts its anti-inflammatory action via the 
cholinergic anti-inflammatory pathway. Wu et al looked at a rat model of gut 
ischaemia in which the superior mesenteric artery was occluded for 90 minutes. 
Rats administered ghrelin had reduced inflammatory cytokines and reduced 
ischaemic injury. This result was lost with both ghrelin receptor antagonism and 
vagotomy (Wu et al., 2008). Similar results were found by Cheyuo et al. in a rat 
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model of stroke in which the right middle cerebral artery was ligated causing 
ischaemic brain injury. Half of the rats also underwent vagotomy. Rats were 
given vehicle or ghrelin intravenously post-operatively. Rats given ghrelin who 
had an intact vagus nerve had reduced infarct size compared with rats given 
vehicle or ghrelin and vagotomy. Levels of the inflammatory cytokines TNF-α 
and IL-6 were similarly reduced (Cheyuo et al., 2011).  
There is surprisingly little in the literature regarding exogenous ghrelin in 
inflammatory conditions in humans. One randomised crossover study examined 
the ghrelin response to LPS when given to 10 healthy men. They found that 
ghrelin surged after LPS administration, suggesting that ghrelin is important in 
immunomodulation in humans (Vila et al., 2007). 
Ghrelin and other hormones  
Ghrelin was first identified as the ligand for growth hormone secretagogue 
receptor (GHSR1a). As the name suggests, ghrelin increases GH secretion 
through binding with this receptor to stimulate GH release at the pituitary (Date 
et al., 2000b, Kojima et al., 2001, Peino et al., 2000, Wren et al., 2000). It has 
been shown to have a more potent effect on GH secretion than growth hormone 
releasing hormone (GHRH) when administered exogenously (Arvat et al., 
2000). Furthermore, ghrelin acts synergistically with GHRH to augment the GH 
release in response to GHRH (Arvat et al., 2001). Interestingly, the GH 
response to ghrelin is blunted in older adults (Nass et al., 2013). Growth 
hormone is thought to be important for feelings of vitality. Its secretion is 
pulsatile and this pattern appears to be lost with ageing. The somatopause has 
been linked with sarcopaenia and frailty (Lanfranco et al., 2003). It is possible 
that blunting of the nocturnal ghrelin peak and deteriorating GH response to 
ghrelin may be important in sarcopaenic patients. Interestingly, decreased 
nocturnal GH has also been seen in PD (Bellomo et al., 1991) 
A downstream effect of GH is to stimulate insulin-like growth factor-1 (IGF-1) 
production from the liver. Insulin-like growth factor 1 is thought to be important 
in learning and memory and IGF-1 deficiency has been implicated in 
neurodegenerative diseases including PD and AD (Giordano et al., 2012). As 
you might expect, IGF-1 levels decline with age and are part of the 
      
 33 
somatopause (Lanfranco et al., 2003). Insulin-like growth factor-1 will be 
discussed in depth in a later section of this thesis. 
In addition to augmenting the somatotropic axis ghrelin has an important role in 
glucose metabolism. Ghrelin is required for the maintenance of blood sugar 
levels in the face of starvation, may promote adiposity independently of food 
intake and may have an influence on basal metabolic rate. Ghrelin and 
GHRS1a knockout mice have significantly lower blood glucose under calorie 
restriction than wild types (Sun et al., 2008). Moreover, GOAT knockout mice 
become hypoglycaemic and moribund when calorie restricted (Zhao et al., 
2010). Exogenous ghrelin impairs glucose tolerance in humans (Broglio et al., 
2001, Chuang et al., 2011, Claret et al., 2007, Melville et al., 1990, Smith and 
Thorner, 2012, Tong et al., 2016, Tong et al., 2010). Ghrelin suppresses insulin 
in a paracrine fashion through AG binding at GHSR1a receptors in pancreatic 
islet cells. Growth hormone is known to increase insulin resistance (Rizza et al., 
1982). However, the anti-insulin effect of ghrelin is abolished by GHSR1a 
blockade (Dezaki et al., 2012) and exogenous ghrelin still induces insulin 
resistance people with GH and ACTH deficiency. Taken together, these data 
suggest that ghrelin antagonises insulin independently of GH and ACTH 
(Vestergaard et al., 2008). 
Ghrelin in cognition 
There is a wealth of evidence from animal studies suggesting a role for ghrelin 
in learning and memory. The hippocampus is an important structure for laying 
down new memories (Lynch, 2004). It is situated in the temporal lobes, which 
are frequently atrophied early in the course of AD (Scheltens et al., 1992). 
Ghrelin is thought to acts at the hippocampus to improve learning and spatial 
memory in rodents. The first group to show this was Carlini et al, who 
demonstrated that intra-cerebroventricular (ICV) ghrelin administration 
increased the time taken for rats to step down onto a platform where they had 
recently received a shock (increased step-down latency), suggesting improved 
memory retention (Carlini et al., 2002). The same group later went on to 
demonstrate that ICV ghrelin improved memory for object recognition in 
chronically food restricted mice (Carlini et al., 2002, Carlini et al., 2008), whilst 
intra-hippocampal ghrelin improved long term but not short term memory in rats 
performing the step-down test (Carlini et al., 2010a). All of these studies used 
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total ghrelin. Synthetic ghrelin agonists also positively impact memory in rats. 
Treatment with two different synthetic ghrelin receptor agonists (GSK894490A 
and CP-464709-18) improved object recognition and spatial memory compared 
with rats treated with vehicle (Atcha et al., 2009).  
The pro-cognitive effects of ghrelin may be mediated through GHSR1a, which is 
expressed in the hippocampus (Guan et al., 1997). Intra-amygdaloid and 
intrahippocampal total ghrelin both increase step-down latency in rats but not 
when co-administered with a GHSR1a blocker (Tóth et al., 2009). Moreover, 
GHSR1a knockout mice have significantly impaired spatial memory compared 
to wild types (Davis et al., 2011). Not all studies support the finding that ghrelin 
improves learning and memory via GHSR1a, however. Albarran-Zeckler et al. 
found that GHSR1a knockout mice had superior performance in the Morris 
water maze compared to wild types. The authors speculate that the discrepancy 
between their results and those of Davies et al. and Ghersi et al could be due to 
the different breeding techniques used, resulting in a different phenotype 
despite the same gene deletion, or to differences in mouse age (Albarran-
Zeckler et al., 2012). The balance of evidence suggests, however, that ghrelin 
signalling via GHSR1a enhances learning and memory at the hippocampus in 
rodents. This may be through enhanced synaptic plasticity and neurogenesis. 
Increased synaptic plasticity, due to enhanced long term potentiation (LTP) and 
synaptogenesis, has been proposed as a mechanism by which ghrelin may 
positively impact learning and memory (Carlini et al., 2010b). Long term 
potentiation is the process by which repeated stimulation of a neurone leads to 
a lasting (long term) up-regulation (potentiation) of neuronal activity in post 
synaptic neurones. It has been demonstrated to be important in the laying down 
of new memories and especially for hippocampal learning (Lynch, 2004). 
Electrophysiological studies have demonstrated that intra-hippocampal total 
ghrelin reduces the threshold for LTP and improves spatial memory in rats 
(Carlini et al., 2010b). An elegant study by Ghersi et al. used 
immunohistochemistry, electrophysiology and behavioural techniques to show 
that total ghrelin increased LTP and that enhanced LTP improved memory in 
rats. They did this by labelling NR2B-1R cells, which are important for LTP, and 
found that these cells are increased with ghrelin administration. The 
electrophysiological threshold for LTP was reduced in ghrelin treated animals 
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but this effect was abolished with NR2B-1R antagonism. Finally, step down 
latency was reduced when ghrelin infusion was preceded by a NR2B-1R 
antagonist (Ghersi et al., 2015). Total ghrelin has also been shown to increase 
pre-synaptic glutamate release, which is thought to be the first step in the 
process of inducing LTP (Izquierdo et al., 2006). Long-term potentiation 
increases the strength of synaptic connections in response to afferent stimuli. 
Diano et al. showed that total ghrelin administration increases synaptic density 
in the hippocampus of wild type mice and ghrelin knockout mice (Diano et al., 
2006). The exact means by which ghrelin reduces the threshold for LTP in the 
hippocampus remains to be elucidated but may include ghrelin induced 
stimulation of receptor expression (AMPA and NMDA receptors) and 
neurotransmitter release in excitatory synapses (Carlini et al., 2010b, Ghersi et 
al., 2015, Ribeiro et al., 2014). Despite uncertainty regarding the underlying 
mechanism, it seems clear that ghrelin enhances LTP and that LTP mediates at 
least some of the pro-cognitive effects of ghrelin seen in rodents.  
Neurogenesis, or the birth of new neurones, occurs in the adult mammalian 
hippocampus, including in humans (Eriksson et al., 1998). It has been proposed 
that these new-born neurones may be important in learning and memory (Deng 
et al., 2010). Animal studies using bromodeoxyuridine (BrdU), which labels 
newborn neurones by binding to DNA during mitosis, have shown that 
neurogenesis is enhanced if exogenous ghrelin is administered. Rats treated 
with total ghrelin and AG have better performance in tests of spatial memory 
including the spontaneous location recognition task, Y-maze and Morris water 
maze. These improvements are accompanied by greater numbers of BrdU 
labelled hippocampal cells, indicating increased neurogenesis compared with 
animals treated with saline (Kent et al., 2015). A study in ghrelin knock out mice 
demonstrated that they have fewer progenitor cells in the subgranular zone of 
the hippocampus than wild types. This corresponded with worse performance 
on the Y maze task and in novel object recognition. All of the deleterious effects 
in the ghrelin knockout mice were rescued with exogenous ghrelin 
administration (Li et al., 2013a). More recently, Cahill et al showed that young 
GHSR1a knockout rats had fewer dendritic spines and fewer newborn neurones 
in the hippocampus compared with young wild type rats. The young rats’ brains 
appeared to have aged prematurely, with dendritic spine density and 
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neurogenesis comparable to middle aged wild type rats. Interestingly, this was 
not reflected in their cognitive performance as tested by the radial arm maze 
and Morris water maze. Middle aged rats did worse with the radial arm maze 
than younger rats, regardless of genotype, and there were no differences in the 
water maze (Cahill et al., 2014). This is interesting as it has been suggested 
that ghrelin may improve memory and may enhance neurogenesis but that 
these effects may be distinct from each other and due to different mechanisms. 
This assertion is based on work in which mice were administered IP or 
intrahippocampal total ghrelin, underwent testing of learning and memory, and 
newborn neurones were labelled in vivo using BrdU. Intraperitoneal, but not 
intrahippocampal, ghrelin increased hippocampal neurogenesis. Conversely 
intrahippocampal, but not IP, ghrelin improved performance on the Morris water 
maze (Zhao et al., 2014). Overall however, the evidence from animal models 
would suggest that ghrelin enhances neurogenesis and that this may have 
positive cognitive effects. 
Most of the animal studies above examined learning and memory acquisition in 
the context of normal cognitive ageing. Cognitive impairment in PD and in other 
dementias does not occur in this context, however. Dementias develop due to 
neurodegeneration of brain structures involved in attention, memory, executive 
functioning, visuospatial function and language. Accordingly, in vitro and in vivo 
studies have been carried out using models of neurodegenerative disease, 
especially AD. In in vitro studies looking at embryonic hypothalamic mouse cell 
lines treated with Aβ oligomers (ABO), ABO caused neuronal cell death via 
apoptosis. This cell death was accompanied by mitochondrial dysfunction and 
increased reactive oxygen species (ROS). These toxic effects were rescued 
when cells were pre-treated with total ghrelin. Moreover, GHSR-1a blockade 
abolished ghrelin’s protective effects (Gomes et al., 2014). Similar results were 
seen for hippocampal neurones, in which total ghrelin improved cell survival, 
reduced oxidative damage and stabilised mitochondria when cells were treated 
with ABO (Martins et al., 2013).  
In vivo, a number of different models have been used and most show positive 
effects of ghrelin on the resultant cognitive deficits. SAMP-8 and 5XFAD mice 
over-express Aβ and develop early cognitive problems as a result. These mice 
have improved cognition, fewer amyloid plaques, a reduced Aβ load and more 
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neurogenesis when treated with total ghrelin (Moon et al., 2014). In a different 
model, in which Aβ is injected into the mouse hippocampi, co-administration of 
intra-hippocampal total ghrelin attenuated the resultant spatial memory 
impairment and improved neuronal survival (Moon et al., 2011). Exogenous AG 
also reduced Aβ deposition and improved memory performance in rats infused 
with ICV Aβ25-35 (Kang et al., 2015b). Finally, APP over-expressing APP-SwDI 
mice had improved Morris water maze performance following treatment with the 
synthetic ghrelin agonist LY444711 (Dhurandhar et al., 2013).  
To date only one animal study has failed to demonstrate positive effect of 
ghrelin on cognition in the context of neurodegeneration. In 2015 Madhavas et 
al created a rat model of AD using treatment with mono-sodium glutamate 
(MSG), which causes obesity in rats. They then looked at Aβ burden, acetyl-
cholinesterase (AChE) levels, known to be high in AD, and performance in the 
Barnes maze task, a test that requires animals to navigate using learned visual 
cues. Obese MSG treated rats had a greater Aβ burden, greater AChE activity 
and reduced performance on Barnes maze. A GHRS1a blocker, [D-Lys3] 
GHRP-6, reduced Aβ burden and AChE and improved Barnes maze test 
performance. Interestingly, [D-Lys3] GHRP-6 also resulted in weight loss and 
increased endogenous ghrelin levels in MSG treated rats. The metabolic profile 
of the animals with regard glucose and lipid handling also improved. It may be 
that improvement in weight and restoration of metabolic profile, including 
increased endogenous ghrelin levels, could have had a hand in the molecular 
and behavioural improvements seen with [D-Lys3] GHRP-6 (Madhavadas et al., 
2014). The overall body of evidence is strongly in favour of a role for ghrelin in 
ameliorating cognitive decline in animal models of dementia. 
Given the strength of the data for rodent models of AD it may be expected that 
human studies would show a strong link between ghrelin and learning and 
memory. There are several studies in support of this. Bellar et al carried out an 
observational study on 28 healthy older adults aged 60-94. Participants had 
fasting total ghrelin levels taken followed by a light snack before undergoing 
cognitive testing. Learning and memory was assessed using the Hopkins verbal 
learning test (HVLT) and global cognition using the mini mental state 
examination (MMSE). Higher fasting total ghrelin levels were associated with 
better performance on HVLT (Bellar et al., 2013).The following year a large 
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observational study looked at single nucleotide polymorphisms (SNPs) of 
ghrelin and cognition in 280 people (137 men and 143 women). Global 
cognition was assessed using the MMSE and people were grouped according 
to MMSE performance, those with a score less than 24 were deemed to have 
cognitive impairment and those with an MMSE of 24 or above cognitively intact. 
They found that SNPs in the ghrelin gene were not associated with altered 
ghrelin levels but that one particular polymorphism called L90G was associated 
with cognitive impairment, even after adjusting for age, gender, alcohol, 
depression, glucose impairment, education and ApoE status (Mora et al., 2014). 
In 2015, Alosco et al looked at fasting total ghrelin, leptin and cognition in 84 
obese patients aged 20-70 prior to and 12 months following bariatric surgery for 
the treatment of morbid obesity. Cognition was tested using IntegNeuro 
computer based cognitive testing which tests attention, executive function, 
verbal interference, memory and language. The authors found that total ghrelin 
levels increased after surgery and that these changes predicted improvements 
in attention and executive function on regression analysis (Alosco et al., 2015). 
More recently, a study of 356 middle aged women, 247 of whom have chronic 
HIV infection demonstrated a positive correlation between cognition and AG 
levels as tested by trail making tests and stroop interference (McFarlane et al., 
2017). Finally, a double-blind placebo controlled randomised crossover study 
examined 21 young men who were administered AG or saline prior to carrying 
out memory tasks during functional MRI (fMRI). The AG treated group had 
increased cortical activity on fMRI after ghrelin infusion. The AG treated 
participants did not demonstrate improved performance in remembering food 
items that they had been shown on a virtual conveyor belt, however. This was a 
small study and may have been underpowered to detect differences in memory 
performance. It could be argued that if there has been a type 2 error here, the 
degree of improvement may not be clinically significant (Kunath et al., 2016). 
Other studies have also shown no, or negative correlations between ghrelin and 
memory performance in healthy adults. Spitznagel et al. studied 35 cognitively 
intact elderly participants. Participants with higher AG levels had worse 
cognitive performance than those with lower levels (Spitznagel et al., 2010). In 
the same year Dresler et al administered ghrelin to healthy adults over night but 
found no improvement in memory consolidation with ghrelin treatment (Dresler 
      
 39 
et al., 2010). It remains to be clarified, therefore, whether or not ghrelin is 
important for learning and memory in adult humans. 
The role of ghrelin in patients with neurodegenerative dementia is similarly 
unclear. Theodoropoulou et al. investigated dynamic total ghrelin levels in 10 
men and 17 women (17) with AD and age- and sex-matched controls. They 
found that the area under the curve for total ghrelin was significantly lower in 
men, but not women, with AD (Theodoropoulou et al., 2012). A study from the 
Netherlands Brain Bank showed that ghrelin, GHSR1a and GOAT expression 
were lower in the inferior temporal lobes of AD patients compared with controls. 
Moreover, GHSR1b, a receptor whose downstream effect is to inhibit ghrelin, 
was increased in AD patients. Together, these data suggest a disordered 
ghrelin response in AD (Gahete et al., 2010). Finally, a Japanese study found a 
small but significant association between a SNP (Leu90GLn) in the gene 
encoding ghrelin and AD. They found this region to be highly polymorphic, 
however, and no other SNPs shared this association (Shibata et al., 2011). 
Conversely, an Iranian study looking at 37 people with AD and 34 controls 
found that fasting AG levels were higher in AD than in control groups. It is worth 
noting that the control group was significantly younger than the AD group, which 
may have confounded results (Akbarzadeh et al., 2013). No studies have 
examined ghrelin in PDD to date. 
Evidence from animal models would suggest that ghrelin is important for 
memory acquisition, especially spatial memory. Despite this, human studies are 
not yet able to clarify whether or not ghrelin is important for cognitive function in 
man. A role for ghrelin in spatial memory is intuitive when we consider the 
problem in evolutionary terms. Ghrelin levels are high in times of calorie 
restriction when improved memory for how and where to acquire food may be 
beneficial. It has been proposed that ghrelin is the “missing link” between 
calorie restriction and cognitive performance. Like ghrelin, calorie restriction has 
been shown to increase neurogenesis in rodents (Ferreira-Marques et al., 2016, 
Li et al., 2013a, Lee et al., 2002). Calorie restriction has also been shown to 
improve cognition in elderly humans (Witte et al., 2009). Even if ghrelin is not a 
cognitive enhancer in and of itself, it may have an important role in 
neuroprotection in neurodegenerative dementias, including PDD. 
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Ghrelin and neuroprotection 
In addition to having a putative role in cognitive enhancement, ghrelin has been 
shown to be neuroprotective in animal models of stroke, traumatic brain injury 
and PD. Although, cell death from necrosis does occur in these conditions, 
apoptosis, or programmed cell death, is a major cause of neuronal loss 
(Anglade et al., 1997, Cheyuo et al., 2011, Lopez et al., 2012). There is 
evidence from animal models that ghrelin reduces neuronal apoptosis and 
improves cell survival in the face of cellular insult. This was first demonstrated in 
2006 by Liu et al who created an ischaemia/ reperfusion brain injury rat model 
by ligating both vertebral arteries and then clamping both carotid arteries for 8 
minutes a control group underwent sham operation. Rats from each group were 
treated with i.p. saline or total ghrelin. The animals were sacrificed and their 
hippocampi examined. Saline treated rats who underwent cerebral 
ischaemia/reperfusion injury had marked hippocampal apoptosis compared to 
animals undergoing sham operation. Ghrelin treated rats had little hippocampal 
apoptosis, whether or not they had ischaemia/reperfusion injury (Liu et al., 
2006). This was then replicated in vitro when hypothalamic cells were deprived 
of oxygen and glucose for 30 minutes, 50% of them underwent apoptosis and 
50% remained viable. Pre-treatment with total ghrelin shifted this balance so 
that up to 83.7% of cells were viable after 30 minutes of glucose and oxygen 
deprivation. The authors demonstrated that ghrelin prevents apoptosis via 
activation of the ERK pathway, an effect which was abolished with GHRS1a 
inhibition (Chung et al., 2007). Since then a number of studies have shown that 
ghrelin increases the  Bcl-2-bax ratio, inhibiting caspase 3 activation and 
thereby reducing apoptosis in neuronal cells in response to a number of 
different insults (Chung et al., 2011, Chung et al., 2008, Hwang et al., 2009, Lim 
et al., 2011a, Xu et al., 2009).  
When mitochondria are damaged, their membranes depolarise and ROS are 
produced, augmenting cellular damage and promoting apoptosis. Ghrelin has 
been shown to reduce apoptosis by preventing both mitochondrial 
depolarisation (Martins et al., 2013) and the release of pro-apoptotic factors 
such as cytochrome C (Dong et al., 2009, Lee et al., 2010a, Lee et al., 2010b, 
Yu et al., 2016). These protective effects may be achieved through uncoupling 
proteins (UCPs), which reduce mitochondrial respiration by diverting oxidative 
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phosphorylation away from the electron transport chain. Uncoupling of 
respiration from mitochondria results in membrane stabilisation, a reduction of 
ROS production and reduced apoptosis. It has been demonstrated that ghrelin 
increases UCP2 expression in hippocampal cells in vitro (Liu et al., 2009). 
Lopez et al demonstrated increased UCP2 in ghrelin treated rats following 
traumatic brain injury. This was associated with reduced caspase 3 activation 
and reduced apoptosis in vivo (Lopez et al., 2012). 
Other ways in which apoptosis may be prevented is through the removal of toxic 
proteins and damaged organelles via autophagy and through a reduction of 
inflammation. Autophagy is important in cellular maintenance and, if disrupted, 
the cellular environment may become toxic leading to mitochondrial damage 
and ultimately cell death. Ghrelin has very recently been shown to increase 
autophagy in rat neurones in vitro via the GHSR1a receptor (Ferreira-Marques 
et al., 2016). Dysregulation of autophagy is thought to be important in 
neurodegenerative disease, including PD. As discussed above, ghrelin is a 
powerful anti-inflammatory. This has been proposed as a further mechanism by 
which ghrelin may be neuroprotective. Neuroinflammation is characterised by 
microglial activation. Ghrelin treatment has been shown to reduce microglial 
activation and neuronal apoptosis in rodents treated with neurotoxins such as 
AβO, kainic acid and 1-methyl-4-phenyl-1,2,3,4-tetrahydropridine (MPTP), with 
attendant improvement in neurological performance in each case (Jiang et al., 
2008, Lee et al., 2010a, Moon et al., 2011, Moon et al., 2009, Yu et al., 2016). 
MPTP is a compound known to be toxic to dopaminergic cells and often used to 
generate animal models of PD (Andrews et al., 2009, Jiang et al., 2008). 
There is good evidence that ghrelin is neuroprotective at least in the context of 
acute insults in rodents. To date, there have been no published trials evaluating 
ghrelin as a neuroprotective agent in humans. 
Ghrelin in Parkinson’s disease 
There is accumulating evidence that ghrelin may be disrupted in PD and 
decreased ghrelin levels have even been proposed as a biomarker for the 
development of PD. In 2011, Unger et al. carried out a cross-sectional study of 
39 PD patients, 11 with REM-sleep behaviour disorder (iRBD) and 20 healthy 
controls. Patients with iRBD are at greatly increased risk of PD compared to the 
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general population and iRBD has therefore been proposed as a pre-motor 
phase of PD. The authors found that recovery of total ghrelin levels after eating 
was attenuated in both the PD and iRBD groups compared to controls and that 
this difference was significant (p=0.002 and p=0.037 respectively) (Unger et al., 
2011). There are limitations to this research. Total ghrelin, rather than AG was 
used. When PD participants were sub-divided into treated and drug naïve PD 
there was no difference between drug naïve participants compared with healthy 
controls, though this may have been due to small sample size. Finally, 
progression from iRBD to PD is not inevitable. Despite this, it suggest that 
ghrelin secretion may be disordered in PD patients. There is further evidence to 
support this hypothesis. A cross-sectional study investigating AG levels in 
patients with PD with weight loss, without weight loss and controls found a 
paradoxical correlation between AG levels and BMI in PD patients with weight 
loss, that is to say that as BMI dropped, ghrelin levels dropped. This is the 
opposite to the trend seen in healthy people in whom weight loss triggers 
increased ghrelin production in order to stimulate feeding behaviour and restore 
body weight. It is worth noting that despite these results, there was no 
significant difference in AG levels between groups (Fiszer et al., 2010). More 
robust evidence comes from a very recent study of fasting AG and total ghrelin 
in 291 people with PD and 303 age matched controls. The authors found that 
both AG and total ghrelin levels were lower in the PD group (p<0.05). 
Interestingly, there was no difference in AG or total ghrelin according to Hoehn 
and Yahr stage. They went on to study the dynamic AG and total ghrelin 
responses to glucose ingestion. Participants with PD had an attenuated AG and 
total ghrelin recovery at 180 minutes (Song et al., 2017). This was a large, well 
designed study measuring both AG and total ghrelin. Taking all of this research 
together it seems likely that that ghrelin secretion is abnormal in PD. We know 
from Braak et al that the DMNV is frequently damaged early in the course of 
PD. Unger et al speculate that disruption of the brain-gut axis via the vagus 
nerve may result in disordered ghrelin secretion in PD (Unger and Oertel, 
2014). 
Ghrelin is likely to be neuroprotective in PD. Neuroinflammation, mitochondrial 
instability, disordered autophagy and, ultimately, apoptosis are all implicated in 
the pathogenesis of PD and reduced by ghrelin. Studies using animal models of 
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PD support this. Jiang et al. pre-treated mice with intra-cerebroventricular total 
ghrelin prior to administering MPTP and found that ghrelin prevented MPTP 
induced nigral cell apoptosis (Jiang et al., 2008). Similarly, Andrews et al. 
demonstrated that intraperitoneal ghrelin protected mice from MPTP-mediated 
dopaminergic cell loss through upregulation of UCP2 and consequent 
mitochondrial membrane stabilisation. Ghrelin and GHSR1a knockout mice 
were more susceptible to dopaminergic cell loss from MPTP than wild types 
(Andrews et al., 2009). In the same year, Dong et al showed that total ghrelin 
stabilised mitochondria and reduced apoptosis in dopaminergic cells in vitro and 
Moon et al. found that total ghrelin pre-treatment reduced microglial activation 
and reduced dopaminergic cell loss in the mouse SNpc in vivo (Dong et al., 
2009, Moon et al., 2009, Yu et al., 2016). More recently, Yu et al treated 
dopaminergic cells with the mitochondrial poison rotenone, which causes 
parkinsonism in animal models. The cells showed mitochondrial dysfunction 
and apoptosis following treatment and these effects were ameliorated by pre-
treatment with total ghrelin (Yu et al., 2016). Finally, Bayless et al showed that 
AG, not UAG is responsible for neuroprotection against MPTP as cell loss was 
reduced with AG, but not UAG, administration to ghrelin knock out mice (Bayliss 
et al., 2016a). There is, in summary, good evidence for a role for ghrelin in 
neuroprotection in PD. 
If ghrelin levels are low in PD and ghrelin is neuroprotective, it is possible that 
pathological progression in PD is accelerated by the loss of endogenous 
neuroprotection by ghrelin. Ghrelin would therefore appear to be an attractive 
area for research in the development of disease modifying therapy, with 
potential roles in slowing disease progression and preventing cognitive decline. 
Ghrelin may also be a candidate for symptomatic treatments in PD. GHSR1a 
and D1 dopamine receptors co localise throughout the brain, including in the 
substantia nigra (Jiang et al., 2006). There is evidence that ghrelin increases 
augments dopamine release in the SNpc, at least in response to MPTP in 
animal models (Andrews et al., 2009). Ghrelin has also been demonstrated to 
augment extracellular dopamine release in the dopaminergic-cholinergic reward 
circuits (NAc and VTA) of rodents (Jerlhag et al., 2007, Jiang et al., 2006, 
Abizaid et al., 2006). This effect is attenuated by GHSR1a antagonism, 
suggesting that ghrelin induced dopamine release is mediated by ghrelin acting 
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at GHSR1a (Jerlhag et al., 2012b). It is therefore plausible that ghrelin could 
improve motor symptoms. Moreover, ghrelin increases gut motility and may 
improve symptoms of gastroparesis and constipation, which are common in PD 
(Barboza et al., 2015). Animal studies have shown that ghrelin reverses 
levodopa-induced gastroparesis and the ghrelin agonist HM01 is prokinetic and 
relieves constipation in animal models of PD (Wang et al., 2012, Karasawa et 
al., 2014). A ghrelin agonist is currently being trialled as a treatment for 
constipation in people with PD (Schrag et al., 2015).  
The effects of dopamine on ghrelin activity are less clear. A study using cultured 
ghrelin-producing MGN3-1 (mouse ghrelinoma) cells found that the D1 agonist 
fenoldopam stimulated ghrelin release but the D2/D3 agonist bromocriptine did 
not (Iwakura et al., 2011). Another study in Sprague-Dawley rats found that high 
dose antagonism of D1 (with the experimental drug SCH23390) and D2 and D3 
receptors (with eticlopride) reduced ghrelin-induced food intake in these 
animals. The authors also found that D1 and D2 stimulation with the agonists 
SKF38393 (D1) and quinpirole (D2) attenuated the orexigenic effects of 
exogenous ghrelin, an apparently directly opposing finding (Romero-Picó et al., 
2013). The role of dopamine in the control of ghrelin release and signalling 
therefore remains unclear. Weight gain has been reported in patients treated 
with dopamine agonists, largely attributed to compulsive eating (Nirenberg and 
Waters, 2006). It is difficult to fully exclude ghrelin as a contributor to this 
phenomenon. Against this, only D1 agonism has been shown to increase ghrelin 
and even then only in vitro studies (Iwakura et al., 2011). The most commonly 
prescribed dopamine agonists pramipexole and ropinirole have negligible D1 
activity, exerting their effects on D2 and D3 receptors instead (Gerlach et al., 
2003). Further research is needed to definitively clarify this relationship. 
No studies have yet been carried out looking at cognition and ghrelin in PD. 
Taking together the evidence suggesting that; 1) weight loss predisposes to 
cognitive decline in PD, 2) weight loss in PD may be associated with abnormally 
low ghrelin levels, 3) ghrelin may be a cognitive enhancer and 4) ghrelin is likely 
to be neuroprotective in PD, it is reasonable to hypothesise that lower ghrelin 
levels may be associated with cognitive decline in PD.  
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Insulin-like growth factor-1  
Insulin-like growth factor 1(IGF-1) is not directly involved in the maintenance of 
body energy stores, and may not therefore be described as a hormone of 
energy homeostasis. It is, however, intimately linked to ghrelin, may have a role 
in learning and memory and has been proposed to be neuroprotective in 
neurodegenerative disease so it is important to consider here. The majority of 
IGF-1 is produced by the liver in response to GH, which is itself stimulated by 
ghrelin. Ghrelin has been shown to increase insulin-like growth factor when 
administered to rats (Nagaya et al., 2001b). Interestingly, this has not yet been 
demonstrated in humans (Nagaya et al., 2001a). Up to 80% of IGF-1in the 
circulation and CSF is protein bound to IGF-1 binding proteins (IGFBP) 
(Paolisso et al., 1997). Insulin-like growth factor-1 is actively transported across 
the BBB at the choroid plexus (Torres-Aleman, 2000) and locally within the 
brain, especially during neural development and synaptogenesis (Åberg et al., 
2006). IGF-1 binds with its receptor but also insulin and insulin-like growth 
factor-2 receptors, though it has greatest affinity for its own receptor (Sara and 
Hall, 1990). IGF-1 receptors are expressed throughout the BBB and brain but 
especially in the choroid plexus, cortex and striatum (Åberg et al., 2006). As 
with GH, levels of IGF-1 decline with age (Al-Delaimy et al., 2009, van Dam and 
Aleman, 2004) and, in keeping with its’ relationship to ghrelin, IGF-1 levels tend 
to decline with increasing BMI (Faupel-Badger et al., 2009). IGF-1 is a 
mitogenic hormone, which is to say that it promotes tissue maintenance through 
the birth of new cells. This has been shown to occur in the brain as well as in 
other tissues (Åberg et al., 2000, Åberg et al., 2006). This was recognised as 
early as the 1990s and there is therefore a large body of research investigating 
putative cognitive enhancement and neuroprotective properties of IGF-1. 
To my knowledge, the first study to show that IGF-1 may be important in 
cognition was carried out in 1997 by Paolisso et al who demonstrated that free 
IGF-1 expressed as a high IGF-1:IGFBP ratio correlated with MMSE 
performance in Italian centenarians (Paolisso et al., 1997). Two further 
confirmatory studies quickly followed. In 1998 Rollero et al demonstrated that 
serum IGF-1 levels correlated with MMSE in older adults. The following year 
Aleman et al. demonstrated that IGF-1 levels were positively correlated with 
performance on the digit symbol substitution test and concept shifting tasks in 
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25 healthy older men, even after adjustment for age. Performance in these tests 
commonly declines with age, whereas reading ability, general knowledge and 
vocabulary do not. The authors proposed that declining IGF-1 levels may be 
responsible for, or at least contribute towards cognitive decline with ageing 
(Aleman et al., 1999). Since then, these findings have been widely replicated 
(Table 4) and a meta-analysis in 2009 confirmed that IGF-1 levels positively 
correlate with cognition in healthy older people (Arwert et al., 2009).  




Table 4. Human studies exploring the relationship between IGF-1 and cognition 
Study Population studied Mean age (years ± SD) Study 
design 
Outcome 
(Aleman et al., 
1999) 




IGF-1 levels correlated with performance on digit symbol substitution test 
(p=0.009)and concept shifting task (p=0.005) 
(Adamis et al., 
2009) 
67 people aged over 70 admitted to 
elderly medical unit (48 women) 
82.4 ± 6.3 Observational 
prospective 
IGF-1 negatively correlated with presence and severity of delirium (p<0.05)  
(Adamis et al., 
2014) 
142 people admitted consecutively 
to elderly care  (98 women) 
84.8 ± 6.4 Longitudinal 
observational 
IGF-1 negatively correlated with disease severity IGF-1 positively correlated 




1535 Healthy older people adults 
from Rancho Bernardo Study (899 
women) 
Median age 74 Retrospective 
cross-
sectional  
IGF-1 positively correlated with IGFBP-1. MMSE, trail making B and verbal 
fluency performance in men but not women (p=o.oo1). IGFBP-1 was 
inversely correlated with MMSE in men (p=0.02).  
(Aleman et al., 
2000) 
17 healthy men aged 66-76 
 
70.1 ± 3.39 Cross-
sectional 
IGF-1 positively correlated with concept shifting task (p≤0.01) No correlation 
with tests that do not decline with age (Benton judgment line of orientation 
test and Brus reading test). 
(Angelini et 
al.) 
75 people with hypertension 
 (48 women) 
78 Cross-
sectional 
IGF-1 correlated with improved global cognition (MMSE p=0.012, CAMCOG 
0.027 and FAB 0.004) 
(Arai et al.) 49 Japanese male and female 




The cohort was divided along the 50th percentile for IGF-1. The high IGF-1 
group had significantly less dementia than the low IGF-1 group (9=0.043)  
(Arwert et al., 
2005) 
24 elderly people  (10 women) 
 
80.8±2.3 low IGF-1 and 




The cohort was split into high and low IGF-1 groups. The high IGF-1 group 
had improved reaction times on the (p<0.04). 
(Bellar et al., 
2011) 





Higher levels of IGF-1 correlated with improved TMTB performance (p=0.01) 
and Ruff’s test for attention (p=0.011). 
(Dik et al., 
2003) 
1318 older people from the 
Longitudinal Aging Study 
Amsterdam 
N= 1022 at 3 years  




3 year follow 
up 
Cognitive performance worst in the lowest IGF-1 quintile at baseline Possible 
threshold effect after 3rd quintile. The lowest 3 quintiles had greater cognitive 
decline over 3 years (RR 2.5 CI 1.37-3.44 in lowest quintile). 
 
(Doi et al., 
2014) 
3355 Japanese older people from 
the Obu Study of Health Promotion 




All positively correlated with IGD-1 (p<0.001) 




Study Population studied Mean age (years ± SD) Study design Outcome 
(Euser et al., 
2008) 
1015 men and women over 85 from 
the Leiden 85-plus study (68% 
women) 
87.4 ±3.1 Longitudinal 
(5 year follow 
up) 
Number of SNPs in the IGF-1 gene(suggesting disrupted IGF-1 signalling)  
negatively correlated with cognition in women (OR of cognitive decline 1.28 
CI 1.06-1.53 per polymorphism)  
(Green et al., 
2014) 
746 men from the Caerphilly 
Prospective Study who had blood 






No association between baseline IGF-1 and cognition at follow up. 




IGF-1 was positively correlated with TMT A performance but no other 
cognitive tests (p<0.001) 
(Kalmijn et al., 
2000) 
186 healthy older men and women 
from the Rotterdam Study (50% 
women) 
67.4 ±5.6 at baseline Longitudinal 
(1.9 year 
follow up) 
Reduced rate of cognitive decline with higher IGF-1 levels (OR 0.65 CI 0.44-
0.95) 
(Landi et al.) 353 older Men and women from the 
Invechiamento e Longivita nel 




Lower IGHF-1 levels were associated with cognitive impairment 




IGF-1 positively correlated with performance on AVLT and negatively 
correlated with mood. Depression and poor cognitive performance were 
correlated in low, but not high LGF-1 groups.  
(Okereke et 
al., 2005) 












460 men from the Physicians’ 






Higher levels of free IGF-1 correlated with improved global cognition 
(p=0.02) 
(Rollero et al., 
1998) 
22 older Men and women (7 
women) 
 




IGF-1 correlated with performance on MMSE 
(Paolisso et 
al., 1997) 
30 adults <50, 30 adults aged 75-
99, 19 adults >100 
Men and women (46%, 56% and 
57% women respectively) 
44.5±1.8, 78±0.7 and 





IGF and IGFBP-3 declined with age. Centenarians had a greater IGF-
1/IGFBP-3 ratio. IGF-1IGFBP-3 correlated with cognition in centenarians 
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The picture is less clear in neurodegenerative dementias, with high, low and 
normal levels of IGF-1 associated with dementia depending on the study (Table 
5). This may be due, in part, to different subject selection between studies and 
may reflect the complex interaction with other hormones and dynamic nature of 
IGF-1 and insulin signaling across the life course. It has been suggested that 
IGF-1 action may be disordered in AD due to BBB pathology and disrupted 
receptor signaling. This is supported by the literature as some of the studies 
showing higher serum IGF-1 in AD have found that CSF IGF-1 is not elevated 
(Johansson et al., 2013, Tham et al., 1993). In this model higher IGF in the 
peripheral circulation may be compensatory (Trejo et al., 2007b). A post-
mortem study of the brains of AD sufferers and controls found Aβ induced IGF-1 
resistance and disordered downstream signaling (Talbot et al., 2012). 
Alternatively, the relationship between cognition and IGF-1 may not be linear in 
degenerative dementias. In support of this some human studies have 
demonstrated a threshold effect for cognition and IGF-1 in degenerative 
dementias, below which lower IGF-1 is associated with greater impairment but 
above which further increase in IGF-1 does not confer added benefit (Watanabe 
et al., 2005, Westwood et al., 2014). It therefore remains possible that IGF-1 
has positive effects on cognition in neurodegenerative disease. There is 
certainly compelling evidence from animal studies that brain IGF-1 may be 
neuroprotective. Numerous studies have shown increased neurogenesis, 
reduced apoptosis, reduced neuroinflammation and increased cell survival with 
IGF-1 treatment in animal and in vitro models of  diabetes-induced cognitive 
impairment, head injury, stroke and AD (Åberg et al., 2000, Bake et al., 2014, 
Carro et al., 2006, Carro et al., 2002, De Geyter et al., 2016, De Magalhaes 
Filho et al., 2016, Doré et al., 1997, Hu et al., 2015, Lichtenwalner et al., 2001, 
Lupien et al., 2003, Lupien et al., 2005, Saatman et al., 1997, Trejo et al., 
2007a, Trejo et al., 2007b). Furthermore, the anti-apoptotic actions of IGF-1 
appear to be mediated by PI3K/Akt activation, which is implicated in Aβ 
handling and reduced tau hyperphosphorylation (Wen et al., 2008). Finally, 
there is good evidence that IGF-1 has positive effects on Aβ clearance from the 
brain parenchyma through recruitment of amyloid binding proteins such as 
albumin and transthyretin across the blood brain barrier (Carro et al., 2002). 
Despite this, therapeutic trials of IGF-1 replacement have been disappointing, 
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and no clinically meaningful improvement in cognition has yet been 
demonstrated with exogenous IGF-1 in humans (Sevigny et al., 2008).  
In addition to work in AD, there are a number of studies examining IGF-1 in PD. 
Again, there is discordance in the literature (Table 6) but meta-analysis 
suggests that IGF-1 levels are increased in early PD compared to controls (Li et 
al., 2015b). The pattern of change in IGF-1 levels with disease progression is 
still debated. One study reports greater disease severity (measured by the part 
3 of the movement disorder society unified Parkinson’s disease rating scale 
[MDS UPDRS]) in the highest quartile of IGF-1, though similar levels of disease 
severity are seen in the lowest quartile (Numao et al., 2013). Conversely, 
another study reported a negative correlation between IGF-1 and disease 
severity though statistical significance was lost with correction for both age and 
BMI (Suzuki et al., 2014). Disease duration has also been reported to negatively 
correlate with IGF-1 levels in PD (Godau et al., 2009). It has been argued that 
increased IGF-1 in early PD may represent upregulation in the face of neuronal 
damage (Godau et al., 2009). An alternative interpretation of these data is that 
elevated IGF-1 levels increase the risk of PD, through as yet unclear means 
(Godau et al., 2011). This has been suggested due to the observation that 
reduced IGF-1 signaling may increase longevity, even in humans, and may also 
increase neuronal tolerance to oxidative stress, implicated in neuronal loss in 
PD (Holzenberger et al., 2003, Van Heemst et al., 2005). Against this 
hypothesis, there is evidence of disordered IGF-1 signaling in PD, which would 
be unexpected if reduced signaling was protective. A post-mortem study of the 
brains of people with PD, DLB and controls demonstrated impaired IGF-1 
signaling in PD and DLB compared to controls, with a greater degree of 
impairment in DLB. Moreover, data from an epigenetic studies showed that 
gene regulation for IGF-1/PI3K/AKT signalling was impaired in post-mortem 
brains of people with PD compared to controls, again suggesting that reduced 
IGF-1 signalling failed to confer an advantage (Kim et al., 2014). Moreover, 
there is a wealth of evidence from animal models that IGF-1 may be 
neuroprotective in PD, through neuroproliferative, anti-inflammatory and anti-
apoptotic mechanisms similar to those described above (Arboleda et al., 2007, 
Guan et al., 2000, Quesada et al., 2008, Wang et al., 2010), along with changes 
in α-synuclein handling. An in vitro study of cultured SH-SY5Y neuroblastoma 
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cells showed that exogenous IGF-1 was able to prevent α-synuclein 
aggregation in response to dopamine treatment, through activation of the 
PI3K/Akt pathway (Kao, 2009).  
There has been one study attempting to examine IGF-1 in cognition in PD to 
date. Pellecchia et al. carried out a longitudinal observational study of 65 people 
with newly diagnosed PD. They found that baseline IGF-1 positively correlated 
with executive function at baseline and at 2 years. Moreover, lower IGF-1 levels 
at baseline were associated with steeper cognitive decline (Pellecchia et al., 
2013).  
Although ongoing research is needed to clarify the role of IGF-1 in 
neurodegenerative disease, it is plausible that it is neuroprotective in PD and 
may even ameliorate cognitive impairment in PD. It is possible that this is a 
further means by which ghrelin may exert neuroprotective effects.
       




Table 5. Studies exploring the relationship between IGF-1 and dementia 
Study Population studied Mean age years (±SD) Study design Outcome 
(Alvarez et 
al., 2005) 
141 AD, 56 MCI and 30 controls (total 227) 
 
75.25 ± 8.59 AD, 72.87 
±8.14 MCI and 68.87 
±8.77 controls 
Case control IGF-1 lower in AD than controls after age adjustment ( p<0.05) 
(Duron et 
al., 2012) 
694 older Men and women with and without 
AD 
N=224 AD, 257 MCI, 213 controls  
78.6±6.7 Case control IGF-1 positively correlated with cognition in men across all groups 
(p<0.01) and higher IGF-1 levels correlated with a reduced risk of 




367 older adults 72 AD, 75 VaD, 14 mixed 
dementia, 209 controls 
77±6 dementia  
69 ±5 controls 
Case control IGF-1R gene polymorphisms were more common in women with 
VaD than other groups.  
(Johansson 
et al., 2013) 
80 older men and women  
N= 32 AD, 13 stable MCI, 15 other dementia 
and 20 controls. 
75 AD, 72 MCI, 74 
other dementias, 75 
controls 
Case control Serum IGF-1 elevated in AD (p=0.01) and other dementias 
(p<0.05). Over the whole cohort IGF-1 negatively correlated with 
CSF amyloid. CSF/serum IGF-1 ratio lower in the dementia group, 
(Kimoto et 
al., 2015) 
70 Japanese men and women with AD and 
10 with MCI 
 
Median age 78 
 
Cross-sectional IGF-1 levels correlated with Aβ42/Aβ40 ratio (p=0.007), which is 
thought to represent improved Aβ42 clearance IGF-1 was 
correlated with performance on cognitive tests (p<0.001). 
(Salehi et 
al., 2008) 
82 men and women  
N=41 with AD and 41 controls 
61-75 Cross-sectional CSF IGF-1 is higher in AD than in controls  
(Talbot et 
al., 2012) 
Post mortem AD and normal controls from 
the University of Pennsylvania and the 
Religious Orders Study.  
 Post-mortem Severe insulin and IGF-1 resistance in AD brains compared with 
controls, IGF-1 levels were not different between groups  
(Rivera et 
al., 2005) 
Post mortem study of brains from people 
with AD 




20 people; 10 healthy men, 6 men and 4 
women with AD 
65-83 (controls) 
63-74 (AD) 
Case-control Serum IGF-1 was elevated in people with AD compared to 
controls, though CSF IGF-1 was not. 
(Watanabe 
et al., 2005) 
436 Japanese men and women N=106 AD, 
103 VaD, 227 controls 
79±7 AD, 77±8VaD, 
76±10 control  
Case control IGF correlated with MMSE across the whole cohort. No added 
benefit above 50th percentile. Low IGF-1 associated with AD (OR 
2.1 CI 1.21-3.64) and VaD (OR 3.4 CI 2.1-5.61) 
(Watanabe 
et al., 2004) 
60 Japanese men and women over 65, 35 
VaD and 25 controls 
79±9 VaD, 76±6 
controls 
Case control IGF-1 correlated with performance on MMSE across all groups. 
IGF-1 was lower in VaD patients than controls. 
(Westwood 
et al., 2014) 
3582 dementia-free older men and women 
from the Framingham Study 
65±11 Longitudinal ( 7.9 
year follow up) 
230 incident cases of AD and 49 with other dementias. Lowest 
quartile of IGF-1 at baseline was associated with increased risk of 
AD (HR 1.51 CI 1.14-2.00) 
(Van Exel 
et al., 2014) 
406 adults, 206 children of people with AD 
and 200 people with no family history of AD 
 Case control IGF-1 levels higher in the children of AD sufferers than controls. 
 
 
       




Table 6. Studies exploring the relationship between IGF-1 and Parkinson’s disease 
Study Population studied Mean age years 
(±SD) 
Study design Outcome 
(Bernhard et 
al., 2016) 
37 men and women with PD and 22 healthy 
controls from the Modelling Epidemiological data to 
Study Parkinson’s disease progression (MODEP) 
study  
64±7 Longitudinal 4 year 
follow up  
IGF-1 higher in PD than controls at baseline (p=0.026). 
When stratified for disease severity levels only significant 
in moderate PD (p=0.004). No differences in IGF-1 
decline over time between groups 
(Godau et al., 
2009) 
12 men and women with established PD 6 with 
newly diagnosed PD and 12 controls for 
established PD and controls, 33% for new PD 
66±6 established PD 
and controls,  
67±9 new PD 
Longitudinal 6 month 
follow up 
IGF-1 levels higher in PD patients (p<0.001). IGF-1 
negatively correlated with disease duration. 
(Godau et al., 
2011) 
15 men and women with untreated PD and 139 
healthy controls 
69±9.3 PD and 60.6 
±6.6 controls 
Cross-sectional IGF-1 higher in PD than controls (p=0.004. Motor  
disease severity(MDS UPDRS) negatively correlated with 
IGF-1  
(Ma et al., 
2015) 
216 Chinese men and women 100 with PD, 40 with 
essential tremor (ET) and 76 controls  
67.84 ± 9.89 PD, 
70.85 ± 11.39 ET and 
67.75 ± 8.55 controls 
Cross-sectional IGF-1 increased in PD compared to ET and controls 
(p<0.001). No correlation between IGF-1 and disease 
duration or levodopa dose equivalent (LED). IGF-1 
correlated with cognition in PD (p=0.026). 
(Mashayekhi et 
al., 2010) 
76 Iranian men and women people 38 with PD and 
38 controls 
58-78 Cross-sectional IGF-1 and IGFBP higher in PD (both p<0.001 
(Numao et al., 
2013) 
172 Japanese Men and women, 79 with PD, 25 
with MSA, 16 with PSP and 52 healthy controls 
 
66.9±1.9 for MSA, 
68.1± 1.1 PD, 72.7 
±2.0 PSP and  65.6 
±1.2controls 
Cross-sectional IGF-1 levels were higher in MSA patients compared to 
PD and controls (p<0.001). Trend towards increased 
IGF-1 in early PD compared to controls not statistically 
significant. In PD patient IGF negatively correlated with 
disease severity but significance was lost when corrected 
for BMI and age (Suzuki et al.). 
(Pellecchia et 
al., 2013) 
65 men and women  with newly diagnosed PD  
  
58.5±8.3 Longitudinal (2 year 
follow up) 
IGF-1 correlated with executive function at baseline and 
baseline IGF negatively correlated with cognitive decline 
over 2 years.  
(Picillo et al., 
2013) 
37 men and women with newly diagnosed PD and 
60 controls 
 
59.4 ±9 PD and 58.8 
±7 controls 
Longitudinal (2 year 
follow up) 
IGF-1 was higher in PD than in controls (p=0.01). The 
highest IGF-1 quartile has significantly more severe 
motor symptoms compared to the third and second 
quartiles, but not the lowest quartile (p=0.002. 0.005 and 
0.1 respectively). 
(Tong et al., 
2009) 
Brains from 7 people with PD, 8 with DLB and 8 
controls 
 Post-mortem IGF-1 receptor expression reduced in PD and DLB 
brains. IGF-1 resistance more pronounced in DLB 
(Tuncel et al., 
2009) 
25 men and women people with PD and 25 
controls 
Mean age  
67.9±9.4 PD and 
64.3±8 controls 
Cross-sectional There was a trend toward higher IGF-1 levels in PD but 
this did not reach significance. 
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2.3.3 Insulin 
Insulin is a 51 amino acid protein that was identified and isolated by Banting 
and Best in 1921(Banting et al., 1922). Their discovery was lifesaving and 
revolutionised the treatment of type 1 diabetes, where there is profound insulin 
deficiency. Insulin is produced by pancreatic β-cells in the islet of Langerhans in 
response to rises in serum glucose. Insulin must be cleaved to release C-
peptide before becoming biologically active (Begg and Woods, 2012). It acts via 
its receptor (IR) to enable glucose uptake into cells for respiration, suppress 
gluconeogenesis (production of glucose from fats) and glycogenolysis 
(breakdown of glycogen into glucose) in liver and stimulation of glycogen 
storage in muscle (Begg and Woods, 2012, Møller et al., 2004). The net result 
is a reduction in circulating glucose levels. As with ghrelin there is both phasic 
and tonic variation in insulin levels. Phasic secretion of insulin occurs in 
response to ingestion of carbohydrates (Holt et al., 1992). Tonic or “basal” 
insulin secretion is proportional to body fat (Bagdade et al., 1967, Woods et al., 
1979). 
Insulin is predominantly a metabolic hormone but, like ghrelin, it demonstrates 
pleiotropy (Kullmann et al., 2016). It was thought historically that insulin did not 
act within the brain as it cannot diffuse across the blood brain barrier. We now 
know that insulin crosses the BBB through a saturable transporter system 
(Banks et al., 1997). There are insulin receptors throughout the brain as well as 
the peripheral tissues (Hill et al., 1986). Once insulin crosses the BBB it binds 
with IR throughout the brain and is proposed to reduce food intake, enhance 
cognition and modulate reward (Lattemann, 2008).  
Although insulin is proportional to body fat, type 2 diabetes often occurs in 
obesity. Obesity and hyperglycaemia in the face of high levels of circulating 
insulin illustrate the phenomenon of insulin resistance (Reaven, 1988). The 
exact mechanism of insulin resistance is controversial but may be due to 
chronically elevated insulin levels leading to inactivation of insulin receptors. 
This then leads to tissues becoming relatively insensitive to circulating insulin 
(Shulman, 2000). It is thought that this process occurs both centrally, in brain 
tissue, and peripherally in tissues such as muscle and solid organs (Anthony et 
al., 2006, Hallschmid and Schultes, 2009, Reaven, 1988). 
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Insulin resistance and diminished insulin production are more common as 
people age due to increased adiposity and sarcopaenia (Møller et al., 2004). It 
has been suggested that relative insulin deficiency and insulin resistance are an 
inevitable consequence of biological senescence (Elahi et al., 2002). Neither 
increased adiposity or sarcopaenia is inevitable in old age, however, and recent 
studies suggest that type 2 diabetes may be reversible with calorie restriction 
and its attendant weight loss (Lim et al., 2011b). This would argue against 
insulin deficiency and resistance as a normal part of ageing. 
Insulin and appetite control 
There is strong evidence from animal studies that insulin is an appetite 
suppressant hormone. This may surprise some clinicians as it has long been 
noted that exogenous insulin therapy in diabetes is associated with weight gain 
(Russell‐Jones and Khan, 2007). It was previously thought that this was due to 
insulin itself (Rodin, 1985) but it is now felt that weight gain associated with 
insulin therapy is not due to insulin but due to improved utilisation of ingested 
glucose and increased carbohydrate intake due to fear of hypoglycaemia 
(Russell‐Jones and Khan, 2007). As previously mentioned, basal insulin levels 
are proportional to adiposity and insulin is transported across the BBB into the 
CNS. Insulin is therefore able to provide negative feedback to the brain about 
total peripheral energy stores as an adiposity signal. Once in the CNS insulin 
acts via IR at the hypothalamus to suppress appetite in three main ways; 1) 
increased POMC neurone activity, leading to an increase in anorexigenic αMSH 
(Benoit et al., 2002), 2) inhibition of orexigenic NPY neurones (Schwartz et al., 
1992) and, 3) modulation of responses to other hormones of energy 
homeostasis such as increased sensitivity to cholecystokinin (CCK) (Riedy et 
al., 1995) and suppression of ghrelin (Griffen et al., 2006, Ryber et al., 2006). 
Central insulin administration has been shown to reduce energy intake in 
baboons, chicks, pigs, mice and rats (Air et al., 2002a, Air et al., 2002b, Anika 
et al., 1980, Brown et al., 2006, Chavez et al., 1996, Foster et al., 1991, Honda 
et al., 2007, Ikeda et al., 1986, McGowan et al., 1992, McGowan et al., 1990, 
Schwartz et al., 1992, Woods et al., 1979). Moreover, treatment with insulin 
receptor anti-sense and insulin antibodies have both been shown to induce 
hyperphagia in animal models (McGowan et al., 1992, Obici et al., 2002). 
Human studies have also shown insulin to be anorexigenic (Flint et al., 2006, 
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Kroemer et al., 2013, Pal and Ellis, 2010, Pasiakos et al., 2011, van Golen et 
al., 2014). Not all findings have been consistent, however, with some studies 
finding no relationship between insulin levels and appetite (Chapman et al., 
1998, Holt et al., 1992, Lavin et al., 1998). To resolve this, a meta-analysis was 
conducted in 2007 looked at data from 7 test-meal studies in human subjects. 
One hundred and eighty participants were included in the studies, 136 normal 
weight and 44 overweight or obese individuals. In all 7 studies insulin levels and 
measures of hunger were assessed after an overnight fast and participants 
were offered an ad libitum meal where their food choices and caloric intake 
were recorded. Multivariate analysis showed that insulin level correlated with 
post-prandial fullness, and had an inverse correlation with energy intake and 
hunger in normal weight but not obese individuals (Flint et al., 2007). This is 
supported by subsequent work carried out by Pal and Ellis, who showed that 
increased insulin responses to ingesting proteins were associated with lower 
hunger and reduced ad libitum intake at a subsequent meal (Pal and Ellis, 
2010). More recently, Kroemer et al used functional magnetic fMRI to examine 
neural responses to food images whilst asking participants to rate their 
subjective hunger using a visual analogue scale. They found that higher insulin 
levels in response to an oral glucose tolerance test were associated with 
reduced subjective hunger and reduced activation of a number of brain areas, 
(including the temporal and parietal cortices, thalamus, amygdala and 
hippocampus) which had been activated by food imagery but not by control 
pictures (Kroemer et al., 2013). Finally, there has been a great deal of interest 
in the synthetic insulin detemir as this appears to cause less weight gain than 
other insulins used in the treatment of diabetes. It has been suggested that this 
is due to changes in its structure making it lipophilic, and therefore able to cross 
the blood brain barrier, so having a central effect on appetite. A double blind 
randomised control trial of 32 people with type 1 diabetes found that CNS 
insulin levels were higher with detemir treatment than with other isophane 
insulins. Detemir treatment was associated with weight loss of 0.8kg, rather 
than the weight gain of 0.5kg seen with isophane insulin over the 12 week study 
period. It is worth noting that this was a drug-company funded study and should, 
perhaps, be interpreted with caution (van Golen et al., 2014). 
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Part of the reason that it has taken time for insulin to be recognised as an 
anorexigenic hormone is due to the confounding effects of hypoglycaemia in the 
presence of hyperinsulinaemia. Attempts have therefore been made to 
dissociate the peripheral effects of insulin from its CNS effects. One way that 
this has been achieved is with intranasal insulin. Intranasal insulin is absorbed 
into the CSF but does not pass into the peripheral circulation and, therefore, 
does not cause hypoglycaemia (Kern et al., 1999). In 2004, Hallschmid et al. 
carried out a double blind randomised control trial in which they administered 
intranasal insulin or placebo to 20 healthy volunteers (12 men and 8 women) 
over a period of 8 weeks. The men in the treatment group lost on average 
1.38kg of adipose tissue compared to the placebo group (p<0.05) but no effect 
was seen for women. The authors propose that insulin may be a relatively more 
potent appetite suppressant in men compared to women as men have relatively 
more insulin-producing visceral fat. Women, by contrast, are proposed to be 
more responsive to leptin as their fat stores tend to be subcutaneous 
(Hallschmid et al., 2004). This was corroborated by Benedict et al who found 
that intranasal insulin reduced ad libitum food intake in men but not women 
following a fast (Benedict et al., 2008). 
Insulin and cognition 
Insulin receptors are found throughout the brain, not just at the ARC. There are 
areas of dense expression in the cortex, hippocampus and olfactory bulb 
(Fernandez and Torres-Alemán, 2012).  Over the last 20 years or so it has 
become increasingly clear that CNS insulin is important in cognition and in 
neurodegenerative diseases, including PD and AD. Diabetes, especially in mid-
life, has been shown to increase the risk of developing AD with an odds ratio of 
1.65 according to a recent meta-analysis (Cooper et al., 2015). This may be due 
at least in part to cerebrovascular disease, analogous to the micro- and macro-
vascular sequelae of diabetes seen in the kidneys, peripheral nervous system 
and retina (Ribe and Lovestone, 2016). There is also, however, good evidence 
for a more direct link between insulin and cognition. Insulin signalling results in 
the downstream reduction of glycogen synthase 3 (GSK3) activity, which is pro-
apoptotic, tau phosphorylating, reduces LTP and is itself inactivated by LTP 
(Hooper et al., 2007). In keeping with this, numerous animal studies have 
shown that hippocampus dependent learning is improved with acute insulin 
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administration (Biessels et al., 1998, Haj-Ali et al., 2009, Moosavi et al., 2007, 
Park et al., 2000, Stern et al., 2014). This has been replicated in humans with 
several studies in people with and without dementia demonstrating improved 
cognition with acute euglycaemic administration of exogenous insulin IV or 
intranasally (Benedict et al., 2004, Benedict et al., 2008, Claxton et al., 2015, 
Craft et al., 2003, Craft et al., 1999, Craft et al., 2012, Craft et al., 1996, Krug et 
al., 2010, Reger et al., 2008, Watson et al., 2003, Watson et al., 2009). There 
appears to be a u-shaped relationship between circulating insulin and cognition. 
Several studies have shown that hyperinsulinaemia, even in people without 
diabetes, is associated with poorer cognitive performance (Burns et al., 2012, 
Luchsinger et al., 2001, Schrijvers et al., 2010, Stolk et al., 1997). It is felt that 
hyperinsulinaemia is associated with down-regulation of IR in the CNS, causing 
brain insulin resistance (Cholerton et al., 2013). People with AD have been 
demonstrated to have a lower CSF to plasma insulin ratio compared to age 
matched controls, despite higher circulating plasma levels (Craft et al., 1998). 
Brain insulin resistance has been described as the metabolic link between type 
2 diabetes and AD (Kullmann et al., 2016). Alzheimer’s disease is associated 
with peripheral insulin resistance in vivo and CNS resistance in post-mortem 
studies. The degree of resistance correlates with cognitive decline (Ekblad et 
al., 2015, Matsuzaki et al., 2010, Morris et al., 2016, Schrijvers et al., 2010, 
Talbot et al., 2012). 
Insulin sensitisation with rosiglitazone has been shown to reduce Aβ induced 
tau hyperphosphorylation in vitro (Tokutake et al., 2012). This is likely mediated 
by an insulin-induced reduction in GSK3 activity resulting in a reduction of tau 
phosphorylation and prevention of toxic tau protein accumulation (Hooper et al., 
2008). Moreover, insulin may shunt APP processing away from toxic Aβ and 
towards soluble amyloid species, which are non-pathogenic. This occurs via 
cleavage of APP in the Aβ domain due to insulin-induced activation of 
phosphatidyl-inositol 3 kinase (PI3K) (Solano et al., 2000). Finally, acute insulin 
administration appears to increase clearance of Aβ from the cytosol to the 
extracellular compartment in vitro (Gasparini et al., 2001, Pandini et al., 2012). 
This provides an intuitive model in which acute insulin administration improves 
cognition through enhancement of hippocampus dependent learning and 
reduction of toxic proteins in the CNS, whilst chronic hyperinsulinaemia results 
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in disrupted insulin signalling, impaired hippocampal learning and the 
accumulation of AD pathology. This may not provide the whole picture, 
however. Insulin is broken down in the CNS by IDE. This protein also breaks 
down Aβ. In the presence of insulin, IDE will preferentially clear insulin and Aβ 
therefore accumulates. Hyperinsulinaemia increases IDE expression but 
prevents IDE from clearing Aβ. This is a potential mechanism by which 
hyperinsulinaemia may contribute to the pathogenesis of AD. The literature 
around the role of insulin in cognitive impairment is vast and several 
comprehensive reviews have recently been published (Biessels and Reagan, 
2015, Cholerton et al., 2013, Hooper et al., 2008, Kullmann et al., 2016, Messier 
and Teutenberg, 2005, Ribe and Lovestone, 2016, Stanley et al., 2016, Zhao et 
al., 2004). As a result, it can now be taken as canon that diabetes and chronic 
hyperinsulinaemia are associated with the development of AD whilst acute 
insulin administration appears to ameliorate cognitive deficits, though the 
mechanisms underlying are yet to be fully elucidated.  
Insulin, Parkinson’s disease and neuroprotection 
It is possible that insulin is protective in PD. Insulin receptors co-localise to 
dopaminergic neurones in the SNpc (Unger et al., 1991). A post-mortem study 
of 3 people with PD and 3 controls found that IR and tyrosine hydroxylase (TH), 
an enzyme important for dopamine synthesis, were reduced in the SNpc of 
patients with PD compared to controls (Takahashi et al., 1996). Furthermore, 
streptozotocin treatment resulted in both hypoinsulinaemia and decreased TH 
expression in SNpc of rats (Figlewicz et al., 1996). Insulin receptor expression 
in the SNpc may be of functional significance as there is evidence that insulin 
modulates dopamine release in the basal ganglia and that this relationship may 
be reciprocal. Morris et al. induced insulin resistance in rats by feeding them a 
high fat diet. Dopamine release was measured in the striatum using 
micropipettes inserted under stereotactic MRI guidance. Levels of dopamine 
were significantly reduced in insulin resistant animals. Moreover, there was 
evidence of a greater degree of neurodegeneration in the SNpc  of insulin 
resistant rats on MRI (Morris et al., 2011b). The same authors found that 
intracerebral administration of the 6-ODHA resulted in striatal but not peripheral 
insulin resistance (Morris et al., 2011a) and that more severe dopaminergic cell 
loss was associated with a greater degree of neuronal insulin resistance (Morris 
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et al., 2008). Insulin may also be important in dopamine handling at the synaptic 
cleft, through changes in dopamine transporter (DaT) expression. Dopamine re-
uptake at the synaptic cleft may also be modulated by insulin. Dopamine 
transporters are essential for reuptake of dopamine into the cytosol enabling it 
to be re-released at a later stage. Chronic intracerebroventricular administration 
of insulin to rats increases DaT expression in the SNpc compared with those 
treated with vehicle (Figlewicz et al., 1994). Finally, dysfunctional insulin 
signalling has been proposed to precede dopaminergic cell death in PD. This is 
based on a post-mortem study of the brains of 6 people with PD, 5 with AD, 1 
with vascular parkinsonism and 2 with amyotrophic lateral sclerosis. Insulin 
receptor expression was lost in surviving dopaminergic neurones in the SNpc of 
people with PD but preserved in the other patients (Moroo et al., 1994). Taken 
together these data suggest that insulin signalling may modulate neuronal 
dopamine synthesis, release and reuptake in the SNpc, and may be disrupted 
in PD. 
Human studies have largely focused on PD and its relationship with diabetes as 
opposed to insulin per se. Results have been conflicting with studies variously 
reporting an increased risk of PD with diabetes, no association between PD and 
diabetes and reduced risk of PD with diabetes (Table 7). A 2013 meta-analysis 
of 6 studies that met the authors’ inclusion criteria found an increased risk of PD 
in people with diabetes, with a RR of 1.26 (95% CI, 1.03-1.55). This significance 
was retained when results were corrected to exclude vascular parkinsonism and 
bias from increased medical monitoring in people with diabetes (RR 1.25, 95% 
CI 0.93-1.68, p=0.01) (Cereda et al., 2011, Cereda et al., 2013). These results 
suggest that diabetes may confer a small additional risk of developing PD over 
the life course.





Table 7. Studies examining the relationship between diabetes and Parkinson’s disease 
Study Population studied Mean age (years ± SD) Study design Outcome 
(Simon et al., 2007) 121046 women and 50833 men from the Nurses’ 
Health Study and Health Professionals Follow up 
Study 
Women 30-55 and Men 
40-75 at baseline 
Prospective (follow 
up 12- 22.9 years) 
No increase in PD seen in people with diabetes 
(Scigliano et al., 
2006) 
178 PD patients and 533 controls 58.1±11.4 PD 
59.8 ±10.2 controls 
Case-control Diabetes less common in PD (OR 0.3 CI 0.13-0.72)  
(Savica et al., 2012) 196 PD and 196 matched non PD Age matched cohort Case control No association between PD and diabetes 
(Bohnen et al., 
2014) 
148 PD patients with DM (n=15) and without DM 
(n=133) 
65.96 ±7.4 Cross-sectional PD patients with DM had lower global cognition (composite 
measure) than those without (p=0.006) 
(Sun et al., 2012) 603416 people with diabetes and 472188 people 
without diabetes in Taiwan 
Adults > 20 Retrospective Diabetes increased the risk of PD (OR 1.37 (CI 1.32-1.41)) 
association stronger in women 
(Schernhammer et 
al., 2011) 
1931 patients with new onset PD and 9651 
healthy controls in Denmark 
72.2 ± 10.2   Case control DM increased the risk of PD (OR 1.36 CI 1.08-1.71) 
association stronger in women 
(D'Amelio et al., 
2009) 
318 PWP and 318 controls 66.7 Case control People with PD were less likely to have diabetes preceding 
diagnosis than controls (OR 0.3 CI 0.1-0.9) 
(Hu et al., 2007) 51552 people without PD 25-74 at baseline Prospective (follow 
up 18 years) 
Type 2 diabetes increased risk of PD (OR 1.85 CI 1.23-
3.15) 
(Jimenez-Jimenez 
et al., 2000) 
24 PD patients 24 controls 67.6±11.5 PD 
64.5±9.5 controls 
Case control Fasted CSF insulin levels no different between groups 
(Kotagal et al., 
2013) 
13 PD with diabetes and 26 PD without diabetes 66.4±5.5  
 
Case control Patients with PD and DM had more PIGD issues than those 
no DM (p=0.0005) 
(Powers et al., 
2005) 
352 new PD and 484 controls Median 69 PD 
Median 71 controls 
Case control Diabetes reduced the risk of PD in men (OR 0.52 CI 0.28-
0.) but not women 
(Moroo et al., 1994) 6 PD,1 vascular PD, 5 AD, 2 ALS and 5 controls  Post-mortem PD brains had reduced insulin receptor expression in 
SNpc. This was not seen in vascular parkinsonism  
(Morris et al., 2014) 20 AD, 22 PD and 21 healthy controls 71.0 ±5.7 PD 
72.4 ±5.7 AD 
71.7±6.2 controls 
Case control Insulin resistance increased PD compared to controls 
(p=0.003) with corresponding reduction in grey matter on 
voxel based MRI. 
(Palacios et al., 
2011) 
147096 people from the Cancer Prevention Study 
II Nutrition Cohort 
>18 years at baseline Prospective (follow 
up 7 years) 
No increased risk of PD with diabetes 
(Takahashi et al., 
1996) 
3 people with PD and 3 controls  Post-mortem study Insulin receptor levels lower in SNpc of people with PD  
(Pablo‐Fernandez 
et al., 2017) 
Neurological Disorders in Central Spain cohort 
79 PD and 4919 controls 
Mean 73 years, inter 
quartile range 68-79 
Cross-sectional There was no association between PD and diabetes except 
where diabetes disease duration was >10 years (p=0.02) 
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Many of the mechanisms by which insulin exerts positive effects on cognition 
have also been proposed to be neuroprotective in PD. Insulin binding to its 
receptor results in activation of PI3k/Akt pathway, which inactivates pro-
apoptotic GSK-3, promotes anti-apoptotic mediators and reduces pro-
inflammatory cytokines. As mentioned above the PI3K/Akt pathway is involved 
in the shunting of APP towards benign amyloid species and away from toxic Aβ 
(Bassil et al., 2014, Golpich et al., 2015). The net result is that neuronal cell 
death is reduced. This model is corroborated by a recent study using intra-nasal 
insulin in 6-ODHA treated rats. Insulin was commenced 24 hours after 6-ODHA 
treatment and continued for 2 weeks. The insulin treated animals had less 
motor impairment and a 74.8% increase in dopaminergic cell survival compared 
to those treated with vehicle (Pang et al., 2016). Finally, insulin may have an 
indirect role in α-synuclein handling via upregulation of IDE as IDE binds to α-
synuclein and prevents aggregation in vitro (Sharma et al., 2015). 
Given that insulin may be neuroprotective, and treatments for insulin resistance 
are freely available, there has been a great deal of interest in anti-diabetic 
medications as potential treatments for PD. The peroxisome proliferator-
activated receptor γ agonists pioglitazone and rosiglitazone are insulin 
sensitising agents that appear to be neuroprotective in animal models(Dehmer 
et al., 2004, Laloux et al., 2012, Lee et al., 2012, Quinn et al., 2008, Swanson et 
al., 2011). Results in human studies have been disappointing, however. A 
recent multicentre, double-blind randomised control trial of 210 patients with PD 
was unable to demonstrate any disease modification or symptomatic benefit 
with pioglitazone (Simuni et al., 2015). Rosiglitazone has been withdrawn from 
use in the UK due to cardiovascular side effects. Glucagon-like peptide -1(GLP-
1) agonists and dipeptidyl peptase-4 inhibitors (DPP4i) are treatments for 
diabetes that may be neuroprotective in PD. Their main action is through 
modulation of GLP-1, another hormone of energy homeostasis, and they will 
therefore be considered in that section of this thesis. 
There are three studies published to date examining insulin in Parkinson’s 
disease dementia. In the context of diabetes, a longitudinal study of 77 PD 
patients, 12 with diabetes and 65 without, demonstrated that diabetes was 
associated with a greater rate of cognitive decline over 2.4 years. This equated 
to a decline in 0.55 points out of 30 on the MoCA in the no diabetes group 
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compared with 3.29 points in participants with diabetes (p=0.016). This 
represents a clinically meaningful change over time. There were no differences 
in disease severity or cognition at baseline (Ong et al., 2017). The two studies 
examining insulin and insulin resistance in PD and PDD have shown opposing 
results. A well- conducted 2012 observational study of 53 people with PDD and 
57 people with PD and normal cognition found a positive association between 
insulin resistance and dementia. Patients had blood drawn for glucose and 
insulin after an 8 hour fast and 120 minutes after an oral glucose tolerance test. 
Insulin resistance was calculated using the homeostasis model assessment 
(HOMA- IR), calculated by multiplying insulin and glucose levels and dividing by 
a constant, and an oral glucose tolerance test. The dementia group had more 
insulin resistance (p= 0.01) and higher insulin levels (p=0.05) than cognitively 
intact people with PD. This result persisted after correction for disease duration 
and motor severity (Bosco et al., 2012). Conversely, a 2017 cross-sectional 
observational study of 122 people with PD with (n=75) and without (n=47) 
dementia found that insulin resistance measured by HOMA-IR was lower in the 
dementia group than those with normal cognition (p<0.01). The reduction in 
calculated insulin resistance was due to reduced insulin secretion in the face of 
similar fat mass and BMI. The authors report that this may represent metabolic 
failure but do not comment on how their findings may contribute to cognitive 
decline (Schelp et al., 2017). The opposing findings in these studies are difficult 
to explain. The age, sex, disease duration of participants was similar between 
the studies but BMI was lower in the Bosco study. Participants with diabetes 
were not excluded in the Schelp study and rates of diabetes per group were not 
disclosed. Motor severity was not reported or accounted for in the Schelp study. 
The role of insulin resistance in PDD therefore remains to be elucidated. 
Taking all of the available research into consideration one could propose a 
model by which people with PDD have chronic hyperinsulinaemia leading to 
central insulin resistance, impaired insulin signalling and loss of insulin 
mediated neuroprotection with resultant motor and cognitive decline. In this 
model hyperinsulinaemia could link weight-loss and dementia if it also leads to 
appetite suppression and weight loss. Against this, animal studies do not 
suggest that areas involved in appetite suppression are spared from insulin 
resistance in the face of hyperinsulinaemia (Obici et al., 2002). Despite this, it is 
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possible that the relative effects of insulin resistance are different in different 
brain tissues, or insulin sensitivity is lost due to neurodegeneration in brain 
areas involved in cognition and motor control, with relative preservation of 
hypothalamic areas controlling appetite. This is highly speculative. 
Nevertheless, insulin cannot be discounted as a possible neurohumoral link 
between weight loss and cognition  
2.3.4 Glucagon-like peptide 1  
Glucagon-like peptide 1 is a 30 amino-acid hormone produced in L-cells 
throughout the gastrointestinal (GI) mucosa with levels increasing distally to the 
stomach (Athauda and Foltynie, 2016). Secretion occurs shortly after ingestion 
of nutrients, especially carbohydrates and fats, under autonomic control via the 
vagal nerve. A second wave of secretion occurs when nutrients reach L-cells in 
the bowel (Hellstrom and Naslund, 2001). Glucagon-like peptide-1 has a very 
short half-life in the blood stream as it is rapidly broken down by dipeptidyl 
peptase-4 (DPP-4) (Alagiakrishnan et al., 2013). Its receptors are found 
throughout the body, including the gut, lungs, muscle, fat and brain. GLP-1 
crosses the blood brain barrier by passive diffusion (Alagiakrishnan et al., 
2013). In the brain GLP-1 receptor is expressed in areas involved with appetite 
such as the NTS and PVN but not in the ARC. There are also GLP-1 receptors 
in the brain stem, hippocampus and amygdala (Hellstrom and Naslund, 2001, 
McIntyre et al.). Glucagon-like peptide 1 has been shown to decrease food 
intake in obese and normal weight humans as well as those with type 2 
diabetes (Gutzwiller et al., 1999a, Gutzwiller et al., 1999b, Verdich et al., 2001). 
It slows gastric emptying and forms part of the “ileal brake” (Verdich et al., 
2001); in which GI transit slows when the ileum comes into contact with food, 
resulting in optimal nutrient absorption (Van Citters and Lin, 1999). It is thought 
that GLP-1 helps to signal fullness or satiation through its GI effects and 
through increasing sensitivity to CCK, another anorexigenic hormone discussed 
below (Dailey and Moran, 2013). It may have satiating effects through 
stimulation of the PVN, which in turn increases corticotropin-releasing hormone 
and oxytocin release (Katsurada et al., 2014). Glucagon like peptide 1 may also 
modulate taste responses, decreasing sensitivity to sweetness and increasing 
sensitivity to umami (savoury flavours) (Martin et al., 2009). Peak levels of 
secretion tend to fall with higher BMI and advancing age (Nauck et al., 2011) 
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Finally, GLP-1 induces peripheral insulin secretion from pancreatic β cells, 
though not during hypoglycaemia. This has led to the development of 
pharmacologically stable GLP-1 mimetic drugs such as exenatide, liragludide 
and lixisenatide and DPP-4 inhibitors (DPP-4i); the “gliptins” such as sitagliptin, 
linagliptin and vildagliptin for use in the treatment of type 2 diabetes. These 
drugs have a modest effect on glycosylated haemoglobin without 
hypoglycaemia and reduced glycaemic variability (Brunton, 2014, Nauck et al., 
2002). 
Glucagon-like peptide and cognition 
The link between type 2 diabetes and dementia has spurred a huge body of 
research into anti-diabetic agents to treat cognitive impairment. GLP-1, GLP-1 
analogues and DPP4is are not exceptions to this and studies in animals have 
been promising. GLP-1 receptor deficient rodents have impaired hippocampal 
learning measured by performance in the Morris water maze and novel object 
recognition. These cognitive deficits can be rescued with GLP-1 receptor gene 
transfer. Moreover, performance was improved with GLP-1 receptor over-
expression (Abbas et al., 2009, During et al., 2003). The GLP analogues 
exenatide, liraglutide, lixisenatide and GLP-1 itself have all been shown to 
increase long term potentiation in rodents in vivo; (Cai et al., 2014, Gault and 
Hölscher, 2008, Gault et al., 2010, McClean et al., 2010, Porter et al., 2010) and 
GLP-1 analogues have been shown to induce neurogenesis in rodents 
(Bertilsson et al., 2008, Hamilton et al., 2011, Hunter and Hölscher, 2012). 
There is also evidence that they may ameliorate AD pathology. The DPP4i 
vildagliptin, linagliptin and DPP4 inhibiting ayurvedic plants (pterocarpus 
marsupium and Eugeia jambolana) have all been shown to reduce tau 
phosphorylation in streptozotocin treated rats  in vivo (Kosaraju et al., 2014, 
Kosaraju et al., 2013) or in SK-MC cells in vitro (Kornelius et al., 2015). This 
may be via inactivation of GSK3b (Cai et al., 2014), much like the mechanism 
seen in insulin described above. Moreover, Aβ levels have been shown to be 
reduced following long-term vildagliptin treatment in streptozotocin treated mice 
(Kosaraju et al., 2013), whilst double transgenic Aβ over-expressing mice had 
reduced Aβ load following treatment with sitagliptin. The latter also had reduced 
APP and reduced neuronal inflammation, with correspondingly improved 
performance on the open field test and contextual fear conditioning (D’Amico et 
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al., 2010). These results have been replicated using liraglutide in APP/PS1 
over-expressing mice and are further supported by in vitro studies showing that 
exenatide reduces APP in neurone-like rat PC12 cells (McClean et al., 2011). 
Finally, there is evidence that GLP-1 analogues may be neuroprotective in in 
vitro models of AD. Exenatide has been shown to prevent axonal degradation in 
cultured Neurobasal-27 neuronal cells treated with ABO and cultured rat 
hippocampal neurons treated with glutamate (Bomfim et al., 2012). Linagliptin 
also prevented apoptosis of SK-MC cells in response to treatment with Aβ 
(Kornelius et al., 2015). Finally, DPP4is have been shown to up-regulate IDE, 
and may therefore reduce amyloid burden in AD (Yin et al., 2012). 
Despite the large body of promising research in animals, there is very little 
published research into GLP-1, GLP-1 analogues and DPP4i in cognitive 
impairment in humans. One retrospective observational study followed 240 
people in Naples with diabetes and MCI at baseline and measured cognition at 
2 years. Participants were not on any medication for cognition or diabetes at 
baseline. One hundred and twenty of these went on to be treated with DPP4i 
and metformin and 120 with sulfonylurea and metformin. The DPP4i treated 
group had improved cognition, better glycaemic control, reduced glycaemic 
variability and fewer asymptomatic hypoglycaemic episodes than the 
sulfonylurea treated group. Cognition correlated with HbA1c across all groups. It 
is therefore difficult to tease apart any pro-cognitive effects of DPP4is over and 
above loss of hypoglycaemia and improved glycaemic control in these patients 
(Rizzo et al., 2014). A randomized controlled trial was started in 2012 looking at 
treatment of people with AD with liraglutide or placebo for 6 months. No data 
have yet been published (Egefjord et al., 2012). Another phase 2 randomised 
control study of people with early AD or MCI treated with exenatide for 18 
months completed follow up in November 2016 but again no data have yet been 
published (NCT01255163). Finally, there is a multicenter randomized control 
phase 2b trial due to complete in 2019 in which people with AD are randomized 
to liraglutide or control for 12 months (NCT01843075). There are no studies to 
date examining whether levels differ between people with normal cognition and 
dementia. As such it is not possible to determine whether disordered GLP-1 
signaling may contribute to cognitive decline in AD or PDD.  
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Glucagon-like peptide, Parkinson’s disease and neuroprotection 
GLP-1has been recognized as a neurotrophic factor (Perry et al., 2002). As 
such, there has been considerable research into GLP-1 analogues and DPP-4i 
as potential neuroprotective agents for conditions as wide ranging as peripheral 
neuropathy, stroke, AD and PD (Darsalia et al., 2013, Holscher, 2012, Perry et 
al., 2007). There is good evidence from animal studies that GLP-1 analogues 
and DPP4i may be neuroprotective in PD through anti-inflammatory and anti-
apoptotic effects, increased mitochondrial stability and altered α-synuclein 
handling. Intra-peritoneal exendin-4 has been shown to reduce microgliosis, 
inflammatory cytokines and dopaminergic neurone loss in mice treated with 
MPTP (Kim et al., 2009). Similar results were found when systemic saxagliptin, 
a DPP4i, was administered to a rotenone rat model of PD. The rats had an 
improved phenotype, with reduced akinesia and improved dopaminergic 
neuronal survival in the SNpc. This was accompanied by reduced neuronal 
inflammation, lower levels of inflammatory cytokines and a shift in the ratio of 
pro-apoptotic to anti-apoptotic factors favouring cell survival (increased bcl2 and 
reduced bax, caspase3 and cytochrome c) (Nassar et al., 2015). Another GLP-1 
receptor agonist derived from Chinese medicine was found to improve motor 
deficits and prevent neuronal apoptosis in a mouse MPTP model of PD. The 
authors found that the usual pro-apoptotic response to MPTP was blunted by 
geniposide treatment, with a reduced active (cleaved) caspase 3: inactive (pro-) 
caspase 3 ratio resulting in increased cell survival (Chen et al., 2015). It has 
been proposed that GLP-1 analogues and DPP-4is may reduce α-synuclein 
deposition through upregulation of IDE (Athauda and Foltynie, 2016). This 
hypothesis is based on the observations that GLP-1 and DPP-4is both increase 
IDE in experimental models and that IDE reduces α-synuclein aggregation 
(Sharma et al., 2015, Yin et al., 2012). GLP-1 analogues and DPP-4is appear to 
induce neurogenesis in rodent models of PD. Two in vivo studies have shown 
increased BrdU labelling in 6-ODHA treated rats when exendin-4 was 
administered 7 days after lesioning. These changes were associated with 
improved motor phenotypes and improved dopaminergic cell survival 
(Bertilsson et al., 2008, Harkavyi et al., 2013). Finally, it has been suggested 
that GLP-1 analogues and DPP4is could be neuroprotective through 
mitochondrial stabilization and mitochondrial biogenesis, as GLP-1 has been 
shown to increase mitochondrial numbers and survival in animal models of 
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diabetes and spinal cord injury (Fan et al., 2010, Foltynie and Aviles-Olmos, 
2014, Kang et al., 2015a, Li et al., 2015c). 
In contrast to many potential neuroprotective agents which show promise in 
animals and in vitro but fail to benefit humans, there is evidence from human 
studies that GLP-1 analogues and DPP4is may be neuroprotective in people 
with PD. A small randomized, single-blind open label study of 45 people 
improved motor and cognitive symptoms as measured by part 3 of the MDS-
UPDRS and Mattis dementia rating scale respectively compared to the control 
group receiving usual care (Aviles-Olmos et al., 2013). Interestingly, these 
effects persisted 12 months after exenatide was stopped (Aviles-Olmos et al., 
2014). A phase 2 randomized control trial into the use of exenatide as a 
neuroprotective agent in PD has recently been published. Sixty-two patients 
with moderate PD were randomized to receive 48 weeks of exenatide or 
placebo. The primary outcome measure was motor symptoms of PD measured 
using part 3 of the MDS-UPDRS in the “off” state and secondary measures 
included tolerability and cognitive performance. Participants with diabetes or 
dementia were excluded. The authors found that exenatide treatment resulted 
in 2.3 points of motor improvement in the MDS-UPDRS compared with a 1.7 
point decline in the placebo group after 48 weeks of treatment. This 
improvement was sustained, though slightly diminished, following 12 weeks of 
washout. One point of improvement was retained in the treatment group 
compared to a 2.3 point decline in the placebo arm. These results were 
statistically significant but the clinical significance is less clear as changes in 
“on”-state motor scores, quality of life measures and non-motor symptoms did 
not differ between groups. Interestingly levodopa equivalent dose (LED) 
increased proportionally more in the treatment group. The authors adjusted for 
this in their analysis and felt the difference reflects slightly higher disease 
severity at baseline. There was no difference in the Mattis Dementia Rating 
Scale between groups in this cognitively intact cohort. Though further research 
is needed, this study supports exenatide as an exciting potential disease 
modifying agent in PD (Athauda et al., 2017). 
Despite its potential as a potential neuroprotective agent with respect to both 
the motor and cognitive symptoms of Parkinson’s disease, GLP-1 may not be a 
major mechanistic contributor to the link between weight loss and dementia in 
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PD as neurodegeneration would seem likely to render the brain less, not more, 
sensitive to the satiating effects of GLP-1 through loss of signaling pathways. 
Alternatively, a relatively more permeable BBB due to neurodegeneration, as is 
seen in late AD (Bonda et al., 2014) may result in greater influx of GLP-1 and 
reduced appetite, though perhaps ameliorating the attendant cognitive and 
motor deficits. Further research is needed to clarify the physiological role of 
GLP-1 in dementia and PD. 
2.3.5 Leptin 
Leptin is a 16Kda protein produced by adipocytes. It was originally identified in 
1994 as the missing protein in mutant mice with an obese phenotype (Zhang et 
al., 1994). Leptin levels are proportional to body fat and show diurnal variation, 
with a nocturnal peak (Mantzoros et al., 2001). Levels may decrease with 
prolonged fasting (Chan et al., 2003) and increase with severe overfeeding 
(Kolaczynski et al., 1996) but are not altered by physiological calorie intake 
(Korbonits et al., 1997, Ullrich et al., 2015). As with insulin, leptin levels increase 
with adiposity and provide negative feedback in times of positive energy 
balance (Friedman and Halaas, 1998, Korbonits et al., 1997). This is possible 
as leptin crosses the BBB via a saturable transporter (Caro et al., 1996) where it 
binds with LepR receptors. There are 6 known LepRs, also known as OB-R, 
which are grouped together according to size as short, long and soluble 
isoforms (Magalhães et al., 2015). Soluble receptors are detectable in blood 
and are proportionate to membrane bound receptors (Albala et al., 2016). 
With regard to appetite leptin can be considered a direct antagonist to ghrelin, 
with expression in many of the same neuronal structures and with opposite 
effects. Leptin acts at the hypothalamus to suppress orexigenic NPY and AgRP 
neurones and stimulate anorexigenic POMC neurones (Cowley et al., 2001, 
Erickson et al., 1996, Friedman and Halaas, 1998, Korbonits et al., 1997). 
Where ghrelin positively stimulates the cholinergic dopaminergic reward 
system, leptin suppresses it (Leinninger, 2009). Humans who are deficient in 
leptin due to a mutation in the LEP gene lose this negative feedback and 
become morbidly obese (Friedman and Halaas, 1998). Leptin replacement in 
this context normalises body weight and improves metabolic profile (Oral et al., 
2002). Understandably, therefore, there has been considerable interest in leptin 
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as an anti-obesity therapy. Unfortunately, exogenous leptin treatment has not 
proven to be as effective at inducing weight loss in obese humans without leptin 
deficiency. Leptin treatment may, however, augment weight loss in calorie 
restricted humans (Heymsfield et al., 1999), and has been shown to reduce 
hunger in the context of severe calorie restriction (Rosenbaum and Leibel, 
2014). Again, like insulin, leptin resistance occurs in obesity such that negative 
feedback is lost. This has been proposed to be due to down-regulation of the 
saturable transporter across the BBB and disordered leptin signalling due to the 
accumulation of inhibitory proteins (Münzberg and Myers, 2005). 
Interestingly, leptin has also been demonstrated to modulate insulin sensitivity. 
Patients with leptin deficiency due to LEP mutations or severe lipodystrophy 
demonstrate marked insulin resistance, which is corrected by leptin 
replacement (Licinio et al., 2004, Oral et al., 2002). Conversely, 
hyperinsulinaemia has been shown to increase leptin in women during glucose 
clamp testing (Kennedy et al., 1997). Leptin is higher in women than in men at 
comparable BMIs. This is proposed to be related to differences in the 
distribution of adipose tissue between men and women (Kennedy et al., 1997). 
It has been suggested that leptin may be more important for weight regulation in 
women, whilst insulin is more important in men (Hallschmid et al., 2004). 
It may be anticipated that leptin levels may increase with ageing due to relative 
loss of muscle mass and increased adiposity. This does not appear to be the 
case, however, with BMI-adjusted leptin levels tending to decline with age, 
especially in women (Isidori et al., 2000). It has been proposed that a shift 
towards visceral as opposed to peripheral fat storage and adipocyte dysfunction 
may account for this (Carter et al., 2013). 
Leptin in cognition  
Like ghrelin and insulin, leptin demonstrates pleiotropy. Leptin receptors are not 
confined to the hypothalamus but are found widely throughout the brain; in the 
VTA where leptin affects the mesolimbic dopaminergic system “reward” 
responses, the hippocampus where it may have a role in synaptic plasticity and 
memory formation and the SNpc where its actions are as yet unclear (Harvey, 
2007, Zupancic and Mahajan, 2011). Animal studies suggest an important role 
for leptin in learning and memory. Leptin facilitates long-term potentiation in 
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rodents in vitro and in vivo (O'Malley et al., 2007, Oomura et al., 2006, Shanley 
et al., 2001) and has been shown to improve spatial memory in rats undertaking 
the Morris water maze (Oomura et al., 2011). Conversely, leptin receptor 
deficient rodents have reduced spatial memory and impaired long term 
potentiation compared to wild types (Li et al., 2002).  
Leptin may also be important in dementia as it appears to ameliorate the toxic 
effects of Alzheimer’s pathology in rodents. Leptin reduces extracellular Aβ in 
mice in vivo and in SH- SY5Y human neuroblastoma cells in vitro via reduced 
synthesis by β-secretase and increased clearance by endocytosis (Fewlass et 
al., 2004, Greco et al., 2009). Moreover, leptin administration reduces tau 
phosphorylation in mouse neurones, SH-SY5Y cells and human embryonic 
kidney 293 cells in vitro (Greco et al., 2009, Greco et al., 2008, Platt et al., 
2016). This reduction of tau phosphorylation appears to be mediated via 
activation of AMPK and inactivation of GSK-3b (Greco et al., 2009), similar to 
the downstream actions of insulin binding. These effects may be clinically 
relevant as Farr et al. demonstrated that exogenous leptin improved memory 
performance in Aβ-over-expressing SAMP8 mice (Farr et al., 2006, Fewlass et 
al., 2004). 
There have been a number of human studies looking at a possible role for leptin 
in learning and cognitive impairment. As may be expected from the animal 
studies described above leptin deficiency is associated with learning difficulties 
in humans. Learning difficulties in leptin deficient humans, like the attendant 
obesity and metabolic abnormalities, are ameliorated by exogenous leptin 
therapy (Paz-Filho et al., 2008). In 2001 Power et al hypothesised that 
inappropriately elevated leptin levels may account for weight loss in dementia, 
especially AD. They found, however, that leptin levels were low in underweight 
dementia patients, most likely representing a normal physiological response to 
weight loss. Interestingly, however, this trend was lower for AD patients than 
those with vascular dementia despite similar mean BMI in both groups (Power 
et al., 2001). The literature exploring a putative link between cognition and leptin 
has been conflicting, with a number of studies finding a positive correlation 
between leptin and cognition (Table 8) and a comparable number showing no 
relationship or an inverse correlation (Table 9). There is therefore a lack of 
consensus regarding the role of leptin in cognition in humans. The differences in 
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results may be due to methodological differences, especially the inclusion or 
exclusion of obese participants who are likely to have a degree of leptin 
resistance (Zeki Al Hazzouri et al., 2012).
          




Table 8. Studies showing a positive correlation between leptin and cognition 
Study Population studied Leptin Follow up (years) Outcome 
(Huang et al., 
2007) 
HIV positive men 
N=59 
Patients with dementia not excluded 




Low CSF leptin correlated with impaired learning (ρ=−0.31, 
p=0.02)  and memory (ρ= 
−0.39, p=0.002) as tested by the neuropsychological battery. 
(Holden et al., 
2009) 
Health, Ageing and Biology (Health ABC) study 
N=2871 
Dementia free at baseline  
Age; 70-79  
BMI; stratified by leptin tertile low 23.2± 3.1, middle 
27.0± 4.0 and high 31.1 ± 4.8  
Blood 5  
 
High leptin >1 standard deviation [SD] above the mean 
associated with reduced risk of cognitive decline (OR 0.66 CI 
0.48-0.91) 
Remained significant after correction for BMI 
 
(Lieb et al., 2009) Framingham Cohort 
N= 785 
Dementia free at baseline 
Age; 79± 5 years at baseline 
BMI 28 ±5 
Blood 13-17  
 
High leptin associated with reduced risk of all cause dementia 
(HR 0.68 CI 0.54-0.87) and Alzheimer’s dementia (HR 0.60 CI 
0.46-0.79) 
Causes of non-AD dementia not given 
Results only significant if BMI <30 
(Zeki Al Hazzouri 
et al., 2012). 
Sacramento Area Latino Study on Aging (SALSA) 
cohort 
N= 1,480 
Dementia free at baseline 
Age; 60-101 at baseline 
BMI grouped as <25,25-<30 and ≥30 
Blood 10  
 
High leptin and small waist circumference reduced cognitive 
decline vs. low leptin and small waist (p=0.01).  
Significance lost in participants with larger waist measurements  
(Zeki Al Hazzouri 
et al., 2013). 
Study of Osteoporotic Fractures cohort 
N= 579 
Dementia free at baseline 
Age; mean 82.6  
BMI grouped as 25-<30 and ≥30 
Blood 4  
 
High leptin associated with reduced risk of dementia/MCI (OR 
0.68, CI 0.46-0.99) 
Leptin not protective in obese women 
Type of dementia and MCI not recorded 
(Beydoun et al., 
2012) 
National Health and Nutrition Examination Study III 
cohort 
N= 1293 aged 20-59 , 1673 aged 60-90  
BMI; 26.2 ± 0.2 aged 20-59 and 26.6 ±0.1 aged 60-
90 
blood Cross-sectional Better performance on symbol digits substitution testing in second 
tertile of leptin in the 20-59 age group. No other positive 
associations for leptin. No difference in performance between 
third and first tertiles. 
          




(Littlejohns et al., 
2015) 
Invecchiare in Chianti (InCHIANTI) study 
N=809 
Dementia free older Italians aged 73.6 ±6.6 at 
baseline 
BMI grouped as <25,25-<30 and ≥30 
blood Mean 8  Higher leptin was protective against significant cognitive decline 
defined as ≥5 point change on MMSE (RR 0.84, 95% CI 0.73-
0.97) and the relationship persisted in obese individuals. 
(Xing et al., 2015) Non-obese Chinese women with normal cognition 
or amnestic MCI 
N= 42, MCI; 23, controls; 19 
Age; MCI; 67.2 ±6.9, controls; 68.1±7.3 
BMI 23.5 ±1.5 MCI and 24.7 ±3.1 controls 
Fasting 
blood 
Cross-sectional Leptin levels were lower in the MCI group, even after adjustment 
for BMI and age (p<0.001). Leptin levels did not correlate with 
cognitive performance.  
(Witte et al., 
2016) 
German MCI patients and healthy controls 
N=80 MCI;40, controls 40 age, body fat and sex 
matched 
Age 67±7 




Cross-sectional MCI group had lower leptin levels than healthy controls (p<0.001) 
with associated lower hippocampal volume on MRI 
(Baranowska-Bik 
et al., 2015) 
Polish women with and without AD 
N= 18 severe AD, 40 early AD and 42 age and BMI 
matched controls 
BMI 24.4 ±3.6 in AD and 25.9 ±4.0 in controls  
Fasting 
blood 
Cross-sectional Leptin levels were lower in AD than in controls despite no 
significant difference in BMI (P<0.05) and lower in severe AD 
than early AD (p<0.05) 
          




Table 9. Studies showing no, or inverse, correlation between leptin and cognition 
Study Population studied Leptin Follow up 
(years) 
Outcome 
(Gunstad et al., 
2008). 
Dementia free Americans 
N=35 
Age; 73.69 +/- 6.62  





Negative correlation between leptin levels and executive 
function as tested by Trail making B test (r=.46, p=.01). 
Not significant for other measures of cognitive impairment. 
 
(Narita et al., 2009) Cognitively normal non-obese Japanese people 
N=34 
Age men; 64.8±5.1, 64.3 ±4.4 
BMI men 23.2 ±2.7 women 21.9±1.8 
Participants with BMI >27 excluded 
 
Blood Cross-sectional Higher leptin levels associated with larger hippocampal 
volumes on Voxel-based morphometric MRI. There was no 
demonstrable correlation with cognition. This may represent a 
ceiling effect in this cognitively normal cohort. 
(Kamogawa et al., 
2010) 
Japanese Shimanami Health Promoting 
Program (J-SHIPP) cohort 
N=524 
Age; mean 67 for normal cognition 72 for MCI 
BMI mean 23.0 normal cognition and mean 
22.7 in MCI 
Blood Cross-sectional  No significant correlation between leptin and cognition when 
corrected for BMI. 
Greater central adiposity was associated with a lower risk of 
MCI. 
 
(Gustafson et al., 
2012). 
Prospective Population Study of Women cohort. 
Dementia free at baseline 
N=1462 
Age;38-60 at baseline 
BMI; 24.1 ±3.8 
Blood samples 
taken in 1968 
Median 32 
 
No association between leptin and AD, vascular dementia or 
mixed vascular and Alzheimer’s dementia 
(OR 1.00 CI 0.98-1.03) 
(Warren et al., 2012) Dallas Heart Study Cohort 
N=2,731 
Dementia free at baseline 
Age; 30-65 at baseline 






No significant correlation between cognition (tested using 
MoCA) and leptin. 
Trend towards lower leptin with greater cognitive impairment 
 
(Labad et al., 2012) Edinburgh Type 2 Diabetes Study (ET2DS) 
N=1057 




Cross-sectional Higher leptin levels associated with poorer cognitive 
performance on psychometric battery in men. No relationship 
for women. Most subjects were obese so leptin resistance may 
account for these results 
1.(M Johnston et al., 
2014) 




3 1.  Leptin levels were lower in MCI than in controls but 
significance was lost with BM>27 and; 
          




2. (Oania and 
McEvoy, 2015) 
N=352 adults with MCI 
BMI 27±4.1 normal cognition 26.1 ±4 MCI and 
25.6 AD 
2. There was no association between baseline leptin levels 
rate of cognitive decline or development of dementia 
(Teunissen et al., 
2014) 
non-obese people with AD, MCI, VaD or healthy 
controls 
n= total; 295 AD; 100, MCI; 99, VaD; 31, 
controls; 65 
Age; AD; 63±6, MCI; 62±7, VaD 67±8, controls; 
58 ±7 




Cross-sectional Leptin levels were not significantly different between groups. 
No relationship between leptin and hippocampal atrophy on 
MRI 
(Alosco et al., 2015) Dementia free patients undergoing bariatric 
surgery 
N=84 
Age 43.86 ±10.39 
BMI 46.88 ± 6.08 at baseline and 30.51±5.39 at 
12 months 
Fasting blood 1- Baseline and 
post-operatively 
Leptin associated with worse attention/executive function (digit 
span backwards, trail-making A and B tests) and memory 
(verbal list learning). Post-operative reduction in leptin 
predicted improved cognition. Correlation disappeared after 
correction for BMI. 
(Gustafson et al., 
2015) 
American women without dementia 
N=354, 247 HIV+ and 107 HIV – 
Age 38.9±9.1 
BMI 29.2 ±7.9 
Non-fasting 
blood sample 
Cross-sectional Leptin inversely correlated with cognition. Most of the 
participants were overweight or obese but the correlation 
persisted after correction for BMI, age, education, race and 









Retrospective Hyperleptinaemia was associated with a lower grade point 
average at school, even after controlling for obesity (p=0.004) 
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Several studies demonstrating a correlation between cognitive function and 
leptin have found that significance is lost when subjects are obese (Lieb et al., 
2009, Zeki Al Hazzouri et al., 2012, Zeki Al Hazzouri et al., 2013). This would be 
in keeping with leptin resistance in obesity resulting in loss of putative positive 
cognitive effects. Against this are studies carried out in Japan and the 
Netherlands which excluded obese people and still found no correlation 
between cognition and leptin following correction for BMI (Kamogawa et al., 
2010, Narita et al., 2009, Teunissen et al., 2014). Evidence for circulating levels 
of leptin directly impacting on cognition in humans in a linear fashion is 
therefore lacking. It is worth noting that animal studies have suggested that the 
cognitive response to exogenous leptin may have a U shaped relationship, with 
benefit seen at low doses but lost at high doses (Oomura et al., 2011). There 
are no studies to clarify if this is true of physiological leptin levels in humans. 
The issue is unlikely to be resolved without a good quality meta-analysis, which 
is likely to be challenging in view of experimental heterogeneity. 
Another possibility is that leptin signalling in dementia is disrupted or disordered 
in such a way that peripheral blood and one-off CSF measurements cannot 
detect. A 2014 post-mortem study by Bonda et al examined the brains of 21 
people with AD, 8 with MCI and 13 controls. They found that CSF and 
intrahippocampal leptin were higher in AD brains compared to controls but Ob-
R expression was decreased. This was especially the case for severe AD, while 
conversely there was a trend towards lower leptin in MCI than in controls. None 
of these findings correlated with age or BMI. The authors suggest that reduced 
leptin levels early in disease may accelerate AD pathology but disruption of the 
BBB in severe AD may lead to leptin influx, downregulation of Ob-R and 
abnormal leptin signalling (Bonda et al., 2014). These results were corroborated 
by Maioli et al. the following year who found AD patients had reduced Ob-R 
throughout the brain, including in the hippocampus post-mortem.  Meanwhile, 
the distribution of leptin within the hippocampus differed between controls and 
AD patients, with controls showing staining for leptin in neurones and AD 
patients showing staining in reactive astrocytes (Maioli et al., 2015). Finally, it 
may be that free, unbound, leptin is more relevant to cognitive impairment than 
total leptin. Soluble Ob-R (sOb-R) binds leptin in peripheral blood and prevents 
it from binding to membrane bound leptin receptors in the brain. Albala et al 
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looked at 667 older people enrolled in longitudinal studies in Chile with baseline 
blood test available. 42 of these had developed dementia during follow up. 
Participants were over 65 years old and dementia free at baseline. They had 
been followed up for an average of 15 years at the time of the study. Leptin and 
sOb-R were measured in frozen baseline samples. The authors found that 
reduced leptin availability due to higher levels of circulating sOb-R was seen in 
people who went on to develop all cause dementia on follow up. They also 
found that lower body weight increased the likelihood of developing dementia, in 
line with the literature around weight loss and dementia (Albala et al., 2016). 
Given the apparent anti-amyloid and anti-tau properties of leptin in vitro, lower 
leptin levels with reduced BMI and increased risk of dementia with low BMI, 
leptin remains a candidate for a link between neurodegeneration and weight 
loss.  
Leptin, Parkinson’s disease and neuroprotection 
Leptin may also be important in PD, perhaps related to LepRb expression in the 
SNpc. Dopamine stores have been found to be low in leptin-deficient mice 
(Roseberry et al., 2007) and α-synuclein over-expressing mice are underweight 
and hypoleptinaemic compared to wild types(Rothman et al., 2013). Leptin is 
also proposed to be neuroprotective in rodent models of PD. Weng et al. 
injected 6-OHDA unilaterally into the SNpc of mice and found that co-
administration of leptin prevented nigral cell death. Furthermore, these mice 
were rescued from developing a dopamine deficient phenotype. They then went 
on to look at dopaminergic mouse neurones in culture and found that leptin 
reduced pro-apoptotic proteins such as caspase-9 and caspase-3 in response 
to 6-ODHA treatment and that this was associated with improved neuronal 
survival (Weng et al., 2007). Leptin has also been shown to be neuroprotective 
in human neuroblastoma cells, (dopaminergic SH-SY5Y cells). Leptin treatment 
improved cell survival following treatment with 1-methyl-4-pyrinium (MPP+) 
PI3/Akt activation(Lu et al., 2006). Finally, leptin has been shown to act as a 
mitochondrial stabiliser in SH-SY5Y cells treated with MPP+, via activation of 
mitochondrial UCP-2 (Ho et al., 2010). 
In humans, Lorefalt et al. carried out a small case control study investigating 
leptin and weight loss in PD patients. They found that leptin levels were lower in 
women with PD with weight loss compared to weight stable patients and 
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controls. This is in keeping with reduced fat mass in the weight loss group 
(Lorefalt et al., 2009). These findings were corroborated by Aziz et al who 
measured serum leptin every 20 minutes for 24 hours in 8 volunteers with PD 
who were not on medication and 8 weight matched controls. They found no 
significant difference between groups and leptin levels correlated with adiposity 
as expected (Aziz et al., 2011). More interestingly, Fiszer et al. demonstrated 
lower levels of leptin in PD patients with unintentional weight loss than in those 
with stable weights, despite no significant differences in BMI (Fiszer et al., 
2010). Very similar results were obtained by Evidente et al. nearly a decade 
earlier, but the observed trend towards lower leptin in PD patients with weight 
loss did not reach statistical significance (Evidente et al., 2001). The dominant 
view in the literature is that leptin levels may be low in PD due to reduced 
adiposity from another cause (Davis et al., 2014, Folch et al., 2012). That 
weight losing PD patients have lower leptin than their weight stable counterparts 
suggests that weight losers respond inadequately to a state of negative energy 
balance. It has been suggested that weight loss in PD may result in loss of 
neuroprotection from leptin and exacerbate neurodegeneration and cognitive 
impairment in PD (Davis et al., 2014, Kim et al., 2012). No studies have yet 
been published examining a role for leptin in PDD and, to my knowledge, there 
have been no trials of leptin as a neuroprotective agent to date.  
2.3.6 Other hormones of energy homeostasis 
There are a number of other hormones of energy homeostasis. These have not 
yet been demonstrated to have cognitive or neuroprotective effects. The two 
most important are peptide YY (PYY) and CCK. Peptide YY is produced by the 
same L-cells in the GI mucosa that produce GLP-1. It acts to reduce motility 
and slow transit time in both the stomach and the lower GI tract. PYY is 
secreted in response to the presence of nutrients and bile salts in the lumen of 
the gastrointestinal tract. It may also be under neural control via the vagus 
nerve. Levels peak after eating and show a dose response, with higher levels 
achieved after greater calorie intake (Adrian et al., 1985). Cholecystokinin is 
produced by the small bowel post-prandially, especially after consumption of 
peptides and fatty acids. The level of CCK secreted corresponds to the nutrient 
load consumed. It signals satiety and reduces meal size resulting in reduction of 
energy intake through binding to its receptor CCK1-R in vagal afferent nerve 
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fibres. Vagal afferent stimulation of the NTS then promotes satiety and meal 
termination (Lancha et al., 2012, Morton et al., 2006, Woods and D'Alessio). 
CCK is a modulator of ghrelin, inhibiting the ghrelin response to fasting when 
administered to rats (Kobelt et al., 2005). It acts synergistically with other 
anorexigenic hormones; increasing the anorectic response when co-
administered with leptin (Wang et al., 2000) and insulin (Riedy et al., 1995). 
Finally, CCK also has a number of effects on the GI tract; reduction in gastric 
emptying, stimulation of gall bladder contraction and increasing exocrine 
pancreatic secretions (Little et al., 2005). Whilst important for regulation of 
energy intake, these hormones are unlikely to be linked with neurodegenerative 
disease and will therefore not be discussed further in this thesis. 
2.3.7 Summary 
Weight loss and cognition in PD may be mechanistically linked via hormones of 
energy homeostasis. This may be due to degeneration of ghrelin pathways and 
the somatotropic axis resulting in weight loss, accelerated cognitive decline and 
neurodegeneration; through hyperinsulinaemia causing insulin resistance, 
cognitive impairment, loss of neuroprotection and appetite suppression; or 
through loss of pro-cognitive and neuroprotective leptin due to weight loss 
Figure 8). Each of these pathways may be disordered and could be potential 
biomarkers for cognitive decline in PD but evidence is lacking. Further study is 
therefore needed to help clarify this relationship. This thesis therefore aims to 
explore whether appetite, food intake and hormonal profiles differ between 
patients with PD, PD-CI and controls using a cross-sectional pilot study 
observing these parameters in each group.






Figure 8. Mechanisms by which weight loss and neurodegeneration may interact in PD and PD-CI
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Chapter 3.  Methods- Plasma acyl-ghrelin: A biomarker for 
cognitive decline in Parkinson’s disease? 
3.1 Ethics and consent 
This study received local approval and favourable review by the NHS research 
ethics service committee North East Newcastle and North Tyneside 1 
(reference 14/NE/0002). It was carried out in accordance with the World 
Medical Assembly Declaration of Helsinki 1964 and subsequent revisions. 
Tailored written information was provided to all participants and carers 
according to group. This participant information sheet was given at least 24 
hours prior to recruitment. Participants (patients and carers) with capacity to 
consent to take part signed a consent form prior to screening. In view of the 
need to include people with cognitive impairment, there was a risk that some 
participants may have lacked capacity to decide whether or not to take part in 
the study. All participants in the cognitively impaired group had a formal 
capacity assessment to determine this. If the participant lacked capacity then a 
carer, relative or Independent Mental Capacity Advocate was consulted. The 
consultees were given participant information sheet 24 hours in advance and 
asked to give a view on whether taking part was in keeping with the potential 
participant’s previous wishes, view and beliefs (adhering to the Mental Capacity 
Act 2005). If so, consultees were asked to sign a consultation form to confirm 
this. Consultees were not asked to consent on the potential participant’s behalf. 
Written informed consent was recorded at the first assessment and recorded in 
the site file. Participants and carers were given copies of the signed documents 
to keep. See appendices for evidence of ethical approval, participant 
information sheets, consent forms and consultee forms. 
3.2 Study design and aims 
This study was designed by Prof. David Burn, Dr. Mario Siervo, Prof. Jeff 
Davies and myself. The study design was a single-centre, cross-sectional 
quasi-experimental pilot study. The primary objective was to determine whether 
hormones of energy homeostasis warrant further investigation as putative 
biomarkers for cognitive impairment in PD. The secondary objective was to 
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determine whether perceived and objective measures of appetite and food 
intake differ between patients with PD, PD-CI and controls. The primary 
outcome was fasting and dynamic (area under the curve) hormone levels in PD-
CI, PD and controls. 
3.3 Sample size 
The sample size was calculated by Dr. Shirley Coleman (a statistician at 
Newcastle University) based on the results of the previous study by Unger et al. 
(Unger et al., 2011). That study examined the ratio of ghrelin levels at 60 and 
300 minutes and standard deviations were reported at these time points. Based 
on these values, and taking into account the different study design, Dr Coleman 
calculated that a sample size of 19 participants per group would be sufficient to 
detect a difference in AUC and levels over time at a 5% significance level with 
80% power. She therefore recommended 20 participants in each group. See 
appendix D for more details. 
3.4 Recruitment 
Potential participants with PD and PDD were identified by their clinician within 
the Newcastle upon Tyne Hospitals Foundation NHS Trust Movement Disorder 
Service. Healthy controls were spousal or older people who had previously 
expressed an interest in engaging in research. Potential participants were 
contacted by telephone, e-mail or post. If they were interested in participating 
we sent information leaflets outlining the study as detailed above and followed 
up with a telephone call to further discuss participation. If they were happy to 
proceed at this point we invited them to attend Clinical Ageing Research Unit 
(CARU) at Newcastle University for assessment. 
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3.4.1 Inclusion and exclusion criteria 
Subject Population 
Adults of both sexes aged 60-85 were recruited into three groups; healthy 
controls, PD without cognitive impairment (PD) and PD with cognitive 
impairment (PD-CI). Groups were matched for age and gender. All subjects had 
a stable weight over the preceding 3 months and no history of diabetes mellitus 
(DM), gastrointestinal disease, tobacco use or non-selective anticholinergic 
agents due to potential effects on hormone levels, appetite or cognitive 
performance(Jo et al., 2002, Broglio et al., 2004). Potential participants were 
excluded if they were obese or severely underweight. This was in order to 
reduce confounding factors such as leptin resistance in obesity and abnormal 
hormone levels in cachexia (Caro et al., 1996). Deep brain stimulation was an 
exclusion for participants with PD as this may alter central ghrelin levels 
(Markaki et al., 2012). 
Parkinson’s disease with normal cognition (PD-NC) group 
Participants in this group had an established diagnosis of idiopathic Parkinson’s 
disease made by either a neurologist or a geriatrician with expertise in 
movement disorders. They had normal cognition as defined by a Montreal 
Cognitive assessment (MoCA) score of ≥26 and the absence of functional 
impairment resulting from cognitive symptoms. 
Parkinson’s disease with cognitive impairment (PD-CI) 
This group comprised of participants with PDD and with PD-MCI. Participants in 
both subgroups had diagnoses of PD made by a neurologist or geriatrician with 
expertise in Parkinson’s disease more than 12 months prior to the study. This 
was to distinguish PDD and PD-MCI from Dementia with Lewy bodies (DLB). 
Participants with PDD met the Movement Disorder Society Task Force Criteria 
for PDD, had a MoCA of ≤25/30 and evidence of cognitive deficit impacting on 
activities of daily living (ADLs).Those with PD-MCI had self of carer reported 
neuropsychiatric symptoms (including, but not confined to; hallucinations, 
attention deficit, short term memory loss etc.) and a MoCA of ≤ 25/30. They had 
no evidence of impact of cognition on ADLs. This is in keeping with level 1 
criteria for the diagnosis of PD-MCI (Litvan et al., 2012). We chose a level 1 cut 
off for diagnosing PD-MCI in this pilot study due to time constraints and to 
reduce participant burden. Level 2 criteria requires formal in-depth 
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neuropsychological testing over 5 cognitive domains, which may be time 
consuming to deliver. Level 1 criteria for diagnosing PD-MCI is validated but 
provides a less comprehensive assessment than level 2 criteria and precludes 
comprehensive subtyping of MCI (Litvan et al., 2012). 
Control definition 
Healthy controls had no signs or symptoms of movement disorders or dementia. 
They were spousal or age matched community dwelling adults. 
Inclusion and exclusion criteria 




English language skills sufficient to allow valid use of cognitive tests (MoCA and MMSE) 
Written consent to participate in the study or, if the participant lacks capacity to consent, written 
consultation with an appropriate carer in accordance with the Mental Capacity Act 2005. 
PD PD Cognitive impairment Controls 
 PDD PD-MCI  
PD diagnosed by a 
neurologist or a 
geriatrician  
 
MoCA ≥ 26 
 




PD diagnosed by a 
neurologist or a 
geriatrician  
 
Duration of PD > 1 year 
 
Meets MDS task force 





due to cognition 
PD diagnosed by a 
neurologist or a 
geriatrician  
 








impairment  due to 
cognition 












Table 11. Exclusion criteria 
All Participants 
Age <60 or >85 




BMI ≥ 30kg/m2 
Comorbid gastrointestinal disease 
Concurrent use of non-selective anticholinergic medication 
≥3 kg weight change over the preceding 3 months 
Significant comorbidity 
Difficult venous access 
Allergy to ingredients of test meals 
 
PD PD cognitive impairment Controls 
Evidence of dementia 
Deep brain stimulation (DBS) 
Dementia within 12 months of 
diagnosis of PD 
DBS 
Evidence of Parkinsonism 
Evidence of dementia 
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Challenges and amendments 
Recruitment to this study was challenging due to the older age and comorbidity 
of participants and carers. As a result, a series of amendments from the 
research ethics committee and from research and development were required. 
Reasons for declining to take part in the study are detailed in Figure 9.  
In our original protocol we excluded participants who were already taking part in 
research. Many patients in the movement disorder service who are interested in 
research, however, were already taking part in low-burden longitudinal 
observational studies. We therefore extended recruitment to stop excluding 
participants who are taking part in observational studies.  
 
Figure 9. Reasons for declining by group  
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Similarly, our original protocol specified spousal controls. Healthy spousal 
controls proved difficult to recruit from clinic as their caring commitments made 
attending appointments difficult. Several spousal controls were also unwell 
themselves. We therefore expanded recruitment to include healthy older adults 
who had previously expressed an interest in taking part in research at CARU 
and members of the local Parkinson’s UK branch.  
There was particular difficulty in recruiting participants to the PD-CI group. This 
group was more likely to decline to take part than other groups and a greater 
proportion of participants in this group failed screening (12/30; 40%) compared 
with PD and (4/24; 16%) and controls HC (6/26; 23%). Figure 10 shows the 
reasons for screen failure by group.  
 
Figure 10. Reason for screen failures by group  
We therefore relaxed the inclusion criteria for participants in the cognitively 
impaired group. The original design of the study was to include participants with 
clear dementia only in the PD-CI group, with a cut off MoCA score of 21/30 or 
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below required for inclusion. Following this amendment participants with a 
diagnosis of PDD and a clear impact of cognitive impairment on activities of 
daily living can be included despite scoring >21/30 on MoCA. In order to obtain 
clearly different groups participants in the PDD group were still required to score 
<26/30 on this test for inclusion. We also added PD-MCI as a subgroup. These 
participants met the level 1 criteria for MCI according to the MDS task force 
criteria as detailed above (Litvan et al., 2012). Again, MoCA score was required 
to be <26/30. Recruitment is summarised in Figure 11. 
 
Figure 11. Summary of recruitment  
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Screening 
Once informed consent was obtained participants underwent a screening visit. 
The main objective of this visit was to make sure that inclusion criteria were met 
and that no exclusions were present. Participants underwent a review of past 
medical history, medication review and social history. Impact of cognition on 
activities of daily living was assessed as part of social history through self-report 
or a collateral history from a carer. Physical examination including a general 
examination and examination of the cardiovascular, respiratory, gastrointestinal 
and neurological systems was carried out. This was in order to exclude 
undiagnosed exclusion criteria such as Parkinson’s disease in control groups. 
Participants were weighed and measured and BMI was calculated. Fat mass 
was assessed using bioimpedance using a set of Tanita scales. Where it was 
not possible to measure percentage body fat using Tanita (for example, due to 
pacemaker or inability to stand unaided) fat mass was been calculated using 
the following formulae (Jebb et al., 2000); 
Male % fat = (1.281 x BMI) – 10.13 
 
Female % fat = (1.480 x BMI) - 7.00 
When it was not possible to measure height, previous heights recorded in the 
medical notes was used. 
Motor disease severity was assessed using the movement disorders society 
unified rating scale (UPDRS) motor section. This assessment is well validated 
in the PD population (Martinez-Martin et al., 2013). Mood was assessed using 
the geriatric depression scale (GDS), which is widely used in clinical practice 
but which has not been validated for use in dementia(Yesavage et al., 1983). 
This is a limitation of its application. Participants were therefore not excluded on 
the basis of a high GDS score alone, but only if they had symptoms of 
uncontrolled clinical depression. Cognition was assessed using the Montreal 
Cognitive Assessment (MoCA), which is well validated in PD(Dalrymple-Alford 
et al., 2010). Baseline eating habits were assessed using the three factor eating 
questionnaire (Stunkard and Messick, 1985). Finally, blood tests were taken to 
exclude DM and assess general health.   




Test visits were carried out no more than 5 weeks after screening. Patients 
were tested after a 12 hour fast and “off” i.e. having not taken any of their usual 
PD medication. Other medication was taken as usual. Water was allowed up to 
2 hours prior to testing. Patients were re-weighed if more than 7 days had 
passed since their screening visit. The following standard 300 kcal breakfast 
was offered; 
 One slice of white toast with butter 
 One Activia Strawberry yoghurt 
 Jam 
 Short bread biscuit 
 A 200 ml glass of water 
Participants were allowed 20 minutes to complete their meal and were required 
to eat all of it. One hundred and twenty mls of water was given at 60 minutes 
and 120 minutes for participant comfort and to prevent dehydration. 
Assessment of appetite 
Visual analogue scales (VAS) were administered to assess fullness and satiety 
prior to breakfast and then 5,15,30,60,120 and 180 minutes post-prandially 
(Flint et al., 2000). Usual eating behaviour was assessed using the three-factor 
eating questionnaire (TFEQ) (Stunkard and Messick, 1985). 
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Assessment of intake 
At 180 minutes participants were given an ad libitum meal comprising a pre-
measured selection of foods. They were invited to eat as much as they liked 
and to take their usual PD medications at this time. Presentation of the meal 
was standardised (see appendix E). The meal comprised of; 
 1 medium  banana 
 1 chocolate mousse 
 I bag ready salted crisps 
 Grated cheddar cheese 
 Tomato and mozzarella pasta bake 
 1 large glass of water 
Each food item was weighed before and after the meal to gain an accurate 
measure of the food ingested. Energy and macronutrient intake was calculated 
using the Tesco supermarket’s published nutritional data. 
A bite counter was also used to measure mouthfuls of food consumed. Bite 
counters are wrist-worn accelerometers which record each hand movement 
towards the mouth. They have been used to estimate food consumption in 
healthy adults as bite rate has been found to correlate with energy intake (Dong 
et al., 2012, Scisco et al., 2011). No research has evaluated their use in PD 
patients to date. Bite count and frequency were recorded both manually and 
using the bite counter during the ad libitum meal. 
Blood sampling 
Blood sampling was carried out via a peripheral venous cannula. Blood was 
drawn at baseline (fasting) and 5,15,30,60,120 and 180 minutes post-prandially 
for glucose, lipid profile, leptin, insulin, GH, PYY, GLP-1, total ghrelin, acyl-
ghrelin and TNFα. Blood taken in order to test glucose and lipids was drawn into 
gold topped SST™ BD vacutainers and analysed at the local hospital according 
to their usual standard operating procedures (SOP). Blood taken in order to 
analyse leptin, insulin, GH, PYY, GLP-1, total ghrelin, acyl-ghrelin (AG), was 
drawn into EDTA-containing vacutainer tubes and processed immediately on 
site before being frozen at -80. Briefly, whole blood treated with EDTA was 
divided into three 2 millilitre (ml) aliquots for each time point. One aliquot was 
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added to 80ul of 4-(2-Aminoethyl)-benzenesulfonyl fluoride stock solution 
(50mg/ml, or 200mM) to give a final concentration of 2mg/ml, or 8mM. This was 
centrifuged immediately along with one other aliquot at 2,000 x g for 15 minutes 
at 4 ± 2 oC and 400 microlitre (µl) of the supernatant pipetted into cryotubes for 
storage at -80 oC. The final fraction was kept on ice until it was centrifuged at 
1,000 x g for 10 mins to produce platelet rich plasma. Again, the supernatant 
was pipetted into crytubes for storage at -80 oC. Please see appendix F for the 
detailed SOP. 
Hormonal Analysis 
Hormone levels were measured by Prof. Jeff Davis and Ms Amanda Hornsby at 
Swansea University. AEBSF treated samples were used to quantify leptin, 
insulin, IL-6, PYY, GLP-1 and AG using the Milliplex MAP Kit-Human Metabolic 
Hormone Magnetic Bead Panel 96-well plate multiplex assay. Total ghrelin was 
assessed using the Human Ghrelin (Total) ELISA Kit (Cat. No. EZGRT-89K, 
Millipore). Insulin-like growth factor-1 was assessed using Human IGF-1 
DuoSet ELISA kit (cat. No. DY291, R&D Systems). Finally, GH was assessed 
using Human GH DuoSet ELISA kit (Cat. No. DY1067, R&D Systems). 
Completion and follow-up 
Each participant completed the study within 6 weeks including follow up contact 
by telephone. Follow up was carried out 7-10 days after the second visit in order 
to answer any questions they may have and to gather feedback about their 
experience. 
3.6 Medication 
As described above, participants were tested “off” their usual dopaminergic 
medication. We asked participants not to take their PD medications on the 
morning of the test visit. In practice, this meant no PD medication from midnight 
until the ad libitum meal; 8-9 hours prior to breakfast and 11-12 hours before 
lunch. This was in order to reduce potential dopaminergic effects on appetite. 
We did not ask participants to withhold long acting dopaminergic medications 
for any longer than their other PD medications, however, as we felt that this 
would be too burdensome. Controlled release levodopa and levodopa in 
combination with the catechol-O-methyl transferase (COMT) inhibitor 
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entacapone fall to less than 10% of peak dose at 6.3 and 7.5 hours respectively 
(Hsu et al., 2015) but “washout” periods of several days to return to baseline 
have been reported in the literature (Khor and Hsu, 2007). Other studies have 
used washout periods of 36 hours for longer acting drugs such as dopamine 
agonists (Athauda et al., 2017). 
Participants were allowed to take other medications, including cholinesterase 
inhibitors during the study period. We therefore compared cholinesterase 
inhibitor, antidepressant and long acting PD medication use between groups. 
We checked each medication that participants were taking for pro-appetitive 
and anorectic side effects using the British National Formulary (BNF) online 
(www.bnf.nice.org.uk). Where there was ambiguity (e.g. “weight change”) in the 
listed side effects, we consulted the manufacturer’s product information. 
Monoamine oxidase inhibitors (MAOIB) are anorectic drugs. Although they were 
not taken on the day of testing they were included in the anorectic drug burden 
as they irreversibly inhibit monoamine oxidase-B(Schapira et al., 2005, LeWitt, 
2009). We also calculated participants’ usual levodopa equivalent dose (LED) in 
the PD and PD-CI groups using the well-validated tool by Tomlinson et al 
(Tomlinson et al., 2010). 
3.7 Statistical analysis 
Statistical analysis was carried out with Dr. Mario Siervo using IBM SPSS 
statistics software version 22. Graphs were produced using StatSoft Statistica 
version 13. Age, disease duration, BMI, fat mass and medications were not 
normally distributed. The demographic characteristics; age, BMI and fat mass 
were therefore compared between groups using Kruskall Wallis testing. Mann-
Whitney U tests were used to compare disease duration and total UPDRS score 
between PD and PDD groups. Non-PD medications were compared using the 
Kruskall Wallis test whilst PD medications and LED were compared using the 
Mann-Whitney U test. Gender was compared using the chi-squared test. All 
other variables that were not normally distributed, such as hormone levels 
scores were log-transformed for analysis. MoCA was reversed and then log 
transformed (Ln [31-MoCA score]) in order to increase normality. Assumptions 
for analysis of variance (ANOVA) and linear regression were checked using 
SPSS. 
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Repeated measures linear regression was used to compare analytes between 
groups over time. Disease duration was included as a covariate in this model. 
Area under the curve was also calculated for each analyte and for visual 
analogue scales using the trapezoidal method. The AUC for each analyte was 
compared between groups using ANOVA. Post-hoc comparisons were carried 
out using the least significant difference method. Analysis was then repeated 
including potentially confounding covariates with analysis of covariance 
(ANCOVA). Where PD duration was included as a covariate disease severity 
measured by motor UPDRS was not included in order to avoid over correction 
for very similar information. We had an accurate record of date of diagnosis for 
each participant in the PD and PD-CI groups. We chose to include disease 
duration rather than UPDRS in our analysis as disease duration is not prone to 
day-to-day fluctuation or medication effects. 
This study was novel in that appetite, energy intake and many of the hormones 
tested had never been examined in the context of cognitive impairment in PD 
previously. Analysis was therefore exploratory rather than hypothesis-driven. To 
this end we tested a large number of potential associations between variables 
using Pearson’s correlation the results of which are presented in Appendix I.  
Variables which correlated with reversed log transformed MoCA were entered 
into a linear regression model to determine predictors of cognition across the 
whole cohort. This process was repeated for energy intake, with the additional 
inclusion of AG in the analysis to ensure that appetite suppressant factors and 
stimulant factors were balanced in the model. 
Retrospective analysis of insulin resistance was undertaken using the 
Homeostasis Assessment Method which is calculated as follows (Wallace et al., 
2004, Matthews et al., 1985); 
HOMA-IR= (fasting plasma insulin microU/l x fasting plasma glucose mmol/l) 
      22.5 
Units were converted as proposed guidelines from the World Health 
Organisation (Burns et al., 2010). 
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Throughout the statistical analysis process, where hormone levels were not 
detectable they were treated as missing values. Missing data was not 
interpolated or extrapolated but area under the curve was recalculated taking 
missing data into account by adjusting the length of time between data points. 
Area under the curve was not calculated where more than 3 values were 
missing per participant.  
   
 96 
Chapter 4. Do appetite and food intake differ between people 
with PD, PD-CI and controls?  
Weight loss is a risk factor for cognitive impairment in PD (Kim et al., 2012, 
Lorefalt et al., 2004, Uc et al., 2006), though the mechanisms underlying this 
are not well understood. It is not yet known whether energy intake is higher in 
people with PD-CI as is seen in people with PD and normal cognition. Energy 
intake could equally be reduced due to higher burden of non-motor symptoms, 
difficulty with self-feeding or hormonal consequences of neurodegeneration 
(Aarsland et al., 2001, Bachmann and Trenkwalder, 2006, Barichella et al., 
2009, Beyer et al., 1995). This study examined 55 weight stable older adults 
with a healthy BMI in three groups 1) healthy controls (n=20), 2) PD without 
cognitive impairment (n=19) and 3) PD-CI (n= 16, 8 PD MCI and 8 PDD). All 
participants in the PD and PD-CI groups were tested “off” their usual PD 
medication to avoid possible confounding effects of levodopa. The aim of this 
chapter is to determine whether perceived and objective measures of appetite 
and food intake differ between patients with PD, PD-CI and controls. 
4.1 Results 
4.1.1 Demographics 
There were no significant differences between age, gender, BMI, fat mass or 
the number of comorbidities other than PD between groups. MoCA was 
significantly lower in the PD-CI group compared to other groups (p<0.001). The 
duration of PD and the severity of motor symptoms as measured by the MDS 
UPDRS part 3 were greater in the PD-CI group than the PD group (p=0.02 and 
p=0.007 respectively) Because PD duration and motor UPDRS reflect similar 
information, PD duration alone was used for correction in this analysis in order 
to prevent over-correction of data. No participant had clinical depression but 
GDS scores were higher in the PD-CI group (Kruskal-Wallis p<0.001, pairwise 
post-hoc test with Bonferroni correction p<0.001 significance between control 
and PD-CI, p=0.000 between PD and PD-CI and p=0.56 between controls and 
PD group)). GDS has therefore been included in the ANCOVA comparing area 
under the curve (AUC). A summary of demographic data is presented in Table 
12.  
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Table 12. Summary of demographic details  
Variable (mean ±SD) Controls PD PD-CI P value 
Age in years  74.00 ±6.28 72.53±5.46 74.31±6.01 P=0.648ǂ 
Gender % female 45 47.4 43.8 P=0.976ǂǂ 
Fat Mass %  28.78 ± 7.25 28.48±8.46 25.39±7.66 P=0.268ǂ 
BMI kg/m2 25.75±2.04 25.18±2.83 24.03±3.31 P=0.242ǂ 
Number of comorbidities 2.85±1.93 2.74±1.56 2.50±1.79 P=0.874ǂ 
MoCA score 28.35±1.14 27.58±1.50 17.25±5.43 P<0.001ǂ 
Motor UPDRS score  NA 31.95±13.22 49.19±19.16 P=0.007ǂǂǂ 
Duration of PD in months  NA 69.53±69.10 107.25±59.48 P=0.022ǂǂǂ 
GDS score  1.25±0.91 2.00±1.41 5.81±2.51 P=0.000ǂ 
ǂ Kuskal-Wallis test  ǂǂ Pearson Chi-squared test  ǂǂǂ Mann-Whitney U test 
There was no significant difference in age (p=0.34, Mann Whitney U test) or 
percentage female (p=0.104 Pearson Chi-squared test) between those who 
passed or failed screening. Our cohort had an average of 2.96 comorbidities 
other than PD overall, with no significant difference between those who passed 
or failed screening (p=0.72)  
4.1.2 Medication 
 
Table 13. Medication use by group 
Medication Controls (n=20) PD (n=19) PD-CI (n=16) P value 
Standard preparation levodopa N/A 16 (84.2%) 16 (100%) P=0.101ǂǂǂ 
Controlled release levodopa N/A 3 (15.8%) 9 (56.2%) P=0.013ǂǂǂ 
Dopamine agonists N/A 7 (36.8%) 0 (0%) P=0.007ǂǂǂ 
MAOIB N/A 11 (57.9%) 2 (12.5%) P=0.006ǂǂǂ 
COMT inhibitors N/A 4 (21.0%) 7 (43.8%) P=0.156ǂǂǂ 
LED N/A 557.8±377.8 737.5±493.3 P=0.259ǂǂǂ 
Cholinesterase inhibitors 0 (0%) 0 (0%) 7 (43.8%) P<0.001ǂ 
Selective anticholinergics 1 (5%) 3 (15.8%) 3 (18.8%) P=0.422ǂ 
 Solifenacin 1 3 1  
 Trospium 0 0 2  
Antidepressants 0 (0 %) 0 (0%) 7 (43.8%) P<0.001ǂ 
 Mirtazapine 0 1  3   
 Citalopram 0 0  1   
 Venlafaxine 0 0  2   
 Fluoxetine 0  0  1   
Pro-appetitive medicines 0 (0%) 0 (0%) 3* (18.8%) P=0.022ǂ 
 Mirtazapine 0  0  3   
 Pregabalin 0  0  2   
Anorectic medications 0 (0%) 11 (57.9%) 6 (37.5%) P<0.000ǂ 
 MAOIB N/A 11 2   
 Citalopram 0  0  1   
 Venlafaxine 0  0  2   
 Fluoxetine 0  0  1   
 Clozapine 0  0  1   
 Amitriptyline 0  1  0   
ǂ Kuskal-Wallis test  ǂǂ Pearson Chi-squared test  ǂǂǂ Mann-Whitney U test  
* 2 PD-CI participants on both mirtazapine and pregabalin  
** 1 PD-CI participant on both clozapine and venlafaxine 
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There was no significant difference in usual LED or COMT inhibitor use 
between the PD and PD-CI groups (p= 0.259 and p=0.156, respectively). 
Dopamine agonist and MAOIB use were significantly greater in the PD group 
compared to the PD-CI group (p=0.007 and p=0.006 respectively), whilst 
controlled release levodopa use was more common in the PD-CI group 
(p=0.013). No participants in the control or PD groups were taking 
antidepressants or cholinesterase inhibitors. Pro-appetitive medication use was 
more common in the PD-CI group (p=0.022). Anorectic medication use was 
more common in the PD group (p<0.001), almost entirely due to MAOIB use. 
There was no significant difference in selective anticholinergic use between 
groups. 
4.1.3 Missing data 
There was no missing demographic data. One participant in the PD-CI group 
did not have the frequency of PD medication recorded due to oversight. Type 
and dose of medication were recorded. There was little missing data regarding 
appetite and energy intake. All participants had visual analogue scales for 
hunger and fullness completed, though 4 participants did not have data 
recorded at 5 minutes due to time pressure. All participants had energy intake 
at the ad libitum meal recorded. Three participants did not have an accurate 
record of the duration of their ad libitum meal. Missing data for appetite and 
intake are summarized in table 14. 
Table 14. Number of participants with data missing by variable 
 Control PD PD-CI Comments 
VAS Hunger 0 1 3 Time point 5 missing in all cases due to time 
pressure all other data complete 
VAS fullness 0 1 3 Time point 5 missing in all cases due to time 
pressure all other data complete 
Duration of ad 
libitum meal 
1 1 1 Time meal finished not documented in source 
data 
4.1.4 Appetite 
Subjective feelings of hunger and fullness were measured using 100mm visual 
analogue scales (VAS). Participants with cognitive impairment were supported 
by their carers in completing the VAS. Participants from all groups showed 
similar patterns of hunger over the course of the morning, with a reduction in 
hunger after breakfast which recovered to baseline at 3 hours. Repeated 
   
 99 
measures ANCOVA showed that change over time was not significantly 
different between groups when corrected for PD duration (p=0.41) (Figure 12).  
 
Figure 12. Hunger over time by group 
Area under the curve for hunger was compared between groups using ANOVA. 
There was no significant difference between groups (p=0.48), even after 
controlling for PD duration and depression in the analysis (p=0.105) (Figure 13). 
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Figure 13.  Mean hunger area under the curve 
Results for fullness followed a similar pattern, with all groups showing an 
increase in fullness after breakfast which declined over 3 hours. Repeated 
measures ANCOVA showed that change over time was not significantly 
different between groups when corrected for PD duration (p=0.15) (Figure14). 
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Figure 14. Fullness over time by group 
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Area under the curve was once again not significantly different between groups 
(p=0.58) even after correction for depression and PD duration (p=0.44) (Figure 
15). 
Figure 15. Mean fullness area under the curve 
Usual eating behaviour with regard to restraint, disinhibition and hunger were 
recorded at the screening visit using the Three Factor Eating Questionnaire 
(TFEQ) (Stunkard and Messick, 1985). Restraint was significantly different 
across the groups (Kruskall-Wallis test p=0.03). Pairwise comparison with 
Bonferroni correction confirmed the PD-CI group had significantly lower restraint 
than the control group (p=0.02). There was no difference in hunger or 
disinhibition between groups 
4.1.5 Energy intake 
Energy intake was calculated by weighing food before and after the meal and 
calculating the total energy consumed in kilocalories (kcal) based on the 
manufacturers published information. Energy intake did not differ significantly 
between groups (p=0.29) (Figure 16). 
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Figure 16. Total energy intake by group 
Energy intake significantly negatively correlated with the satiety hormone PYY 
(r= -0.29, p=0.03) and with AUC fullness (r=-0.55, p<0.001). There was a 
positive correlation between energy intake and hunger (r=0.44, p=0.001) and 
energy intake and duration of the meal (r=0.39, p=0.004). There were no other 
significant correlations between other hormones of energy homeostasis and 
energy intake. There was no significant correlation between cognition (Log 
transformed reversed MoCA) and energy intake (r=-0.06, p=0.66). Scatter plots 
are shown in Figure 17. Time taken to complete the ad libitum meal and PYY 
AUC were not significantly different between groups (p=0.15 and p=0.38 
respectively). 
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Figure 17. Scatter plots showing the relationship between energy intake (Kcal), Ln 
PYY, fullness, hunger and duration of ad libitum meal 
In order to determine whether any of these factors predicted energy intake all 
variables with a significant correlation with energy intake were entered into a 
multiple linear regression model along with AG. Acyl ghrelin was included, 
despite no significant correlation with energy intake, in order to ensure balance 
in the model between factors promoting intake (AG and VAS hunger) and 
factors limiting intake (PYY and VAS fullness). This model predicted energy 
intake, accounting for 44.9% of the variance (F [4-48] 9.79, R squared=0.45). 
Fullness and PYY contributed significantly to the model (p=0.009 and 0.002 
respectively) but hunger and AG did not (p=0.11 and 0.76 respectively). 
Table 15. Multiple linear model regression for predictors of energy intake 
Variable Unstandardised 
coefficient B 
Standard error of 
B 
β significance 
AG AUC -4.861 15.807 -0.036 P=0.760 
PYY AUC -64.532 19.892 -0.348 P=0.002 
Hunger AUC 1.236 0.753 0.243 P=0.107 
Fullness AUC -1.722 0.637 -0.401 P=0.009 
Dependent variable is energy intake 




The majority of research into eating habits in PD has focused on oral intake, 
rather than patient reported measures of appetite. This study is primarily 
concerned with examining hormones of energy homeostasis in PD and PD-CI. 
These hormones profoundly affect eating behaviour through manipulating 
feelings of hunger and fullness generated with the arcuate nucleus of the 
hypothalamus (Cowley et al., 2001, Fan et al., 1997). Weight loss in PD has 
been paradoxically linked to increased energy intake in PD (Barichella et al., 
2017). It has been suggested that appetite may be inadequate in PD, especially 
in those with a higher burden of non-motor symptoms (Politis et al., 2010). 
Given the link between weight loss, increasing numbers of non-motor symptoms 
and the development of cognitive impairment in PD (Lorefalt et al., 2004, Uc et 
al., 2006), we hypothesized that appetite may be diminished in PD-CI. 
Alternatively, appetite may be increased in keeping with the observed increase 
in energy intake in PD (Chen et al., 2003). To date there are no published 
studies examining appetite in PD-CI.  
Appetite was assessed using VAS of hunger and fullness. We found that the 
pattern of hunger between meals was as expected for all groups, with a rapid 
decline after breakfast and recovery towards the ad libitum meal at 180 minutes 
(Figure 12). There was no significant difference in hunger AUC between groups. 
Similarly, we saw an attendant increase in fullness after eating in all three 
groups, which declined over 180 minutes (Figure 14). Again, there was no 
significant difference in fullness between groups. Our findings were similar to 
those seen in the original validation study carried out for VAS in 55 healthy 
men. Here participants were followed for 4.5 hours after a standardised 
breakfast and had VAS for hunger, fullness and a battery of other food 
preferences every 30 minutes. Hunger reached a nadir 30 minutes after 
breakfast and recovered back to baseline between 180 and 300 minutes. 
Similarly, fullness peaked at 30 minutes and returned to baseline at 240 
minutes (Flint et al., 2000). It is possible that validity of VAS was inadvertently 
compromised in the PD-CI group by guidance from the nurse delivering the tool 
or from over-zealous carers. Against this, AUC was positively correlated with 
energy intake whilst fullness AUC was negatively correlated with energy intake 
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across the whole cohort. Moreover, confidence intervals for hunger and fullness 
AUC are also similar between groups. Our data are in keeping with previous 
research showing that energy intake at an ad libitum meal was positively 
predicted by hunger (measured using VAS) and negatively predicted by fullness 
(measured using VAS) in both younger and older adults (Parker et al., 2004a). 
Overall, our results suggest that VAS, whilst not validated for use in PD or PD-
CI, were reasonably accurate in ascertaining feelings of hunger and fullness in 
this study. 
Usual eating behaviour was assessed using the TFEQ. This is a 51 item 
questionnaire which evaluates three domains of eating behaviour; restraint; the 
extent to which a person is conscious of their eating habits and limits their 
intake; disinhibition, the degree to which they eat due to emotional cues; and 
hunger, how hungry they tend to feel. The TFEQ has mainly been used in 
research around obesity and has not been validated for use in a cognitively 
impaired cohort. In the context of obesity, higher levels of restraint can result in 
increased intake at a subsequent meal (Stunkard and Messick, 1985). A score 
of 11 or more in the restraint domain suggests high levels of restraint (Lesdéma 
et al., 2012). In this study of non-obese people it seems unlikely that restraint 
significantly impacted the eventual energy intake at the ad libitum meal. Only 2 
participants, both controls, had restraint scores more than 11. If significant, this 
would have most likely resulted in greater intake in the control group, which was 
not observed (see below). Disinhibition and hunger were not significantly 
different between groups which is in keeping with results from hunger and 
fullness VAS.  
There was no correlation between VAS AUC for hunger or fullness and MoCA, 
disease duration or motor disease severity. Taken together with the normal 
patterns of post-prandial hunger and fullness over time, these data suggest that 
sensations of hunger and fullness are intact in people with PD and PD-CI. 
Overall, our results do not support the hypothesis that appetite is disordered in 
PD-CI. This is perhaps unexpected since it is intuitive that the number of non-
motor symptoms is likely to be higher in the PD-CI group. We did not, 
unfortunately, examine the burden of non-motor symptoms across our cohort so 
no further conclusions may be drawn regarding this.  
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4.2.2 Energy intake 
Several studies suggest that energy intake is increased in PD (Barichella et al., 
2017, Chen et al., 2003). This is the first study to look at energy intake in PD-CI. 
We found no correlation between energy intake and MoCA and there was no 
difference in energy intake between groups. This suggests that cognitive status 
did not alter feeding behaviour in our cohort. Furthermore, there were no 
significant correlations between energy intake and disease duration or disease 
severity. The time taken to complete a meal significantly correlated with energy 
intake across the cohort, even in those with more advanced motor PD. It is 
therefore unlikely that mechanical factors, such as bradykinesia and tremor, 
impacted energy intake in our cohort. Energy intake was predicted by PYY (a 
powerful anorexigenic hormone (Degen et al., 2005)) and fullness across the 
whole cohort, providing further evidence that appetite is not disrupted in our PD-
CI group. Finally, no PD-related parameter predicted energy intake in the linear 
regression. Overall, we did not see the reported increase in energy intake in 
participants with PD (Barichella et al., 2017, Chen et al., 2003) or our proposed 
altered intake in PD-CI (see Chapter 2).  
The design of our study may have confounded our results. Many of the studies 
demonstrating increased energy intake in PD have relied on indirect measures 
of food intake such as food diaries (Davies et al., 1994, Delikanaki-Skaribas et 
al., 2009), semi-quantitative food questionnaires (Logroscino et al., 1996) and 
food frequency questionnaires (Chen et al., 2003). Semi-quantitative food 
questionnaires and food frequency questionnaires reflect dietary habits over 
time, rather than discrete eating episodes, whilst food diaries capture a daily 
record of energy intake (Gibson, 1990). It is possible that energy intake in PD 
and PD-CI is increased through increased meal frequency rather than increased 
meal size. Alternatively, intake could be reduced in PD-CI due to cognitive 
difficulties affecting meal preparation. Our study was not designed to measure 
these factors. We directly weighed food eaten during an ad libitum meal in order 
to calculate energy intake. Whilst this allowed us to accurately record exactly 
what food was eaten during this study, the setting was artificial as participants in 
the PD and PD-CI groups were tested off their usual PD medications. Moreover, 
participants were offered a standardised range of foods, which may not have 
reflected their usual diet or food preferences. The ad libitum meal was quite 
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large and more than many people would eat in a normal lunch sitting (see 
appendix E). This may be important as there is evidence that greater portion 
size results in increased energy intake, irrespective of body habitus or appetite 
(Rolls et al., 2002). Another possible confounder could be medication as both 
the PD and PD-CI groups had relatively high rates of anorectic medication use. 
This could have masked the previously reported increased energy intake in PD 
(Chen et al., 2003). Unfortunately, our study was not powered to correct for this 
effect and we are therefore not able to draw further conclusions regarding the 
impact of medication on appetite or energy intake in PD and PD-CI. Finally, it 
has been suggested that weight-losing and weight stable people with PD may 
be phenotypically different (Sauerbier et al., 2016, Sharma and Turton, 2012). 
Our study excluded participants with recent weight loss. Our results are in 
keeping with a previous study that showed no difference in energy intake 
(measured by 3 day food diary) between controls and people with PD that also 
excluded participants with weight loss (Toth et al., 1997). As a result, we may 
not have been able to capture differences in appetite occurring in people with 
PD and weight loss, who may be at greater risk of more rapid cognitive decline 
than their weight stable counterparts (Kim et al., 2012). Despite these caveats, 
our study allows us to conclude that cognitive impairment in PD does not result 
in increased or reduced meal size in a supported research setting. 
4.3 Summary and conclusions 
We have found no evidence that appetite or energy intake are different in PD or 
PD-CI compared with controls. These results may be confounded by the fact 
that our participants were weight stable or as a result of artificial experimental 
conditions. Further studies into energy intake and cognition in PD should 
include weight-losing participants, measures of non-motor symptoms in PD and 
a mixture of direct observation and food diaries to accurately measure free 
living nutritional intake. There are a number of strengths and limitations of this 
study, which will be discussed in depth in chapter 7. 
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Chapter 5. Do hormones of energy homeostasis levels differ 
between people with PD, PD-CI and controls? 
There is evidence that hormones of energy homeostasis such as AG, insulin 
and leptin may be neuroprotective in the context of neurodegenerative disease 
(see Chapter 2; Introduction and literature review). Moreover, total ghrelin levels 
have been shown to be low in PD patients who lose weight (Fiszer et al., 2010). 
This chapter explores the hypothesis that fasting and post-prandial ghrelin, GH, 
IGF-1, insulin, GLP-1 and leptin concentrations differ between controls, PD and 
PD-CI groups. Participants in the PD and PD-CI groups were tested “off” their 
usual PD medication. Our primary aim was to determine whether hormones of 
energy homeostasis could be used as biomarkers for cognitive decline in PD. 
5.1 Results 
5.1.1 Demographics and medication 
These data are from the same study and participants as chapter 4. 
Demographic and medication data are therefore the same as reported there. 
Groups were matched for age and gender so these have not been corrected for 
in analysing our data. As in chapter 4, PD duration and GDS were included in 
ANCOVA comparing AUC. 
5.1.2 Missing data 
A number of participants were missing data regarding hormone levels, as some 
were undetectable. This was particularly the case for IGF-1 and GLP-1. A 
summary of missing data is outlined in Table 16. 
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Table 16. Number of participants missing data per analyte 
Analyte Control PD PD-CI Comments 
Acyl ghrelin 2 1 1 2 controls all values undetectable. 1 PD and 1 PD-CI 
participant missing data at 5 minutes due to difficult blood 
draw. 
Total ghrelin 0 1 1 1 PD and 1 PD-CI participant missing data at 5 minutes 
due to difficult blood draw. 
PYY 0 2 1 1 PD participant undetectable at baseline. 1 PD and 1 PD-
CI participant missing data at 5 minutes due to difficult 
blood draw. 
Leptin 0 1 2 1 PD and 1 PD-CI participant missing data at 5 minutes 
due to difficult blood draw. 
Insulin 0 1 1 1 PD and 1 PD-CI participant missing data at 5 minutes 
due to difficult blood draw. 
GLP-1 1 9 4 Variable number of undetectable results per participant.  
IGF-1 3 8 6 Variable number of undetectable results per participant. 3 
controls, 7 PD and 1 PD-CI had no recordable data for 
IGF.  
GH 0 1 1 1 PD and 1 PD-CI participant missing data at 5 minutes 
due to difficult blood draw. 
5.1.3 Hormones of energy homeostasis between groups 
The following data were transformed to achieve normal distribution in order to 
aid statistical analysis. For clarity in the text below transformed variables will be 
referred to as follows; 
Table 17. Shorthand nomenclature of transformed data 
Transformed variable Shorthand reference 
Log base 10 reversed (1-score out of 31) Montreal Cognitive Assessment  Reversed MoCA 
Log base 10 transformed glucose glucose 
Log base 10 transformed acyl-ghrelin AG 
Log base 10 transformed total ghrelin TG 
Log base 10 transformed growth hormone GH 
Log base 10 transformed insulin-like growth factor IGF-1 
Log base 10 transformed insulin insulin 
Log base 10 transformed glucagon-like peptide 1 GLP-1 
Log base 10 transformed leptin leptin 
Log base 10 transformed peptide YY  PYY 
Log base 10 transformed HOMA-IR HOMA-IR 
 
Relationships between variables were examined using scatter plots and 
Pearson correlations. Means were compared using ANOVA and ANCOVA with 
inclusion of disease duration and GDS as covariates as outlined above. 
Variables were compared over time using a repeated measure multivariate 
linear model. Please see Chapter 3: Methods for further details. 
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The ghrelin IGF-1 axis 
Fasting AG and AG AUC correlated negatively with age (r=-0.39, p=0.004 and 
r= -0.386, p=0.004, respectively), reversed MoCA (r=-0.35, p=0.011 and r=-
0.38, p=0.005, respectively) and GDS (r=-0.30, p=0.03 and r=-0.30, p=0.03, 
respectively). Fasting AG significantly correlated with fasting TG (r=0.78, 
p<0.001) whilst AG AUC correlated significantly with TG AUC (r=0.78, p<0.001). 
There was a significant negative correlation between fasting AG and BMI (r=-
0.29, p=0.04) but not with fat mass or motor UPDRS disease duration. Scatter 
plots are shown in Figure 18 and Figure 19. There was no demonstrable 
correlation between AG AUC and fat mass, BMI, motor severity of PD 
(measured by UPDRS), PD duration and energy intake or any other hormones 
tested. Visual inspection of scatter plots did not reveal any non-linear 
relationships between AG or TG and any of these variables. 
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Figure 18. Scatterplots of fasting AG with TG, age, BMI, reversed MoCA and Geriatric 
depression scale   
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Figure 19. Scatter plots for AG AUC and age, GDS, reversed MoCA and TG AUC. 
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Repeated measures ANCOVA showed that change in AG over time was not 
significantly different between groups when corrected for PD duration (p=0.99). 
This is represented graphically in Figure 20. 
  
Figure 20. Acyl-ghrelin over time 
Fasting AG was not significantly different between groups with or without 
inclusion of GDS and PD duration in the analysis (p=0.12 and 0.10, 
respectively). There was a non-significant difference in AG AUC between 
groups (p=0.07). In view of the near significant difference post hoc analysis 
using the least significant difference test (LSD) was performed and a significant 
difference was seen between the PD and PD-CI groups, with AG AUC being 
lower in the PD-CI group (p=0.02) (Figure 21). There was no difference 
between groups when AG AUC was compared between groups using ANCOVA 
to account for PD duration and GDS (p=0.16). 
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Figure 21. Mean fasting AG by group 
Figure 22. Mean AG AUC by group  
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One of our control subjects had a vagotomy in early adulthood. They did not 
have active gastrointestinal disease and were therefore included in the study. 
Ghrelin release is thought to be vagal-nerve dependent (Seoane et al., 2007). In 
order to ensure that their inclusion did not bias our results the data were re-
analysed excluding this participant. The results were unchanged, with no 
significant difference in AG AUC between groups (p=0.07) but significantly 
lower AG AUC in the PD-CI group on post-hoc analysis (p=0.02). 
Fasting TG and TG AUC negatively correlated with body mass index (r= -0.33, 
p=0.02 and r=-0.40. p=0.003, respectively). There was a near-significant 
negative correlation between age and TG AUC (p=0.05), which appears 
genuine on inspection of the scatterplot. Fasting TG did not correlate with age. 
There were no other significant correlations seen. Visual inspection of scatter 
plots between fasting TG and TG AUC against other variables did not reveal 
any non-linear relationships. Scatter plots are shown in Figure 23 and Figure 
24. 
Figure 23. Scatter plot for relationship between fasting TG and BMI 
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Figure 24. Scatter plots for relationships between TG AUC and age and BMI 
There was no significant difference in TG over time between groups, even after 
correction for PD duration (p=0.67) (Figure 25). Comparison of fasting TG and 
TG AUC between groups showed no significant difference between groups, with 
or without correction for PD duration or GDS. 
Figure 25. Total ghrelin over time 
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There were no significant differences between fasting TG or TG AUC compared 
between groups (p=0.61 and p=0.80, respectively) even with correction for PD 
duration and GDS (p=0.58 and p=0.60, respectively) (Figure 27 and Figure 28). 
Figure 26. Fasting TG by group  
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Figure 27. Total ghrelin AUC between groups  
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Both fasting GH and GH AUC significantly positively correlated with age (r= 
0.31, p=0.02 and r=0.38, p=0.004, respectively). Growth hormone AUC and 
IGF-1 AUC significantly correlated with each other (r=0.45, p=0.003) but no 
such relationship was seen between fasting GH and fasting IGF-1 (Figure 29 
and Figure 30). There were no other significant correlations and visual 
inspection of scatter plots did not reveal any non-linear relationships between 
variables. 
Figure 28. Scatter plot of fasting GH and age 
 
Figure 29. Scatter plot of GH AUC against age and IGF-1AUC  
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There was no significance difference between groups in GH levels over time, 
even after correction for PD duration (p=0.10) (Figure 31). 
 
Figure 30. Growth hormone over time 
There was no difference in fasting GH between groups, with or without including 
PD duration and GDS in the analysis (p=0.65 and 0.87, respectively). A similar 
pattern was seen for GH AUC (p=0.65 and 0.91, respectively) (Figure 32 and 
Figure 33). 
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Figure 31. Fasting GH by group 
Figure 32. Growth hormone AUC by group 
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Insulin-like growth factor 1 AUC correlated significantly with growth hormone 
(r=0.46, p=0.003) as detailed above (Figure 30). There were no other significant 
correlations between fasting IGF-1 or IGF-1 AUC and any other variable. There 
was no significant difference in IGF-1 levels over time between groups (p=0.96) 
(Figure 34). 
 
Figure 33. Insulin-like growth factor over time by group 
There was a non-significant difference in IGF-1 AUC between groups (p=0.07). 
In view of the near significant difference post hoc testing with LSD was 
performed and a significant difference was seen between the PD and PD-CI 
groups, with IGF-1 AUC being lower in the PD-CI group (p=0.02) (Figure 36). 
There was no difference between groups when IGF-1 AUC was compared 
between groups using ANCOVA to account for PD duration and GDS (p=0.24). 
There was no significant difference in fasting IGF-1 between groups with or 
without the inclusion of covariates (p=0.17 and 0.44, respectively) (Figure 35). 
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Figure 34. Fasting IGF-1 by group 
Figure 35. Area under the curve of IGF-1 between groups 
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Insulin 
Insulin AUC significantly correlated with glucose (r=0.46, p=0.001), fat mass 
(r=0.279, p=0.039), BMI (r=476, p=0.000) and leptin (r=0.50, p<0.001) There 
was a negative correlation between insulin AUC and motor disease severity as 
measured by motor UPDRS (r=-0.36, p=0.04) (Figure 38). Fasting insulin 
correlated with BMI (r=0.41, p=0.002), fasting leptin (r=0.45, p=0.001) and 
fasting glucose (r=0.30, p=0.03) but not moor UPDRS (r=-0.32, p=0.06) (Figure 
37).There were no other significant linear relationships and no non-linear 
relationships were observed on inspection of the scatter plots. 
 
Figure 36. Scatter plots of fasting insulin and BMI, leptin and glucose 
  




Figure 37. Scatter plots for relationships between insulin AUC and glucose AUC, fat 
mass, BMI, motor UPDRS and leptin 
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There was no significant difference between insulin levels over time between 
groups, with or without correction for PD duration (p=0.76) (Figure 39).There 
was no significant difference in fasting insulin or insulin AUC between groups 
(p=0.65 and 0.93, respectively). This remained true after the inclusion of PD 
duration or GDS as covariates (p=0.84 and 0.995, respectively) (Figure 40 and 
Figure 41). 
Figure 38. Log transformed insulin over time by group 
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Figure 39. Fasting insulin by group 
Figure 40. Insulin area under the curve by group 
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Serum glucose AUC was not different between groups, with (p=0.91) or without 
inclusion of disease duration and GDS in the analysis (p=0.96) (Figure 43). No 
correlations were seen between glucose and any variable other than insulin 
(r=0.46, p=0.001). None of our participants had diabetes but 2 controls, 1 PD 
and 1 PD-CI had fasting glucose in the range of impaired glucose tolerance 
(5.6-7.0 mmol/l) (American Diabetes, 1997). One participant in the PD-CI group 
had a single fasting glucose of 7.1 mmol/l, which is in the diabetic range but not 
diagnostic of diabetes in itself. This participant’s random glucose was, however, 
normal (6.8 mmol/l). Fasting glucose was not significantly different between 
groups (p=0.92) even after inclusion of covariates (p=0.95) (Figure 42). 
 
Figure 41. Mean fasting glucose by group 
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Figure 42. Glucose AUC by group 
Insulin resistance measured by HOMA-IR was not significantly different 
between groups (Figure 44) with (p=0.77) or without correction for PD duration 
and GDS (p=0.91). Insulin AUC and HOMA-IR were highly correlated (r=0.74, 
p<0.001) (Figure 45). Visual inspection scatterplots suggested a positive 
correlation between HOMA-IR and motor UPDRS but this was not statistically 
significant (r=-0.37, p=0.07). There was no correlation between Insulin AUC and 
reversed MoCA (r=-0.07, p=0.62) or HOMA-IR and reversed MoCA (r=-0.02, 
p=0.92). 
   
 131 
Figure 43. Log transformed HOMA-IR by group 
 
Figure 44. Scatter plots showing HOMA-IR against insulin AUC and Motor UPDRS 
scores 
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Glucagon-like peptide 1 
Fasting GLP-1 and GLP-1 AUC both significantly correlated with PYY (r=0.41, 
p=0.005 and r=0.46, p=0.001, respectively) (Figure 46). There were no other 
significant correlations. There was no significant difference in GLP-1 levels over 
time between groups (p=0.11) (Figure 47) and no significant difference in 
fasting GLP-1 or GLP-1 AUC between groups with (p=0.76 and p=0.97) or 
without correction for PD duration or GDS (p=0.54 and 0.48, respectively) 
(Figure 48 and Figure 49). 
 
Figure 45. Scatter plots of GLP-1 and PYY 
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Figure 46. GLP-1 over time by group 
Figure 47. Fasting GLP-1 by group 
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Figure 48. Area under the curve of GLP-1 between groups 
Leptin 
Fasting leptin significantly correlated with fat mass (r=0.652, p=0.000), BMI 
(r=0.45, p=0.001) and insulin (r=0.45, p=0.001). Leptin AUC showed the same 
results (r=0.66, p<0.001; r=0.42, p=0.002; and r=0.50, p<0.001 respectively). 
There was a negative correlation between leptin AUC and hunger (r=0.38, 
p=0.005) but not energy intake (Figure 51). There was no such relationship 
between fasting leptin and energy intake. There were no other significant 
correlations. There were no non-linear relationships between fasting leptin or 
leptin AUC and other variables seen on visual inspection of scatter plots. 
Scatter plots of significant correlations are shown in Figure 50 and Figure 51. 
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Figure 49. Scatter plots of fasting leptin and BMI and fat mass 
 
 
Figure 50. Scatter plots for relationships between leptin and fat mass, BMI, insulin 
and hunger  
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There was no significant difference between leptin levels over time between 
groups, with or without correction for PD duration (p=0.41) (Figure 52). There 
was no significant difference in fasting leptin or AUC between groups with 
(p=0.70 and p=0.84, respectively), or without the inclusion of PD duration or 
GDS as covariates (p= 0.73 and 0.70, respectively) (Figure 53 and Figure 54). 
Figure 51. Leptin over time by group 
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Figure 52. Fasting leptin by group  
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Figure 53. Leptin area under the curve by group 
5.1.4 Hormones of energy homeostasis as predictors of cognition 
Our aim in this pilot study was to explore whether hormones of energy 
homeostasis differ between patients with PD, PD-CI and controls, with the goal 
of designing a longitudinal study looking for hormonal predictors of cognitive 
decline in PD. We therefore examined predictors of cognition (MoCA) across 
the whole cohort using multiple linear regression. MoCA was reversed for this 
study to improve normality. Log transformed AG AUC negatively correlated with 
cognition (r=-0.384, p=0.005) whilst PD duration (r=0.51, p<0.001), motor 
UPDRS (r=0.56, p<0.001) and GDS (r=0.68, p<0.001) all positively correlated 
with reversed MoCA .These four variables were therefore included in the 
regression model. The model significantly predicted reversed MoCA accounting 
for 61% of the variance (R squared 0.61, F11.03 [4,30], p<0.001). Acyl ghrelin 
AUC and motor UPDRS contributed significantly to the model (p= 0.003 and 
0.02 respectively). Individually, AG AUC accounted for 15% of the variance (R 
squared 0.15, F 8.81 [1,51], p=0.005). 
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AG AUC -0.151 0.047 -0.393 P=0.003 
Duration of PD 0.000 0.002 0.017 P=0.898 
GDS 0.102 0.050 0.316 P=0.51 
Motor UPDRS 0.017 0.007 0.350 P=0.015 
Dependent variable is LnMoCA (31-value) 
5.2 Discussion 
5.2.1 The Ghrelin-IGF-1 axis 
The ghrelin-IGF-1 axis refers to ghrelin (total ghrelin and AG), GH and IGF-1. 
They are considered collectively here because they are intimately linked (Arvat 
et al., 2000, Nagaya et al., 2001b). Total ghrelin comprises active AG, an 
orexigenic hormone, and UAG, whose role is not yet well understood. 
Unacylated-ghrelin is converted to AG by the enzyme GOAT in the systemic 
circulation (Yang et al., 2008). Acyl-ghrelin then acts in the central nervous 
system to stimulate appetite, GH release and myriad other effects (Arvat et al., 
2000). Growth hormone is produced by the pituitary in response to ghrelin and 
is important for normal growth and feelings of vitality (Carroll et al., 1998). 
Growth hormone also stimulates IGF-1 release from the liver (Chapman et al., 
1996). Insulin-like growth factor-1 is a mitogenic hormone, which is to say that it 
promotes cell turnover through the birth of new cells, including neurons (Dyer et 
al., 2016). As such it is important for normal growth and tissue maintenance 
(Torres-Aleman, 2009).  
Ghrelin BMI, fat mass and energy intake 
Acyl ghrelin and total ghrelin increase as BMI decreases (Beberashvili et al., 
2017, Tschöp et al., 2001b). Exogenous AG is a powerful appetite stimulant 
(Wren et al., 2001). Endogenous AG peaks prior to meal initiation and falls 
dramatically thereafter (Cummings et al., 2001). Together this suggests that AG 
maintains energy homeostasis by providing the stimulus to increase energy 
intake when total body energy stores are depleted. Our data demonstrated a 
negative correlation between TG AUC and BMI across the cohort (r=-0.395. 
p=0.003). Fasting AG and BMI were also significantly negatively correlated (r=-
0.287, p=0.037). No correlations were seen between AG AUC and BMI (r=-
0.186, p=0.183), TG AUC and fat mass (r=-0.016, p=0.909) or AG AUC and fat 
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mass (r=0.410, p=0.318). Overall, our results demonstrate a reduction in ghrelin 
(AG and TG) with increasing BMI as reported in the wider literature. 
We did not observe increased intake, increased hunger or reduced fullness with 
increasing AG. There was no correlation between either AG AUC or TG AUC 
and total energy intake (r=-0.145, p=0.292 and r =-0.070, p=0.617 respectively), 
hunger (r =0.146, p=0.296 and r=0.056, p=0.687 respectively), or fullness (r 
=0.171, p=0.220 and r=0.214, p=0.116 respectively), across the whole cohort. 
Whilst it is intuitive that endogenous AG should have a role in appetite 
stimulation there is a lack of published evidence to support this in humans. In 
fact a small randomized control trial of physiological and low dose 
supraphysiological total ghrelin failed to alter feeding behaviour in 20 healthy 
young men of normal body weight (Lippl et al., 2012). Lack of evidence does 
not necessarily equate to lack of effect of course. There is a good scientific 
basis to believe that endogenous AG acts as an appetite stimulant. Pre- and 
post- prandial endogenous AG changes and a clear and consistent orexigenic 
effect of exogenous AG strongly support this. Moreover, it has been 
demonstrated that rodents treated with anti-ghrelin immunoglobulins have 
marked reduction in oral intake in the face of starvation (Nakazato et al., 2001). 
Overall, however, we did not demonstrate a relationship between endogenous 
AG and energy intake in our cohort. 
Ghrelin and ageing 
Acyl ghrelin AUC significantly negatively correlated with age across the whole 
cohort (r= -0.386, p=0.004). Results for TG AUC did not quite reach statistical 
significance but the scatter plot is suggestive of a genuine relationship (r=-
0.265, p=0.051, see Figure 24). These data are consistent with previous studies 
showing that ghrelin levels decline with age as part of the somatopause 
(Akamizu et al., 2006, Nass et al., 2013, Rigamonti et al., 2002). Our study was 
not designed to identify frailty and therefore no conclusions can be drawn 
regarding the potential interplay between ageing, frailty and declining ghrelin 
levels suggested by some previous research (Schneider et al., 2008). 
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Ghrelin, Parkinson’s disease and cognition 
There is considerable evidence from animal and human studies that AG may 
have pro-cognitive (Carlini et al., 2002) and neuroprotective effects in 
neurodegenerative disease (Liu et al., 2006). Ghrelin secretion may be 
disordered in PD, especially in those patients that lose weight (Fiszer et al., 
2010, Song et al., 2017, Unger and Oertel, 2014). The nature of this relationship 
is not yet clear. A recent study showed no difference in AG or TG between 
groups of PD patients at different stages of disease (Song et al., 2017). Our 
data support these findings as there was no correlation between TG AUC or AG 
AUC and disease duration or motor disease severity as measured by the 
UPDRS. This is the first study to examine AG in people with PD-CI. 
The pattern of AG and TG secretion over time was as expected in all three 
groups, which is to say there was a drop in levels immediately after eating with 
the nadir at 60 minutes followed by recovery towards baseline at 180 minutes. 
We did not see the failure of recovery in ghrelin over time in participants with 
PD that has previously been reported (Fiszer et al., 2010, Song et al., 2017). 
There was a trend towards lower AG in the PD-CI group on visual inspection of 
our graph of AG over time by group. This difference did not reach statistical 
significance when AG AUC was compared across all three groups but there 
was a significant difference between the PD and PD-CI groups, with lower AG 
in the PD-CI group on post-hoc analysis. Significance was lost when PD 
duration and depression were included in the analysis. There was a negative 
correlation between AG AUC and reversed MoCA scores (i.e. the direction of 
correlation one would have predicted from previously published research). Log 
transformed MoCA was reversed in order to increase normality such that better 
performance results in lower transformed scores, which is to say that higher AG 
levels were associated with better cognitive performance on this screening tool 
for global cognition. Together these data suggest lower AG in cognitive 
impairment in PD. 
We explored possible confounders that might lead us to falsely conclude that 
AG is lower in PD-CI than other groups. One of our control participants had 
previously had a vagotomy. We postulated that this may have biased results, as 
ghrelin modulation is thought to require an intact vagal nerve (Seoane et al., 
2007). Acyl-ghrelin data were therefore re-analysed excluding this participant 
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and the results were unchanged, suggesting the difference between groups was 
not explained by failure of dynamic ghrelin release in this participant.  
Another confounder could be differences in medications. The effects of 
dopamine on ghrelin release and signaling are not yet well understood, with 
dopaminergic medication causing ghrelin release in vitro (Iwakura et al., 2011), 
but dopamine receptor stimulation and blockade both attenuating ghrelin 
response to feeding in rats (Romero-Picó et al., 2013). All of our participants 
were tested “off” their usual PD medications in order to minimize confounding. It 
is possible that longer-lasting background effects of levodopa and longer lasting 
PD medications were still exerting an effect. Against this, the background LED 
was not significantly different between the PD and PD-CI groups. This suggests 
that anti-parkinsonian medication could account for a difference between 
controls and PD or PD-CI groups but not the observed reduction in the PD-CI 
group. Cholinergic medications may be relevant, however. Patients taking non-
selective anticholinergics were excluded from taking part. There was no 
significant difference in selective anticholinergic medication use between 
groups, so this is unlikely to have biased our results. Seven of our PD-CI group 
were taking cholinesterase inhibitors, used for the symptomatic treatment of 
dementia and which augment acetylcholine in the brain. Acetylcholine increases 
ghrelin levels in humans whilst anti-cholinergics reduce levels overall (Broglio et 
al., 2004). Given the even spread of anticholinergic medications between 
groups and the high proportion of PD-CI participants taking cholinesterase 
inhibitors (43%) it seems implausible that these medications could account for 
the lower levels of AG in the PD-CI group. This is because cholinesterase 
inhibitor use would tend to increase ghrelin levels. It is more likely that the 
difference in AG between groups was blunted by cholinesterase inhibitor use in 
the PD-CI group. It would be neither medically appropriate nor ethical to 
discontinue these medications for research purposes, however, so future 
studies should be powered to allow statistical adjustment for this. 
A final confounder to our observed results could be depression. Geriatric 
depression scale negatively correlated with AG AUC in our cohort. Moreover, 
GDS scores were significantly higher in the PD-CI group than other groups. 
This is important in the context of cognition in PD as depression in PD is 
associated with a greater risk of cognitive decline (Stern et al., 1993). 
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Conversely, the risk of depression increases with the development of cognitive 
impairment in PD (Lawson et al., 2014). In our study GDS correlated with 
disease duration UPDRS scores and reversed MoCA. None of our patients 
were clinically depressed, however, and GDS has not been validated for use in 
people with cognitive impairment. In fact, there is evidence that GDS validity 
declines in cognitive impairment (Kørner et al., 2006, Burke et al., 1989), which 
is a limitation of the study design. Ghrelin has been proposed to both ameliorate 
and exacerbate anxiety and depressive behaviour in rodents (See review by 
Steiger et al., 2011) and ghrelin levels do not differ between people with and 
without major depression (Kluge et al., 2009). We have included GDS and PD 
duration as covariates in our analysis in order to correct for potential bias. This 
resulted in loss of significance when AG AUC was compared between groups. It 
is not clear whether this is due to the relationship between AG UAG and 
depression scores confounding the original result (type 1 error) or loss of power 
with the inclusion of covariates due to our relatively small sample size (type 2 
error). 
In order to clarify this further we carried out multiple linear regression analysis 
for predictors of cognition across the whole cohort. We found that AG AUC 
significantly predicted cognition, accounting for 15% of the variance. This model 
was improved when other factors correlating with reversed MoCA (Parkinson’s 
disease duration, motor UPDRS and GDS) were included. The final model 
significantly predicted reversed MoCA accounting for 61% of the variance. The 
significant contribution of AG in this model would suggest that the difference 
between groups is likely to be genuine. Overall, our results suggest that there is 
sufficient “signal” to warrant further studies into AG and cognitive impairment in 
PD. It appears likely that that AG levels are lower in the PD-CI group and that 
AG levels predict cognition but that our study is underpowered to detect this 
difference once depression and PD duration are included in the analysis. 
This study was not designed to elucidate the basis of a correlation between 
increasing AG and better cognitive performance. Discussion around possible 
mechanisms responsible for this association is therefore speculative. Broadly, 
there are three main ways in which AG and cognition could be linked in this 
weight-stable cohort. First, AG levels could be reduced as a result of 
neurodegeneration resulting in reduced ghrelin secretion. As previously 
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discussed, cholinergic neurons have been implicated in the control of dynamic 
ghrelin secretion (Seoane et al., 2007). Loss of these neurons due to 
neurodegeneration could therefore decrease ghrelin secretion. This process 
could occur at the level of the DMNV or in the cortical areas contributing to 
higher control of ghrelin secretion (Seoane et al., 2007). The DMNV is usually 
damaged early in PD (Braak et al., 2003a) but we did not demonstrate any 
difference between the PD group and controls in our cohort, even when the 
control with vagotomy was excluded. All participants in the PD group had 
established PD with an average disease duration of nearly 6 years (69.53 
months). It therefore seems unlikely that neurodegeneration at the DMNV is the 
primary cause of reduced AG in PD-CI. Cortical neurodegeneration resulting in 
changes in meal anticipation could be more likely. Animal studies show that 
tease feeding results in ghrelin suppression, suggesting cognitive processes are 
important in the control of ghrelin secretion (Seoane et al., 2007). Moreover, 
human studies in people with PD-MCI have shown that cortical thinning and 
hippocampal atrophy are associated with cognitive impairment in PD (Danti et 
al., 2015, Pereira et al., 2014). Taking these studies together it seems plausible 
that neurodegeneration in PD-CI could result in altered ghrelin secretion. 
Second, a decline in AG as a result of α-synuclein deposition in the gut could 
lead to loss of neuroprotection and increase the likelihood of developing 
cognitive impairment. There is evidence of extensive α-synuclein in the enteric 
nervous system supplying the stomach (Braak et al., 2006). Acyl ghrelin is 
proposed to be pro-cognitive through promotion of LTP and neurogenesis at the 
hippocampus (Carlini et al., 2010b, Kent et al., 2015) and neuroprotective 
through mitochondrial stabilization, regulation of autophagy and anti-
inflammatory actions (Ferreira-Marques et al., 2016, Moon et al., 2009). It is 
possible that gastric ghrelin secretion is lost and levels reach a threshold below 
which these protective effects are lost and cognitive impairment ensues. Finally, 
and perhaps most likely, both of the above mechanisms could be at play, 
resulting in a vicious cycle of neurodegeneration, loss of neuroprotection and 
accelerated cognitive decline in individuals at risk. 
None of these potential explanations can account for normal total ghrelin across 
all three groups and a lack of relationship between total ghrelin and cognition in 
our study. Recent research suggest that acylation of UAG occurs in target 
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organs, not in the blood stream as previously thought (Hopkins et al., 2017). 
Our collaborator, Dr. Jeff Davies and his team, has examined the ratio of 
AG:UAG in our cohort and found that the AG:UAG ratio was significantly lower 
in participants with PD-CI than cognitively intact PD patients or healthy controls 
(p=0.003 and 0.001, respectively). They did not include PD-MCI participants in 
their analysis (Horsby AKE et al. unpublished pers. com). It is possible that 
neurodegeneration results in reduced acylation of UAG to pro-cognitive and 
neuroprotective AG resulting in cognitive decline and accelerated 
neurodegeneration. Further research is needed to clarify the underlying 
processes and help to establish whether AG or AG:UAG ratio may be helpful in 
determining patients at risk of cognitive impairment in PD. 
Growth hormone, IGF-1 and cognition in PD 
Growth hormone followed a similar pattern to AG over time (Figure 31 and 
Figure 20), with a slight delay in the nadir (60 minutes for AG, between 60 and 
120 minutes for GH). Our results are congruent with previous research as 
exogenous AG has been shown to result in GH secretion at around 15 minutes 
in rats (Wren et al., 2001). There was, however, no demonstrable correlation 
between GH AUC and AG AUC. Growth hormone AUC increased with age and 
increased with IGF-1 AUC (Figure 21). This was unexpected as most of the 
literature describes a decline in GH in older age. When the data were analysed 
by group the positive correlation between age and GH only persisted for healthy 
controls (see Appendix I). This may reflect reduced frailty in this cohort, with 
less frail individuals surviving for longer. This is highly speculative as relative 
GH deficiency, whilst associated with advancing age, has not been 
demonstrated to correlate with frailty (Morley, 2016). Moreover, we did not 
measure frailty in our cohort. The underlying cause of this unexpected positive 
correlation therefore remains unclear. There was no significant difference in GH 
between groups and no correlation with cognition. These data suggest that GH 
was not meaningfully disordered in PD or PD-CI. It is worth mentioning that 
nocturnal GH secretion has been shown to be disordered in previous studies of 
people with PD (Bellomo et al., 1991). Our study took place between the hours 
of 0730 and 1230 and we would not, therefore, have been able to detect this. 
There is some evidence that GH may be pro-cognitive, at least where there is 
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GH deficiency (Falleti et al., 2006) but the pulsatile nature of GH secretion 
makes it an unattractive target as a biomarker for cognitive decline overall.  
The pattern of IGF-1 secretion did not follow the pattern of AG, TG or GH 
secretion over time (Figure 34). There are few data regarding the post-prandial 
secretion of IGF-1 available. A study in salmon reported that IGF-1 does not 
change with acute nutritional intake (Shimizu et al., 2009) and a study in cattle 
showed that pulsatile GH secretion was not accompanied by pulses in IGF-
1(Breier et al., 1986). This is unsurprising when one considers that IGF-1 is 
highly protein bound. It has been proposed that protein binding regulates the 
available IGF-1 resulting in a relatively steady state over time (Pan and Kastin, 
2000). There was no correlation between IGF-1 AUC and AG AUC or TG AUC.  
There is a large body of evidence to support a role for IGF in cognition (see 
table 4) and meta-analysis suggests that higher IGF-1 levels are associated 
with improved cognition in the elderly (Arwert et al., 2009). In our study there 
was no correlation between IGF-1 AUC and reversed MoCA. There is a 
suggestion in the literature that the relationship between cognition and IGF-1 
may not be linear, with lower levels being associated with cognitive decline but 
no additional benefit above a certain threshold (Watanabe et al., 2005, 
Westwood et al., 2014). Visual inspection of the scatter plots did not reveal such 
a relationship across our cohort. 
It has also been proposed that IGF-1 is neuroprotective in neurodegenerative 
disease through enhanced neurogenesis (Aberg et al., 2005), reduced 
apoptosis due to improved PI3K/AKT signalling (Quesada et al., 2008) and 
better Aβ clearance (Carro et al., 2002). Interestingly, a 2015 meta-analysis 
found that IGF-1 levels were increased in early PD, a phenomenon that has 
been proposed to be a compensatory response to neurodegeneration (Li et al., 
2015b, Godau et al., 2009). As disease progresses, the picture is less clear with 
both increased (Picillo et al., 2014) and decreased (Suzuki et al., 2014) IGF-1 
levels reported with increasing disease severity. Other studies have reported a 
decline in IGF-1 with PD duration but not disease severity (Godau et al., 2009). 
In our study IGF-1 AUC was not correlated with disease duration or with 
disease severity. Neither was it significantly different between groups. There 
appeared to be a trend toward lower IGF-1 AUC in the PD-CI group. In view of 
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this post hoc testing using LSD was carried out and the IGF-1 AUC was 
significantly lower in the PD-CI group compared to the PD group. Significance 
was lost with correction for disease duration and GDS. There was no significant 
difference between controls and the PD group, or between controls and the PD-
CI group.  
Our results appear somewhat incongruent. We found lower IGF-1 AUC in the 
PD-CI group but there was no demonstrable correlation between IGF-1 AUC 
and cognition, disease duration or disease severity. It may be relevant that large 
amounts of data were missing in our analysis of IGF-1 (table 16). Only 38 of 55 
participants had complete data (17 of 20 controls, 11 of 19 PD and 10 of 16 PD-
CI). The reason for this is unclear but may relate to practical limitations in 
processing samples on site. Insulin-like growth factor 1 samples required 
different handling than other samples (see appendix F). Only one centrifuge 
was available therefore IGF-1 samples were kept on ice and analysed after 
other hormonal assays. Our results should therefore be interpreted with caution. 
Insulin-like growth factor 1 is released from the liver in response to GH 
secretion (Torres-Aleman, 2009). Growth hormone AUC was not lower in the 
PD-CI group in this study. It therefore seems unlikely that there is a 
meaningfully deranged IGF-1 response in this group but further research is 
needed to clarify this. No firm conclusions may be drawn from our study as to 
whether or not IGF-1 is a useful biomarker for cognitive decline in PD. 
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5.2.2 Insulin 
Insulin is a metabolic hormone whose primary action is to lower blood glucose 
and allow cellular glucose utilisation. Insulin insufficiency and resistance cause 
diabetes mellitus, a common chronic disease associated with excess mortality 
from cardiovascular disease and other complications (DeFronzo et al., 1985). 
Insulin, BMI, fat mass and energy intake 
Insulin has been demonstrated to increase with adiposity (Bagdade et al., 1967) 
and to suppress appetite and food intake through actions at the hypothalamus 
(Benoit et al., 2002). We found that insulin AUC showed the expected 
correlations with BMI, fat mass and leptin (Figure 38). There was no correlation 
with hunger, fullness or energy intake. The lack of correlation between insulin 
and intake may be due to our study being underpowered. This would be 
consistent with the literature. Numerous studies did not show a relationship 
between appetite and insulin levels until a meta-analysis pooling data from 
seven studies involving 180 participants was carried out in 2007 (Flint et al., 
2007).  
Insulin, Parkinson’s disease and cognition 
Determining the relationship between insulin levels, cognition and 
neurodegenerative disease, including PD, is challenging. This is because 
insulin deficiency results in diabetes which has an array of confounding 
consequences including vascular damage and nerve damage (Ribe and 
Lovestone, 2016). The picture is further complicated by the phenomenon of 
insulin resistance, in which chronic hyperinsulinaemia results in a reduced 
downstream response to circulating insulin levels. Where insulin resistance 
occurs peripherally it results in type 2 diabetes (Reaven, 1988). Where it occurs 
in the brain it has been linked with cognitive impairment, and in fact AD has 
been described as “type 3 diabetes” (Steen et al., 2005). Insulin resistance has 
been linked with PD in the literature and meta-analysis has confirmed an 
increased risk of PD in people with diabetes, even with correction for vascular 
disease (Cereda et al., 2011, Cereda et al., 2013).  
Our data demonstrate a negative correlation between insulin AUC and motor 
disease severity, which is to say that as disease severity worsens (higher 
UPDRS), insulin levels also decline. We also calculated HOMA-IR for our cohort 
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retrospectively. Initial scatter-plots suggested a negative correlation between 
log-transformed HOMA-IR and disease severity, with greater disease severity 
associated with lower insulin resistance (Figure 45). This correlation did not 
reach statistical significance but is in keeping with the observed reduction in 
insulin with increased disease severity. There was no difference between 
groups with or without correction for PD duration and GDS. Interestingly, our 
data show no correlation between insulin AUC and reversed MoCA or HOMA-IR 
and reversed MoCA. This is in keeping with the conflicting published literature, 
which has shown both increased and decreased insulin sensitivity with cognitive 
impairment in PD (Schelp et al., 2017, Bosco et al., 2012). Unfortunately, our 
study was not prospectively designed to measure insulin resistance. There are 
therefore methodological limitations that make interpretation of retrospective 
HOMA-IR calculations unreliable in our study. The validity of HOMA-IR is 
reduced in people without diabetes and where fasting glucose is drawn prior to 
15 minutes after cannulation due to the stress response to blood sampling 
(Matthews et al., 1985). Moreover, results for our cohort may not be 
generalisable as people with diabetes and obesity were excluded from the 
study. Nevertheless, our data suggest there are lower insulin levels and 
preserved insulin sensitivity in more advanced motor disease but no correlation 
between insulin and cognition. Decreased insulin with advancing motor disease 
could reflect homeostatic failure as a result of neurodegeneration. Our cohort 
was matched for BMI, age and gender, suggesting that the observed correlation 
is not due to differences in these parameters.  
That there is a negative correlation between insulin and motor disease but no 
link between insulin and cognitive decline is surprising as advancing disease 
severity is a risk factor for cognitive decline in PD (Emre, 2003). Our data were 
in keeping with this as reversed MoCA and motor UPDRS were positively 
correlated in our cohort. A possible explanation for lower insulin with increasing 
disease severity but not with cognitive decline may be the different patterns of 
neuronal loss in motor PD and PD-CI. Motor symptoms of PD are associated 
with dopaminergic cell loss (Damier et al., 1999) whilst other neurotransmitters 
such as acetylcholine have been implicated in non-motor symptoms (Chaudhuri 
et al., 2006). Dopaminergic dysfunction is not a cardinal feature of AD. There is 
strong evidence for an interaction between insulin and dopamine signalling in 
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motor PD. Insulin receptors are found in high concentration in dopaminergic 
neurones (Unger et al., 1991). Moreover, IR stimulation has been shown to 
enhance dopaminergic cell function in the SNPc in animal models of PD. Insulin 
resistance is associated with lower dopamine levels and increased 
dopaminergic cell loss (Morris et al., 2011b) whilst DaT expression is increased 
with insulin administration (Figlewicz et al., 1994). In humans IR expression is 
reduced in nigral dopaminergic neurones in people with PD but not in those with 
AD or vascular disease (Moroo et al., 1994). Reduced or disrupted insulin 
signalling at the SNPc may therefore relate to reduced insulin and increased 
motor disease severity in PD. 
An alternative mechanism by which lower insulin might relate to greater motor 
disease severity in PD is via IDE. Insulin degrading enzyme breaks down insulin 
in the CNS but also binds with α-synuclein in vitro (Sharma et al., 2015). On the 
one hand, lower insulin levels result in reduced IDE expression, which may 
exacerbate α-synuclein deposition. On the other hand, insulin directly competes 
with other substrates of IDE and so lower insulin may result in greater α-
synuclein clearance as a compensatory response to greater disease severity. 
Our cross-sectional study cannot determine if lower insulin levels in more 
advanced disease are a cause of neurodegeneration, a negative 
decompensation due to neurodegeneration or a positive compensation in 
response to neurodegeneration in PD. Further longitudinal studies will be 
required to clarify this relationship. Our results support further investigation into 
CNS insulin as a possible disease-modifying agent in PD but do not support its 
use as a biomarker for cognitive decline. 
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5.2.3 Glucagon-like peptide 1 
Glucagon-like peptide 1 is a short acting anorexigenic hormone produced 
mainly in the small intestine in response to vagal stimulation and nutrient 
ingestion (Hellstrom and Naslund, 2001). It increases insulin sensitivity during 
euglycaemia (Nauck et al., 2002) and GLP-1 analogues such as exendin-4 are 
therefore used in the treatment of type 2 diabetes (Brunton, 2014). Glucagon-
like peptide 1 is rapidly broken down by DPP-4 in the blood stream 
(Alagiakrishnan et al., 2013) and DPP-4 inhibitors such as sitagliptin are also 
widely used in patients with diabetes (Brunton, 2014). 
Glucagon-like peptide 1, BMI, fat mass and energy intake 
Higher BMI is usually associated with a reduced post-prandial peak of GLP-1 
(Nauck et al., 2011). There was no correlation between BMI or fat mass and 
GLP-1 in our cohort, which may reflect the narrow range of BMI and small 
sample size of our cohort. The post-prandial pattern of secretion was as 
expected in all three groups (Figure 47). There was no correlation between 
GLP-1 and energy intake at the ad libitum meal. This is unsurprising as GLP-1 
is predominantly a satiety hormone that signals cessation, not initiation, of 
feeding. Intake at breakfast was standardised and we do not have data for GLP-
1 during the ad libitum meal. There was a positive correlation with PYY, which is 
expected as they are both produced by L cells in the gastric mucosa in 
response to nutrient ingestion (Adrian et al., 1985). Overall, our results for GLP-
1 and appetite are as expected across the cohort. 
Glucagon-like peptide-1, Parkinson’s disease and cognition 
Pharmacological augmentation of GLP-1 has been shown to be neuroprotective 
in animal models of PD (Kim et al., 2009, Nassar et al., 2015). This may be 
through up-regulation of IDE (Athauda and Foltynie, 2016), increased 
neurogenesis (Bertilsson et al., 2008, Harkavyi et al., 2013), anti-inflammatory 
(Kim et al., 2009) and anti-apoptotic (Kim et al., 2009) effects and increased 
mitochondrial stability (Fan et al., 2010, Foltynie and Aviles-Olmos, 2014, Kang 
et al., 2015a, Li et al., 2015b). It is unclear, and perhaps irrelevant, if these 
effects are independent of the insulin sensitising and augmenting effects of 
GLP-1 or not. Human studies of GLP-1 agonists in PD are promising. An open 
label pragmatic trial of exenatide in the treatment of PD found improved motor 
and cognitive symptoms in the treatment group (Aviles-Olmos et al., 2014). 
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More recently, a randomized control trial reporting slower motor decline in the 
off state after 48 weeks of treatment. Cognitive and non-motor symptoms were 
not different between treatment and placebo groups (Athauda et al., 2017). Our 
study found no correlation between disease duration, disease severity or 
cognition and GLP-1. Moreover, there was no significant difference between 
groups with or without correction for PD duration or GDS. Given the role of the 
vagus nerve in control of GLP-1 secretion, a relationship between GLP-1 and 
some parameter of neurodegeneration in PD may have been expected. It is 
possible that the second wave of secretion caused by a direct response to 
nutrients in the small bowel (Hellstrom and Naslund, 2001) is sufficient to 
produce a normal response. Our results suggest that GLP-1 is unlikely to be a 
useful biomarker for cognitive decline in and of itself. Even if GLP-1 levels are 
not meaningfully disrupted in PD, GLP-1 agonists and DPP-4 inhibitors remain 
promising potential neuroprotective agents. 
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5.2.4 Leptin 
Leptin is an anorexigenic hormone produced by adipose tissue (Friedman and 
Halaas, 1998). It does not show dynamic variation with meal ingestion but levels 
can be increased by prolonged fasting (Chan et al., 2003). Its actions at the 
hypothalamus are broadly opposite to those of AG (Cowley et al., 2001). Leptin 
levels are increased by insulin in humans under experimental conditions 
(Kennedy et al., 1997). Leptin resistance occurs in obesity, analogous to the 
insulin resistance seen in type 2 diabetes (Münzberg and Myers, 2005). 
Leptin, fat mass, BMI and energy intake 
As may be expected for a hormone that is secreted by fat cells, leptin typically 
increases with increasing BMI and adiposity (Mantzoros et al., 2001). Our study 
found a positive correlation between leptin and BMI and fat mass. Leptin and 
insulin were positively correlated whilst there was a negative correlation 
between leptin and hunger as measured by a visual analogue scale. These 
results are all expected and in keeping with the published literature (see chapter 
2: Introduction and literature review). There was no correlation between energy 
intake and leptin. The relatively narrow range of BMI across our cohort and 
small numbers may have made our study underpowered to detect such a 
relationship. The negative correlation between leptin and hunger, which itself 
positively correlates with energy intake in this study (see chapter 4), suggests 
that leptin is anorexigenic in our cohort. 
Leptin. Parkinson’s disease and cognition 
Like AG, leptin is pleiotropic and may be pro-cognitive in rodents through 
promotion of LTP (Shanley et al., 2001). Leptin is also neuroprotective in animal 
models of AD through altering Aβ handling. The result is lower Aβ due to 
reduced Aβ synthesis and increased Aβ clearance from the cytosol (Fewlass et 
al., 2004, Greco et al., 2009). Animal models of PD have also demonstrated a 
neuroprotective effect of exogenous leptin through mitochondrial stabilization 
(Ho et al., 2010) and anti-apoptotic effects (Weng et al., 2007). Moreover α 
synuclein over-expressing rodents are hypoleptinaemic (Rothman et al., 2013). 
Despite promising results in animal studies, there has not yet been conclusive 
proof of a role for leptin in cognition or neuroprotection in humans. It is true that 
learning difficulties occur in leptin deficient humans (Paz-Filho et al., 2008) but 
large numbers of studies examining leptin and cognition have failed to reach a 
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consensus as to whether leptin is pro-cognitive, negatively correlated with 
cognition or neutral (see tables 8 and 9 in Chapter 2). The true nature of the 
relationship between cognition and leptin in humans is unlikely to be determined 
without high quality meta-analysis. 
Leptin levels may be lower in PD than in healthy older adults due to reduced 
BMI and adiposity from some other cause in PD (Folch et al., Davis et al., 
2014). In keeping with this, we found no correlation between leptin and 
cognition, disease duration or disease severity in our BMI and fat-mass 
matched cohort. The relationship between leptin and cognition may be U 
shaped, with optimal performance in the mid-range of leptin expression 
(Oomura et al., 2011). Examination of scatter plots did not reveal such a 
relationship in our cohort. Moreover, there was no significant difference in leptin 
between groups, with or without correction for disease duration and GDS. It is 
possible that unintended weight loss results in lower leptin levels, which impairs 
neuronal maintenance and contributes to neurodegeneration and cognitive 
decline in PD. Our study is unable to identify such a relationship as it was cross-
sectional and only included weight stable participants within a narrow range of 
BMI. Overall, our results would not support leptin as a biomarker of cognitive 
impairment in PD in the real world as it is likely to reflect weight loss that is 
easier and cheaper to measure. 
5.2.5 Summary and conclusions 
The main aim of this study and the focus of this chapter was to determine 
whether hormones of energy homeostasis warrant further investigation as 
putative biomarkers for cognitive impairment in PD. Our results support further 
research into AG and specifically the AG:UAG ratio as possible biomarkers for 
cognitive decline. Ghrelin dysfunction remains a plausible link between weight 
loss and cognitive impairment in PD. We were unable to draw conclusions 
about whether IGF-1 is a potential biomarker but this could easily be included in 
a further study assessing AG. It appears unlikely that insulin, GLP-1 or leptin 
will be useful biomarkers for cognitive decline in PD and research efforts should 
focus elsewhere. This study has a number of strengths and limitations that are 
discussed later in this thesis along with recommendations for future research. 
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Chapter 6. Does a bite counter predict energy intake in people 
with PD? 
In this study we used a wrist worn device called a bite counter to record how 
many mouthfuls of food were eaten by participants. This has been shown to 
predict energy intake in healthy young adults (Scisco et al., 2011, Salley et al., 
2016, Scisco et al., 2014, Dong et al., 2012) but has never been used in people 
with Parkinson’s disease. This chapter explores the hypothesis that bite count 
measured by a bite counter predicts energy intake in controls, PD and PD-CI. 
6.1 Results 
6.1.1 Demographics 
This was the same cohort as described in Chapter 4. Demographic data is as 
reported in that chapter. 
6.1.2 Missing data 
Missing data is outlined in the table below. 
Table 19. Missing data for bite count 
Ad libitum 
bite count 
Control PD PD-CI Comments 
Manual 1 0 3 3 PD-CI participants were unable to feed themselves. 
Control participant missing data due to oversight. 
Automated 0 1 3 3 PD-CI participants were unable to feed themselves. PD 
participant data missing due to bite counter malfunction 
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6.1.3 Manual and automated bite count 
There was a strong correlation between manually and automatically recorded 
bite count (r=0.74, p<0.001) (Figure 55)  
Figure 54. Scatter plot of manual and automatic bite counts at the ad libitum meal. 
6.1.4 Bite count and energy intake 
There was a strong correlation between automated bite count and energy intake 
at the ad libitum meal (r=0.70, p<0.001) (Figure 56). 
Figure 55. Scatter plot of total energy intake and automated bite count at the ad 
libitum meal. 
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6.2 Discussion 
A bite counter is a wrist-worn accelerometer that records movements towards 
the mouth. It may be calibrated for an individual’s particular bite size. In our 
study, this was not adjusted and we did not use the bite counter to calculate an 
estimated calorie intake. Despite this, our data demonstrate a strong correlation 
between bite count as measured by the bite counter and energy intake, even in 
people with PD and PD-CI. This relationship was actually stronger than that 
reported for healthy young people (Scisco et al., 2014) suggesting good 
predictive value. Although there was a strong relationship between manual and 
automated bite count, it was not a perfect correlation. This may be due to non-
eating movements made with the hand, for example scratching the nose or 
touching the face. Importantly, the degree of correlation did not differ between 
groups (Figure 56), suggesting that tremor did not meaningfully impact upon 
results. Overall, our results show that a bite counter is able to predict energy 
intake in our cohort. 
6.3 Summary and conclusions 
Our results would support the use of bite counters as a proxy measure for 
energy intake in people with PD and PD-CI. This could be a valuable research 
tool in trying to clarify energy intake in free-living study participants. There are 
also potential clinical applications in monitoring intake in those at risk of 
malnutrition in the community. 
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Chapter 7. Strengths and limitations of this study 
7.1 Overview 
This was a cross-sectional pilot study examining hormones of energy 
homeostasis in a weight stable, normal BMI group without diabetes or 
significant other comorbidities. Our primary aim was to determine whether 
hormones of energy homeostasis warrant further investigation as putative 
biomarkers for cognitive impairment in PD. Our secondary aim was to explore 
whether appetite and food intake differ between patients with PD, PD-CI and 
controls  
The main strength of this study is its novelty. To date this is the only study 
looking at appetite, energy intake and a comprehensive profile of hormones of 
energy homeostasis in people with PD-CI. This also is the only study to date to 
directly measure food intake in people with PD, which is both a strength and a 
limitation as the measurements are accurate but the environment is artificial. 
We were able to capture dynamic hormonal changes pre- and post-prandially 
up to 3 hours and to correlate our results with cognition, appetite and energy 
intake. In addition we were able to use robust techniques to prevent de-
acylation of AG in vitro (Delhanty et al., 2015), which has allowed us to 
accurately measure both AG and TG enabling more accurate understanding of 
results.  
Limitations of our study include small sample size, strict inclusion criteria and 
the lack of validated tools with which to assess appetite in people with 
dementia. Our sample size was calculated using previous research into ghrelin 
in PD (Unger et al., 2011). We came close to the target sample size of 20 
participants in each group but fell slightly short due to time pressure. Our study 
may therefore be underpowered to detect differences in some variables 
between groups. Despite this, we have demonstrated significant results that 
warrant further investigation.  
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7.2 Recruitment and selection 
The narrow range of BMI and the exclusion of people with diabetes assisted 
analysis and prevented over-correction for multiple variables in this small study. 
This may have been at the expense of generalisability, however. The study 
tested a weight stable cohort and cannot, therefore, draw conclusions about 
hormone profile or appetite in weight losing people with PD. This could be 
relevant as people with PD who lose weight may be phenotypically different to 
their weight stable counterparts, with more non-motor symptoms and greater 
severity of disease than those who are weight stable (Sauerbier et al., 2016, 
Sharma and Turton, 2012). We also excluded participants at extremes of BMI. 
This may have affected the generalisability of our results. Against this, the 
number of people who failed screening for obesity was similar in the control and 
PD-CI groups and only one participant failed screening due to being 
underweight (Error! Reference source not found.).  
Table 20. Screening failures by group  
BMI >30 BMI <18.5 MoCA >= 26 MoCA < 26 Other Total 
Controls n=6 4 0 0 1 1 6 
PD n=4 1 0 0 2 1 4 
PDD/PDMCI n=12 5 1 6 0 0 12 
Total n=22 10 1 6 3 2 22 
 
It is possible that people who agreed to take part were younger or fitter than 
those who declined. In keeping with good ethical practice we did not collect 
personal data for people who declined to take part. It seems unlikely that those 
who declined were significantly older than those who eventually took part, 
however, as our cohort had an average age of 73.58 and the oldest participants 
were 85 years old. Our cohort had an average of 2.96 comorbidities other than 
PD overall, with no significant difference between those who passed or failed 
screening (p=0.72). This is comparable to the general population, 50% of whom 
have 2 comorbidities at 70-74 years of age (Barnett et al., 2012). The average 
age and gender balance of those who failed screening were not significantly 
different to those who completed testing (p=0.35 and p=0.10 respectively). 
Moreover, we were able to recruit people with a wide spread of cognition, 
including participants with severe dementia. The lowest MoCA score recorded 
in our study was 6/30. Finally, all of our participants were Caucasian, which 
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clearly limits the generalisability of our study with regard to global populations. 
This was not intended at the outset of the study but reflects the ethnic mix of the 
North East of England, which has the highest proportion of people who identify 
as White British in England and Wales (93.6%) (Bradford-Ons, 2012). The older 
age of our cohort, their representative levels of comorbidity and the inclusion of 
people with severe dementia improves the generalisability of our study despite 
the strict inclusion criteria. 
7.3 Missing data 
As previously mentioned, the small sample size of our study may have rendered 
it under-powered to detect some differences in variables between groups. This 
was compounded by missing data. For most variables there was very little 
missing data (Table 21). Insulin-like peptide-1 and GLP-1 were exceptions to 
this, with undetectable hormone levels for multiple participants at multiple time 
points. Despite discussion with our biochemistry collaborators at Swansea, no 
clear cause for this has been identified. There were no known issues with 
transport or ELISA kits. Insulin-like peptide-1 and GLP-1 samples were handled 
differently to those for other analytes at the Newcastle site. They were 
centrifuged for less time and at a lower g-force in order to produce platelet-rich 
plasma according to a standard operating procedure (see appendix F). There 
was only one centrifuge of the appropriate size available so the IGF-1/GLP-1 
samples were kept on ice and processed after the other samples. Although this 
protocol was agreed in advance with the team at Swansea, the difference in on 
site processing seems the most likely reason for the disproportionate amount of 
missing data for IGF-1 and GLP-1. A future study into IGF-1 and GLP-1 in PD-
CI should have sufficient resources available to allow immediate processing on 
site. 
  
   
 161 
Table 21. Number of participants with missing data by variable 
Variable Control PD PD-CI Total 
VAS Hunger 0 1 3 4 
VAS fullness 0 1 3 4 
Duration of ad libitum meal 1 1 1 3 
Acyl ghrelin 2 1 1 4 
Total ghrelin 0 1 1 2 
PYY 0 2 1 3 
Leptin 0 1 2 3 
Insulin 0 1 1 2 
GLP-1 1 9 4 14 
IGF-1 3 8 6 17 
GH 0 1 1 2 
Manual bite count 1 0 3 4 
Automated bite count 0 1 3 4 
 
7.4 Assessment tools 
Three of the assessment tools used in this study were not validated for use in 
cognitive impairment. 
7.4.1 Geriatric depression scale-15 
The geriatric depression scale has not been validated for use in dementia or 
cognitive impairment. There are different versions of this screening test 
available. The 15 item GDS (GDS-15) was used in this study and is widely used 
in clinical practice (D'Ath et al., 1994) (See appendix G). The longer 30-item 
GDS-30 is a valid tool to screen for depression in people with all cause MCI but 
not for people with AD (Debruyne et al., 2009). The GDS-15 has been found to 
be sensitive but not specific in detecting depression in cognitively impaired older 
people, with sensitivity dropping as cognitive impairment advances (de Craen et 
al., 2003, Kørner et al., 2006). Our study included people with severe dementia, 
none of whom were felt to be depressed by their clinician or their carers but yet 
scored highly on the GDS-15. A more appropriate depression screening tool for 
further studies would be the Cornell Scale of Depression in Dementia, which 
has been well validated in people with dementia (Kørner et al., 2006). 
7.4.2 Visual analogue scales 
Visual analogue scales (appendix G) measuring hunger, fullness and other 
aspects of appetite have been well validated in young and older adults (Parker 
et al., 2004b, Flint et al., 2000) but not in those with cognitive impairment. There 
has, however, been research into the use of VAS to assess pain in those with 
cognitive impairment and dementia. A study of 129 people with severe 
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dementia demonstrated that VAS for the assessment of pain had good 
reliability. This study included people with PDD and DLB (Warden et al., 2003). 
The authors do note that those with the most severe dementia had more 
difficulty understanding VAS compared to verbal or pictorial scales. To date 
there are no verbal or pictorial scales available for the assessment of hunger or 
fullness. Our study demonstrated a positive correlation between hunger and 
energy intake and a negative correlation between fullness and energy intake 
across all 3 groups. This suggests that, for our study at least, VAS has provided 
a reasonable measure of appetite in those with cognitive impairment. It is 
difficult, however, to fully exclude bias introduced by the research nurse 
delivering the tool or by the carers supporting participants in completing the 
VAS. Validity may have been improved by simplifying the tool, for example 
removing parameters that were not used in the analysis (e.g. would you like to 
eat something salty?). Other strategies could include presenting one scale per 
page, using larger font or spacing out text whilst maintaining a 10cm line. It 
would be desirable to validate this simplified VAS, or develop and validate a 
verbal scale for appetite for ongoing research in this area. 
7.4.3 Three-factor eating questionnaire 
The TFEQ (see appendix G) (Stunkard and Messick, 1985) is a 51-item 
questionnaire which assesses three aspects of eating behaviour; restraint, 
disinhibition and hunger. It has been used in obesity research (Karlsson et al., 
2000). It is useful as it detects “latent obesity”, in which people who have high 
levels of restraint eat more at a subsequent meal (Stunkard and Messick, 
1985). It therefore allows latent obesity to be accounted for in the analysis of 
data obtained for energy intake. The TFEQ has not been used in cognitively 
impaired populations to date. It was written in 1985 in America. Our experience 
of using this scale in a cohort of older British adults was that many found it 
difficult to understand, even if they did not have cognitive impairment. It was 
also time consuming to administer, taking around 30 minutes for each 
participant. Moreover, the prevalence of latent obesity in our cohort was very 
low (2/55 participants [3.6%]). Overall, the measurement of eating behaviour 
does not appear important in this group and the use of TFEQ in future studies of 
appetite in PD-CI would not be recommended.  
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7.5 Medication 
We attempted to control for potential levodopa effects by asking participants 
with PD and PD-CI to attend the test visit without having taken their usual 
Parkinson’s medications. We also excluded participants on non-selective 
anticholinergic medications to reduce confounding of cognition and ghrelin 
secretion. Despite these measures, we were not able to eliminate medication 
effects as potential confounders to our appetite or hormone data. This was 
because a washout period of 36 hours for dopamine agonists and MAOBs, 
which has been used in other studies (Athauda et al., 2017), was felt to be too 
burdensome. Moreover, we felt that it was neither ethical nor desirable to 
discontinue all potentially confounding medications on the day of the test visit. 
Longer acting dopaminergic medications such as MAOIBs and several 
psychiatric medications such as cholinesterase inhibitors and antidepressants 
may have therefore affected our results. Our study was not powered to control 
for these factors. Future studies should be powered to control for medication 
use without requiring drug discontinuation if possible. This may improve 
recruitment as attending “off” is likely to have been burdensome for our 
participants. Alternatively, a longer period of discontinuation for longer acting 
dopaminergic drugs should be used. 
7.6 Summary  
Despite the limitations outlined here, we believe we devised a well-conducted 
cross-sectional pilot study, which has been able to address its primary 
objective. We have identified acyl-ghrelin as a potential biomarker for cognitive 
decline in PD. We have also achieved our secondary aim of exploring appetite 
and food intake in people with PD, PD-CI and controls. Recruitment was close 
to target and comprehensive hormonal profiling over time was possible. This 
was the first study of its kind and provides an excellent springboard for further 
research. The lessons learned here will be invaluable for the development of a 
longitudinal study into hormones of energy homeostasis as biomarkers for 
cognitive decline in PD. This will be discussed further in chapter 8. 
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Chapter 8. Summary, avenues for future research and 
conclusion 
8.1 Overview 
This study was a pilot study with the primary objective of determining whether 
hormones of energy homeostasis could be putative biomarkers for cognitive 
decline in PD. This hypothesis was based on the observation that several such 
hormones are pro-cognitive or neuroprotective in animal models of PD and also 
influence body weight (see Chapter 2: Introduction and Literature Review). 
Disruption in the regulation of these hormones could potentially link the known 
association between unintended weight loss and dementia in PD. The 
secondary objective was to examine appetite and food intake in patients with 
PD, PD-CI and controls as the causes of weight loss in PD-CI are as yet 
unclear. Our participants were tested after an overnight fast and “off” their usual 
PD medication. There were no differences in BMI, fat mass, gender, degree of 
comorbidity or age between groups. Geriatric depression scale, motor UPDRS 
and disease duration were all greater in the PD-CI group than the PD group. 
8.2 Appetite and energy intake 
8.2.1 Main findings 
There is evidence that energy intake is increased in people with PD and 
continues to increase, despite declining BMI as disease progresses (Barichella 
et al., 2017). This appears to occur in the face of reduced physical activity and 
resting energy expenditure, a phenomenon which has been attributed to 
increased motor fluctuations in more advanced disease (Barichella et al., 2017). 
People with PD are at increased nutritional risk compared to healthy older 
adults (Barichella et al., 2013a) and this carries an attendant increase in 
mortality (Walker et al., 2012). Moreover, those with dementia are especially in 
danger of weight loss (Lorefalt et al., 2004, Uc et al., 2006). Conversely, people 
with PD who lose weight are more likely to develop cognitive decline. Prior to 
this study energy intake in people with PD-CI had not previously been studied. 
We did not observe disordered appetite or a difference in energy intake 
between people with PD, PD-CI and controls. The pattern of hunger was as 
expected across the whole cohort, with a reduction after eating and recovery at 
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3 hours. The opposite pattern was seen for fullness in all three groups. Hunger 
and fullness demonstrated the expected relationships with energy intake across 
the cohort, with both greater hunger and lower fullness associated with greater 
intake. Energy intake was not different between groups at the ad libitum meal. 
Across the whole cohort energy intake positively correlated with meal duration 
suggesting that bradykinesia did not negatively impact intake. Moreover, wrist-
worn accelerometers called bite counters, which measure movements towards 
the mouth, correlated with energy intake across all three groups, suggesting 
minimal if any interference due to tremor. We conclude that appetite and energy 
intake are unchanged in this cohort of weight stable people with PD and PD-CI. 
Weight-losing people with PD may be phenotypically different to those who are 
weight stable. We are unable to draw any conclusions about that group. Further 
research into energy intake in people with PD-CI is therefore warranted. 
8.2.2 Future research 
Understanding the relationship between cognitive decline, weight loss and 
energy intake may allow tailored interventions to improve outcomes. A future 
study should include free-living people with PD, PD-CI and healthy controls. 
This should be a pragmatic, low burden study carried out mainly at home over 
several days. Calorie intake could be approximated using a calibrated wrist 
worn bite counter and food diary. Food diaries have previously been 
successfully used in people with cognitive impairment with interviewer support 
(Gale et al., 1996). The study should not exclude people with recent weight loss 
and should aim to weigh people some months after the initial test period to 
identify people who have subsequently lost weight. The study should measure 
the burden of non-motor symptoms, especially gastrointestinal symptoms. 
Medications should be taken into account in the design and data analysis plan 
as participants will not be able to be “off” during the study. This is because 
levodopa may exacerbate gastrointestinal symptoms in PD (Shaw et al., 1980), 
which could confound results. Moreover, cholinergic and anticholinergic drugs 
may affect appetite through modulation of ghrelin (Broglio et al., 2004). 
Levodopa equivalent dose (LED) and anticholinergic burden should therefore 
be calculated and included in analysis along with cholinesterase inhibitor use.  
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8.3 Hormones of energy homeostasis 
8.3.1 Main findings 
Ghrelin-IGF-1 axis 
We found that AG AUC showed a trend towards being lower in the PD-CI 
group. Post-hoc testing revealed this difference to be significant between PD 
and PD-CI groups. Significance was lost when GDS and PD duration were 
included as covariates in the analysis. This may be due to a genuinely 
confounding relationship between depression and AG or to our study being 
underpowered. None of our cohort were clinically depressed despite scoring 
highly on the GDS, however. Moreover, both fasting AG and AG AUC positively 
correlated with cognition across the cohort (negative correlation with reversed 
MoCA). Finally, AG AUC significantly predicted cognition in multiple linear 
regression, accounting for 15% of the variance. Taken together these data 
suggest sufficient “signal” to warrant further investigation of AG AUC, fasting 
AG or AG:UAG as putative biomarkers for cognitive decline in PD.  
We did not find evidence that total ghrelin or GH were different between groups 
or predicted cognition in our cohort. There was a trend towards lower IGF-1 in 
the PD-CI group. There was a significant difference between the PD and PD-CI 
groups on post-hoc analysis. Unfortunately, IGF-1 was undetectable in a 
number of samples for reasons which have not fully been elucidated but which 
may have been due to sample processing. As a result we were unable to draw 
any conclusions regarding IGF-1 as a potential biomarker for cognitive decline 
in PD. 
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Insulin and GLP-1 
Neither insulin, nor insulin resistance measured by HOMA-IR were different 
between groups. There was, however, a negative correlation between disease 
severity and insulin across the cohort and insulin resistance decreased with 
decreasing insulin levels. There was no correlation with cognition in this cohort, 
however. Similarly, no difference in GLP-1 was seen between groups and there 
was no correlation between GLP-1 and cognition in our cohort. Our results 
provide further support for the ongoing investigation of insulin sensitizing agents 
as possible disease modifying drugs in PD. However, there is no evidence from 
this study that insulin is a potential biomarker for cognitive decline. 
Leptin 
Leptin levels were not different between groups and there was no correlation 
between leptin and cognition in our cohort. Is appears unlikely that leptin could 
be useful as a biomarker for cognitive impairment in PD and future research 
should be focused elsewhere. 
8.3.2 Avenues for future research 
It is possible that fasting AG, AG AUC over 180 minutes post-prandially or 
AG:UAG could be biomarkers for cognitive decline in PD. A future longitudinal 
study should be designed to further explore this. Such a study would require 
baseline fasting AG and AG:UAG ratio to be measured at baseline in controls 
and people with incident PD who are cognitively intact. Although AG AUC is 
more likely to yield a positive result, measuring the AUC may be too time 
consuming and cumbersome to be a useful clinical biomarker for cognitive 
decline. Baseline fasting IGF-1 could be included on an exploratory basis, to 
see if there is a genuine relationship with cognition or not in PD. Participants 
with weight loss and diabetes should be included to improve generalisability and 
to explore whether people with PD who lose weight are metabolically different 
from those who are weight stable. All participants should undergo baseline 
measurement of potential confounders such as LED, cholinergic burden, 
depression and level of education. The study should be powered to allow 
inclusion of these potential confounders in the final analysis. Follow-up should 
be at a sufficient interval to detect cognitive changes. The Sydney multicenter 
study found 20% of people with incident PD developed dementia over 4 years 
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(Hely et al., 2008). The optimal length of follow up will therefore depend on the 
sample size. Participants should be weighed at follow up to allow identification 
of participants with weight-loss. Permission should be sought to review the 
medical notes of participants lost to follow up for new diagnoses of dementia as 
some attrition is inevitable (Chatfield et al., 2005). Acyl-ghrelin, AG:UAG ratio 
and IGF-1 could be incorporated into any new prospective observational 
longitudinal study in PD examining cognition. Unfortunately, though several 
such studies have been carried out or are underway (Yarnall et al., 2014, Malek 
et al., 2015), it is not possible to test samples for AG retrospectively due to the 
need to stabilize samples with AEBSF at the time of blood draw (Delhanty et al., 
2015). 
Another interesting avenue of research could be to investigate whether ghrelin 
receptor agonists could be used as treatment for cognitive impairment in PD. 
There is a current stage two randomised controlled trial being carried out into 
the use of a ghrelin receptor agonist for the management of gastroparesis in PD 
(NCT01955616). Unfortunately, the treatment period of 28 days is too short to 
expect to detect effects on cognition in their cognitively intact cohort of 18 
patients to date. It is feasible that a further phase 2 study using the same 
medication could be carried out in people with PDD to see if there is any benefit 
to cognition acutely, or after a period of more prolonged follow up.  
8.4 Bite counter 
Wrist worn bite counters have been used to calculate energy intake in healthy 
adults in the community (Scisco et al., 2011, Salley et al., 2016, Scisco et al., 
2014, Dong et al., 2012) but had not previously been used in PD. We 
demonstrated a positive correlation between bite count and energy intake 
across the whole cohort, including in people with PD and PD-CI. Future 
research could use this tool as an adjunct to food diaries to more accurately 
assess nutritional intake in people with Parkinson’s disease. Bite counters could 
also be used in clinical practice to help people with PD who are losing weight to 
track their energy intake. This could allow them to increase intake if needed to 
ensure that they meet their energy requirements and stave off malnutrition. 
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8.5 Conclusions 
We have demonstrated that AG may be a potential biomarker for cognitive 
impairment in PD. This hormone could provide the mechanistic link between 
weight loss and cognitive decline in PD. Further research is needed to clarify 
this relationship and to determine if AG will become a clinically useful tool or 
treatment in the management of people at risk of cognitive decline. We have 
also demonstrated that a wrist-worn bite counter accurately counts bites in 
people with PD and PD-CI. This device could be used to estimate energy intake 
in community dwelling people with PD and could be a useful clinical and 
research tool. 
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The favourable opinion is subject to the following conditions being met prior to the start 
of the study.  
  
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned.  
  
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements.  
  
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity.  
  
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.   
  
Sponsors are not required to notify the Committee of approvals from host organisations  
  
Registration of Clinical Trials  
  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees).    
  
There is no requirement to separately notify the REC but you should do so at the 
earliest opportunity e.g. when submitting an amendment.  We will audit the registration 
details as part of the annual progress reporting process.  
  
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory.  
  
If a sponsor wishes to contest the need for registration they should contact Catherine 
Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions to 
be made. Guidance on where to register is provided within IRAS.  
  
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable).  
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Approved documents  
  
The final list of documents reviewed and approved by the Committee is as follows:  
   
Document     Version     Date     
Covering Letter   Dr Fionnuala 
Johnston   
03 December 2013   
GP/Consultant Information Sheets          
Investigator CV   Prof David 
Burn   
05 November 2013   
Letter from Sponsor   Wendy  
Mitson   
26 November 2013   
Letter from Statistician   Dr. Shirley  
Coleman   
30 January 2014   
Letter of invitation to participant   Invitation and 
Brief Info  
Sheet, 1.1   
18 November 2013   
Other: Student CV - Dr Fionnuala Johnston      05 November 2013   
Other: Funder Letter   Zurich  
Municipal   
26 July 2013   
Participant Consent Form: Consultee Declaration Form   1.1   17 December 2013   
Participant Consent Form: Carers   1.1   05 February 2014   
Participant Consent Form: Participants   1.2 (Clean 
and Tracked 
Copies)   
05 February 2014   
Participant Information Sheet: Information for consultees   1.1   18 November 2013   
Participant Information Sheet: Participants with Dementia   2.0   03 February 2014   
Participant Information Sheet: Carers   1.0   05 February 2014   
Participant Information Sheet: Health Volunteers   1.0   03 February 2014   
Participant Information Sheet: Participants   1.2 (Clean 
and Tracked 
Copies)   
06 February 2014   
Protocol   1.1   22 November 2013   
Questionnaire: IQ Code Questionnaire          
Questionnaire: TFEQ Questionnaire          
REC application   3.5   29 November 2013   
Referees or other scientific critique report      06 November 2013   
Response to Request for Further Information   Dr.  
Fionnuala  
Johnston   
21 February 2014   
Summary/Synopsis      03 December 2013   
  
Statement of compliance  
  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
  
After ethical review  
Reporting requirements  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
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• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The NRES website also provides guidance on these topics, which is updated in the light 




You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website.  
  
Further information is available at National Research Ethics Service website > After 
Review  
  
14/NE/0002                          Please quote this number on all correspondence  
  
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/   
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Professor Philip Preshaw Chair  
  
E-mail: nrescommittee.northeast-newcastleandnorthtyneside1@nhs.net  
  
Enclosures:    “After ethical review – guidance for researchers”   
  
 Copy to:      Dr Fionnuala Johnston - Clinical Ageing Research Unit, Newcastle  
                                     Newcastle University  
  
                                   Mr Andrew Johnston – Joint Research Office, Newcastle upon Tyne   
      Hospitals NHS Foundation Trust  
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What is the purpose of the study? 
Our study is looking into the differences between people 
with Parkinson’s disease (PD), people with Parkinson’s 
disease and memory problems and healthy older people 
(controls). PD causes stiffness, tremor, slow movements 
and balance difficulties. As well as these movement 
problems (motor symptoms) sufferers may develop memory 
problems, hallucinations or even dementia. Weight loss is 
also common in PD. People with PD who lose weight are 
more likely to develop memory problems than those who do 
not. The reasons behind this are not yet clear.  
One possibility is that hormones (chemical messengers) 
which act on the brain to both make people hungry and help 
with memory don’t work properly in some people with PD. 
One of these hormones is called ghrelin.  
We would like to find out if people with Parkinson’s disease 
and Parkinson’s disease and memory problems have 
different ghrelin levels from each other and from healthy 
older people. We are interested in ghrelin because it has 
been shown to; 
 Improve memory when given to mice that have too 
much amyloid β in their brains- a protein that is 
thought to be important in Parkinson’s disease 
dementia.  
 improve the ability of brain cells (neurones) to make 
connections with each other- a process needed for 
learning and to make memories 
 Protect dopamine-containing neurones in mouse 
brains from poisons. These are the same cells 
damaged in Parkinson’s disease.  
This is the first time that a study has investigated the link 
between ghrelin, memory and weight loss. This is a small 
study designed to find out information to help us plan a 
bigger study in the future.  
We would also like to find out if; 
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 people with low ghrelin feel fuller before eating, eat 
less food or choose different foods compared with 
people whose levels are normal 
 people with PD, PDD and controls have different levels 
of hunger or food choices 
 a “bite-counter” gives a good measure of how much 
people with Parkinson’s disease eat. This is worn like 
a wrist watch and counts the movements your arm 
makes to your mouth. It is completely safe and doesn’t 
cause any pain. 
This will help us to understand the causes of Parkinson’s 
disease dementia better and may even lead to new 
medicines to treat PD and PDD in the future. 
Why have I been chosen? 
You have been invited to take part in this study because 
you are fit and well and aged 60-85. 
This study is not suitable for people who; 
 Have diabetes 
 Smoke or chew tobacco 
 Have recently lost or gained a lot of weight 
 Have a serious illness  
 Have severe depression 
If you are not sure if any of these apply to you or if you have 
any questions please discuss it with us. Our contact details 
are at the end of this information sheet. We want to make 
sure you have all the information you need before deciding 
to take part.  
Do I have to take part? 
No. If you decide not to take part you do not need to give a 
reason. If you decide to take part but then change your 
mind you can stop anytime without giving a reason. 
Deciding not to take part will not affect any medical care 
you receive now or in the future. 
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What will happen to me if I take part? 
If you decide you would like to take part we will arrange a 
screening visit at the Clinical Ageing Research Unit (CARU) 
at Newcastle University. Screening aims to make sure you 
are well and able to take part in testing. If you are you will 
be invited to a test visit at CARU.  
Screening 
This visit lasts about 2 hours. There are no special 
restrictions to your diet before this visit.  
We will go through the study information with you and 
answer any questions you may have. If you are happy to go 
ahead we will ask you to sign a consent form. We will give 
you a copy to keep for your records.  
You are under no obligation to take part and can withdraw 
from the study at any time and without giving a reason. 
During the screening visit the doctor will ask you questions 
about your general health, previous illnesses, medications, 
smoking, alcohol intake and your home circumstances. 
The team will measure your height, weight and blood 
pressure. The doctor will then examine you.  
We will then measure how much body fat and muscle you 
have using “bioimpedance”. This is a pain free and 
harmless measurement of how electricity passes through 
the body. It is not recommended for people with 
pacemakers though so please let us know if you have one.  
We will then carry out some paper based tests; 
 A memory test which takes about 10 minutes to 
complete. We do not expect people to get full marks 
as it is deliberately quite difficult. 
 A questionnaire to screen for depression. 
 A questionnaire about your appetite which takes 
around 10 minutes. 
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During the visit we will take a blood sample to check your 
kidney, liver and thyroid function. We will also check for 
anaemia and diabetes. 
We will ask you to provide a urine sample whilst you are 
with us which we will test for infection and blood. 
Test Visit 
This will last around 4 hours. For this visit you will need to 
come without having; 
 Anything to eat for 12 hours before arriving at the 
research centre.  
 Any sugary or milky drinks for 12 hours before your 
appointment. You can have plain water until 2 hours 
before the visit but nothing to drink after that. 
The visit will involve blood tests, a “visual analogue scale” 
test to measure how full you feel, a test meal, a bite-counter 
and another meal called an “ad libitum” meal where a 
variety of foods will be on offer.  
Blood tests 
We will check active and inactive ghrelin levels along with a 
number of other hormones which may affect ghrelin results. 
These tests will be repeated during the morning. We will put 
an “intravenous cannula” into your vein. This means that we 
can take blood samples from this tube without having to put 
a needle in again. You will be able to move your arm 
without causing any harm. We will take about 200 mls of 
blood from you throughout the study (including screening 
and the test visit). This is about as much as a tea cup. 
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Visual Analogue Scale 






We will ask you to mark the spot which best describes how 
you feel. This will be repeated at regular intervals 
throughout the morning. 
Test meal (breakfast) 
This will be a standard meal of around 300 calories and you 
will be required to eat all of the food. It will be given at 
around 9 am. It will include; 
 One slice of white toast with butter 
 One Activia Strawberry yoghurt 
 Jam 
 Short bread biscuit 
 A glass of water 
 “Ad libitum” meal (lunch) 
Ad libitum is Latin for “at your pleasure”. The ad libitum 
meal is designed to see how much you would like to eat 
and which foods. A choice of foods will be offered. You can 
eat as much or as little as you like. We will record how 
much you eat and which foods you choose. This meal will 
be at midday.  
Bite counter 
This is a wrist watch sized device which counts the 
movements your arm makes to your mouth. It is completely 
safe and doesn’t cause any pain. It will be fitted for the test 
I have never 
been hungrier 
How hungry do 
you feel? 
  
I am not 
hungry at all 
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meal and the ad libitum meal but can be taken off in 
between. 
Telephone call 
We will telephone you 7-10 days after the test visit to see if 
you have any questions after the study. 
What will I have to do? 
You will have to come to the test visit without having; 
 Anything to eat for 12 hours before arriving at the 
research centre.  
 Any sugary or milky drinks for 12 hours before your 
appointment. You can have plain water until 2 hours 
before the visit but nothing to drink after that. 
During the test visit you will need to 
 Sit down or lie in bed in between meals. This is 
because being active might affect our results. You will 
be able to get up to use the toilet.  
Travel expenses: 
We will arrange taxis to pick you up and take you home 
after each visit. If you would prefer to drive, or have a 
relative drive you, you will be able to use our car park for 
free. You will be able to claim back any travel expenses.  
What are the possible disadvantages or risks of taking 
part? 
Being involved in this study will not directly affect your 
health insurance but we may find a new health problem 
which could. You should consider this before deciding to 
take part. You may wish to seek advice from your insurer if 
you are unsure. 
You will need to attend the test visit without having had 
anything to eat or drink that morning. Some people may find 
this uncomfortable.  
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The intravenous cannula that we take blood samples from 
can be uncomfortable when we put it in. You might get a 
bruise from this. This usually disappears after a few days. 
What are the possible benefits of taking part? 
The benefit of taking part is to help us to find out if the link 
between weight loss and Parkinson’s disease and memory 
problems could be due to ghrelin. This might lead to new 
treatments in the long term. Taking part in this study will not 
help you, but might help people with Parkinson’s disease in 
the future. 
What if relevant new information becomes available? 
Sometimes new scientific information may come to light 
during a study which will influence the way it is carried out. 
If this is the case the research team may change the study 
protocol. If a change is made you will be informed in writing 
and the new information will be discussed with you. No 
changes will be made once you have started the study. 
What happens when the research study stops? 
When the study has finished we will send you a summary of 
the results through the post. 
What will happen if I don’t want to carry on with the 
study? 
You are under no obligation to take part and can withdraw 
from the study at any time and without giving a reason. 
Will my taking part in the study be kept confidential? 
Yes. If you decide to take part you will be given a unique 
code. The medical information we collect from you during 
this study will be entered into our computer system using 
this code. This anonymous information will be stored in our 
computer system for a minimum of 5 years. 
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We may find new information about your health during this 
study. If we do we will share it with you straight away. We 
may also write to your GP but only with your permission. 
What if there is a problem? 
If any problems come to light during this study, for example 
if we diagnose a new medical condition, we will tell you 
straight away.  
Will my GP be told about the study? 
With your permission, we will write to your GP and let them 
know you are taking part. 
What will happen with any samples taken? 
Your blood samples will be labelled with the same code as 
your other study information. They will not have any 
information on them which could identify you. The samples 
will be sent to Swansea for testing. This might be done 
either during the study or in the future. The samples will be 
stored for 6 months after the study.  
What will happen with the results of the research 
study? 
The results will be analysed by our research team at 
Newcastle University. We aim to distribute the results in 
scientific journals and at scientific meetings. Depending on 
the results we will use the study results to design a larger 
study looking at ghrelin levels in Parkinson’s disease and 
how it relates to dementia. 
Who is organising and funding the research? 
This study is organised by Newcastle upon Tyne Hospitals 
NHS Foundation Trust and Newcastle University. It is 
funded by the Newcastle NIHR Biomedical Research Unit in 
Lewy Body Dementia. 
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Who has reviewed the study? 
This study has been reviewed and approved by the National 
Ethics Research Service.  
Who should I contact if I have any questions? 
If you would like to discuss this study further we would be 
happy to hear from you. We are available Monday to Friday 
9am-5pm. 
Study Doctor 









Participant Information Sheet 
Ghrelin and Dementia in Parkinson’s 
disease 
Date 18.11.2014  Version 3.0 
  
   
 uuu 
Contents 
What is the purpose of the study?     Page 3 
Why have I been chosen?      Page 4 
Do I have to take part?       Page 4 
What will happen to me if I take part?    Page 4 
What will I have to do?       Page 8 
Travel expenses        Page 9 
What are the possible disadvantages or risks of taking part? Page 9 
What are the possible benefits of taking part?   Page 9 
What if relevant new information becomes available? Page 9 
What happens when the research study stops?  Page 9  
What will happen if I don’t want to carry on with the study?Page 9 
Will my taking part in the study be kept confidential?  Page 9 
What if there is a problem?      Page 10 
Will my GP be told about the study?    Page 10 
What will happen with any samples taken?   Page 10 
What will happen with the results of the research study? Page 10 
Who is organising and funding the research?   Page 10 
Who has reviewed the study?     Page 10 
Who should I contact if I have any questions?   Page 11 
  
   
 vvv 
What is the purpose of the study? 
Parkinson’s disease (PD) is a complex illness causing stiffness, 
tremor, slow movements and balance problems. As well as these 
movement problems (motor symptoms) sufferers may develop 
problems such as memory problems, hallucinations or even 
dementia. Weight loss is also common in PD. People with PD who 
lose weight are more likely to develop problems with their memory 
than those who do not. The reasons behind this are not yet clear.  
One possibility is that hormones (chemical messengers) which 
normally act on the brain to both make people hungry and help with 
memory don’t work properly in some people with PD. One of these 
hormones is called ghrelin. There is evidence that ghrelin doesn’t 
increase before eating as much in people with PD as it does in other 
people. We are interested in ghrelin because it has been shown to; 
 Improve memory when given to mice that have too much 
amyloid β in their brains- a protein that is thought to be 
important in Parkinson’s disease dementia.  
 improve the ability of brain cells (neurones) in the memory 
centre of the brain (hippocampus) to make connections with 
each other- a process needed for learning and to make 
memories 
 Protect dopamine-containing neurones in mouse brains from 
poisons. These are the same cells damaged in Parkinson’s 
disease.  
So far no studies have compared ghrelin levels in people with 
Parkinson’s who have memory problems, PD with normal memory 
and healthy people. This study is designed to find out if ghrelin 
levels are low in people with memory problems in Parkinson’s. It is a 
pilot study which means it is a small study designed to find out 
information to help us plan a bigger study in the future.  
We would like to find out if; 
 ghrelin levels are lower in people with Parkinson’s disease and 
memory problems compared to people with PD who don’t 
have memory problems and healthy people of similar ages 
(controls) 
 people with low ghrelin feel fuller before eating, eat less food 
or choose different foods compared with people whose levels 
are normal 
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 people with Parkinson’s disease with memory problems, 
without memory problems and controls have different levels of 
hunger, food intake or food choices  
 A “bite-counter” gives a good measure of how much people 
with Parkinson’s disease eat. This is worn like a wrist watch. It 
counts the movements your arm makes to your mouth. It 
doesn’t cause any pain. 
This will help us to understand memory problems in Parkinson’s 
disease better and may even lead to new medicines to treat 
Parkinson’s and Parkinson’s disease dementia in the future. 
Why have I been chosen? 
You have been invited to take part in this study because you are 
aged 60-85 and have Parkinson’s disease (PD) without memory 
problems. 
Not everyone can take part in this study. Appetite, chemical 
messenger (hormone) levels, weight change and even smoking 
could affect our results and make them difficult to interpret. This 
study is not suitable for people who; 
 Have diabetes 
 Smoke or chew tobacco 
 Have recently lost or gained a lot of weight 
 Have another serious illness (other than PD) 
 Have severe depression 
 Have deep brain stimulation for Parkinson’s disease 
If you are not sure if any of these apply to you or if you have any 
questions please discuss it with us. Our contact details are at the 
end of this information sheet. We want to make sure you have all the 
information you need before deciding to take part.  
Do I have to take part? 
It is up to you whether or not you take part in this study. If you 
decide not to take part you do not need to give a reason. If you 
decide to take part but then change your mind you can stop anytime 
without giving a reason. Deciding not to take part will not affect the 
care you receive now or in the future. 
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What will happen to me if I take part? 
If you decide you would like to take part we will arrange a screening 
visit at the Clinical Ageing Research Unit (CARU) at Newcastle 
University. Screening aims to make sure you are well and able to 
take part in testing. If you are you will be invited to a test visit at 
CARU.  
Screening 
This visit lasts about 2 hours. There are no special restrictions to 
your diet or medicines before this visit.  
We will go through the study information with you and answer any 
questions you may have. If you are happy to go ahead we will ask 
you to sign a consent form. We will give you a copy to keep for your 
records.  
You are under no obligation to take part and can withdraw from the 
study at any time and without giving a reason. 
During the screening visit you will have a medical history, a physical 
examination, measurement of your body fat, paper-based tests, 
urine and blood tests. 
Medical history  
This will involve asking questions about; 
 your general health and previous illnesses 
 If you have Parkinson’s disease, how long you have had it 
 which medications you are taking 
 whether or not you have any allergies 
 Smoking and alcohol 
 What kind of place you live in (is it your own home or a 
residential home for example) and who lives with you 
Physical Examination 
This will be similar to examinations you may have had from your 
doctor in the past but is likely to be more detailed. It will involve; 
 Measuring your height, weight and blood pressure 
 A neurological examination carried out by the research doctor. 
They will test; 
 The movements and feeling in your face, arms and 
legs 
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 Your eye movements. 
 The reflexes in your arms and legs 
 The coordination of your arms and legs 
 For stiffness in your arms and legs 
 If you have Parkinson’s disease, the “Movement Disorder 
Society United Parkinson’s Disease Rating Scale Part 3” 
(MDS-UPDRS part III). This is a precise rating scale which
  
 Rates how Parkinson’s disease affects your 
movements 
 takes 5-10 minutes to do 
 Checks for slowness, problems with walking, 
balance stiffness, tremor and speech. 
 Examination of your heart, lungs and abdomen. The doctor 
will; 
 listen to your heart, lungs and tummy (abdomen) 
with a stethoscope 
 Feel your neck, underarms, groins and abdomen 
for any lumps  
 Look for any leg swelling 
Measurement of body fat 
This is done by passing a very small electrical current through you 
and recording the time it takes to flow through your body. This is 
done either through attaching wires to your body with stickers or by 
standing on a special set of scales. The current used is harmless 
and cannot be felt so will not cause any pain. It is not recommended 
for people with pacemakers though so please let us know if you 
have one. Electricity moves more slowly through fat than muscle so 
we can calculate how much body fat you have by how quickly the 
electricity travels.  
Paper-based tests and questionnaires 
These include; 
 Montreal Cognitive Assessment (MoCA). This is a memory 
test which takes about 10 minutes to complete. The study 
doctor will go through it with you. We do not expect people to 
get full marks as it is deliberately quite difficult. 
 15 item Geriatric Depression Scale (GDS 15). This asks 15 
questions related to low mood and can be used to screen for 
depression. 
 Three-Factor Eating Questionnaire. This asks questions about 
your appetite and takes around 10 minutes. 
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Blood tests and urine sample 
We will take a blood sample to check your kidney, liver and thyroid 
function. We will also check for anaemia and diabetes. 
We will ask you to provide a urine sample whilst you are with us 
which we will test for infection and blood. 
Test Visit 
This will last around 4 hours. For this visit you will need to come 
without having; 
 Anything to eat or drink except plain water for 12 hours 
before.  
 Any drinks for 2 hours before.  
 Your usual Parkinson’s disease medication the morning of the 
visit. You can take your other medicines as usual. 
The visit will involve blood tests, a “visual analogue scale” test to 
measure how full you feel, a test meal, a bite-counter and another 
meal called an “ad libitum” meal where a variety of foods will be on 
offer.  
You will be invited to take your Parkinson’s disease medicines at 
around midday.  
Blood tests 
We will check active and inactive ghrelin levels along with a number 
of other hormones which may affect ghrelin results. These tests will 
be repeated at regular intervals throughout the morning. We will put 
an “intravenous cannula” into your vein. This means that we can 
take blood samples from this tube without having to put a needle in 
again. An intravenous cannula is a narrow plastic tube with a needle 
inside it. These are commonly used in hospital to give people fluids 
and medicines into the vein. Once it is in your vein the needle is 
taken out and only the soft plastic tube stays behind. You will be 
able to move your arm without causing any harm. We will take about 
200 mls of blood from you throughout the study (including screening 
and the test visit). This is about as much as a tea cup. 
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Visual Analogue Scale 





We will ask you to mark the spot which best describes how you feel. 
This will be repeated at regular intervals throughout the morning. 
Test meal 
This will be a standard meal of around 300 calories. It will be given 
at around 9 am. It will include; 
 One slice of white toast with butter 
 One Activia Strawberry yoghurt 
 Jam 
 Short bread biscuit 
 A glass of water 
 “Ad libitum” meal 
Ad libitum is Latin for “at your pleasure”. The ad libitum meal is 
designed to see how much you would like to eat and which foods. A 
choice of foods will be offered. You can eat as much or as little as 
you like. We will record how much you eat and which foods you 
choose. This meal will be at midday. You will be able to take your 
Parkinson’s tablets with this meal.  
Bite counter 
This is a wrist watch sized device which counts the movements your 
arm makes to your mouth. It doesn’t cause any pain. It will be fitted 
for the test meal and the ad libitum meal but can be taken off in 
between. 
Telephone call 
We will telephone you 7-10 days after the test visit to see if you have 
any questions after the study. 
  
I have never 
been hungrier 
How hungry do 
you feel? 
  
I am not 
hungry at all 
 
   
 bbbb 
What will I have to do? 
You will have to come to the test visit without having; 
 Anything to eat or drink except plain water for 12 hours 
before.  
 Your usual Parkinson’s disease medication the morning of the 
visit. You can take your other medicines as usual. 
During the test visit you will need to 
 Delay your Parkinson’s medications until around midday. This 
is because they could affect our results. 
 Sit down or lie in bed in between meals. This is because 
being active might affect our results. You will be able to get up 
to use the toilet.  
Travel expenses: 
We will arrange taxis to pick you up and take you home after each 
visit. If you would prefer to drive, or have a relative drive you, you 
will be able to use our car park for free. You will be able to claim 
back any travel expenses.  
What are the possible disadvantages or risks of taking part? 
Being involved in this study will not directly affect your health 
insurance but we may find a new health problem which could. You 
should consider this before deciding to take part. You may wish to 
seek advice from your insurer if you are unsure. 
You will need to attend the test visit without having had anything to 
eat or drink prior and without having your usual Parkinson’s disease 
medication. Some people may find this uncomfortable.  
Some people might find it upsetting to talk about memory problems. 
We are very used to looking after people with Parkinson’s disease 
with and without dementia and will be there to answer any questions 
you may have. 
The intravenous cannula that we take blood samples from can be 
uncomfortable when we put it in. You might get a bruise from this. 
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What are the possible benefits of taking part? 
The benefit of taking part is to help us to find out if the link between 
weight loss and Parkinson’s disease dementia (PDD) could be due 
to ghrelin. This might lead to new treatments in the long term. 
Taking part in this study may not help you, but might help people in 
the future. 
What if relevant new information becomes available?  
Sometimes new information may come to light during a study which 
will influence the way it is carried out. If this is the case the research 
team may change the study protocol. If a change is made you will be 
informed in writing and the new information will be discussed with 
you. No changes will be made once you have started the study. 
What happens when the research study stops? 
When the study has finished we will send you a summary of the 
results through the post. 
What will happen if I don’t want to carry on with the study? 
You are under no obligation to take part and can withdraw from the 
study at any time and without giving a reason. This will not affect 
your care now or in the future. 
Will my taking part in the study be kept confidential? 
Yes. If you decide to take part you will be given a unique code. The 
medical information we collect from you during this study will be 
entered into our computer system using this code. We will not record 
any information that could identify you such as your name, address 
or date of birth. In other words it will be anonymous. This 
anonymous information will be stored in our computer system for a 
minimum of 5 years. 
We may find new information about your health during this study. If 
we do we will share it with you straight away. We may also write to 
your GP but only with your permission. 
What if there is a problem? 
Other than a slight delay in taking your tablets there will be no 
changes to your usual care. If any problems come to light during this 
study, for example if we diagnose a new medical condition, we will 
tell you straight away.  
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Will my GP be told about the study? 
With your permission, we will write to your GP and let them know 
you are taking part. 
What will happen with any samples taken? 
Your blood samples will be labelled with the same code as your 
other study information. They will not have any information on them 
which could identify you. The samples will be sent to Swansea for 
testing. This might be done either during the study or in the future. 
The samples will be stored for 6 months. 
What will happen with the results of the research study? 
The results will be analysed by our research team at Newcastle 
University. We aim to distribute the results in scientific journals and 
at scientific meetings. Depending on the results we will use the 
study results to design a larger study looking at ghrelin levels in 
Parkinson’s disease and how it relates to dementia. 
Who is organising and funding the research? 
This study is organised by Newcastle upon Tyne Hospitals NHS 
Foundation Trust and Newcastle University. It is funded by the 
Newcastle NIHR Biomedical Research Unit in Lewy Body Dementia. 
Who has reviewed the study? 
This study has been reviewed and approved by the National Ethics 
Research Service.  
Who should I contact if I have any questions? 
If you would like to discuss this study further we would be happy to 
hear from you. We are available Monday to Friday 9am-5pm. 
Study Doctor 
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What is the purpose of the study? 
Parkinson’s disease is a complex illness causing stiffness, 
shaking, slow movements and balance problems. Patients 
may also develop memory problems. Patients with 
Parkinson’s disease who lose weight are more likely to 
develop problems with their memory than those who do not. 
We don’t know why this is. It may be because chemical 
messengers that work on the brain to make people hungry 
and help with memory aren’t working properly.  One of 
these chemical messengers is called ghrelin.  
We would like to find out if; 
 ghrelin levels are low in people with Parkinson’s 
disease and memory problems  
 people with low ghrelin eat less food or choose 
different foods 
 people with Parkinson’s disease and memory 
problems  eat less food or choose different foods 
  A “bite-counter” gives a good measure of how much 
people eat. This is worn like a wrist watch and counts 
the bites you take when you eat. 
 This is a small study designed to find out information 
to help us plan a bigger study in the future. We hope 
that our study will help us to understand Parkinson’s 
disease and memory problems better and may even 
lead to new medicines to treat memory problems in the 
future. 
  





Why have I been chosen? 
You have been invited to take part in this study because 
you are aged 60-85 years and have Parkinson’s disease 
and memory problems. 
This study is not suitable for people with diabetes, serious 
illness or severe depression. It is also not suitable for 
people who smoke, have recently lost weight or who have 
deep brain stimulation. 
If you are not sure if you have any of these please talk with 
us. We want to make sure you have all the information you 
need before deciding to take part.  
Do I have to take part? 
No. It is up to you whether or not you take part in this study. 
If you decide not to you do not need to give a reason. If you 
decide to take part but then change your mind you can stop 
anytime without giving a reason. Deciding not to take part 
will not affect the care you receive now or in the future. 
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What will happen to me if I take part? 
If you decide you would like to take part we will arrange to 
see you at the Clinical Ageing Research Unit (CARU) at 
Newcastle University to make sure you are well and able to 
take part. This is called screening. If you are able to take 
part after screening you will be invited to a test visit at 
CARU. We ask you to bring a friend, relative or carer with 
you to both visits. 
CARU inside 
Screening 
The screening visit lasts about 2 hours. You can eat and 
drink and take all of your medicines before this 
appointment.  
We will go through the study with you and answer any 
questions you may have. If you are happy to take part we 
will ask you to sign a consent form. We will give you a copy 
to keep.  
The doctor will ask you questions about your health and 
medicines, whether you smoke or drink alcohol, and your 
home and who lives with you. 
We will measure your height, weight and blood pressure 
and the doctor will examine you.  
Inside CARU- this is where the study will take place. 
   
 jjjj 
We will then measure the amount of body fat you have. The 
machine we use to do this is painless and harmless. It can 
affect pacemakers so please let us know if you have one.  
After this you will be asked to complete some 
questionnaires about your mood and appetite. These will 
take about 15 minutes in total.  
We will then do a memory test which will take 10 minutes. 
We do not expect people to get full marks as it is quite 
difficult. 
During the screening visit we will take a blood sample to 
check your general health. We will also ask you for a urine 
sample which we will test for infection and blood. 
If you are able to take part after screening we will invite you 
for a test visit. 
Test Visit 
This will last around 4 hours. For this visit you will need to 
come without having; 
 Anything to eat for 12 hours before arriving at the 
research centre.  
 Any sugary or milky drinks for 12 hours before your 
appointment. You can have plain water until 2 hours 
before the visit but nothing to drink after that. 
 Your Parkinson’s disease medication the morning of 
the visit. You can take your other medicines as usual. 
You will be able to take your Parkinson’s disease medicines 
at around midday.  
We will take blood test to several times 
during the morning. We will put an 
“intravenous cannula” into your vein so 
that we can take lots of blood samples 
without putting a needle in again. You will 
be able to move your arm without causing 





   
 kkkk 
We will then fit a bite counter. This looks and feels like a 
wrist watch. It is completely safe and doesn’t cause any 
pain. It will be fitted for breakfast and lunch but can be 
taken off in between. 
Before breakfast we will ask you to fill in a short 
questionnaire about how hungry you feel. This will be 
repeated several times during the morning. 
Breakfast 
We will give you a breakfast of toast with butter and jam, a 
strawberry yoghurt, shortbread biscuit and a glass of water 
at around 9 am. You will need to eat all of this. 
Lunch 
Lunch will be at around midday. You will be able to eat as 
much or as little as you like. We want to see how much you 
eat and which foods you choose. You will be able to take 
your Parkinson’s tablets with this meal. 
Telephone call 
We will telephone you 7-10 days after the test visit to see if 
you have any questions. 
What will I have to do? 
You will have to come to the test visit without having; 
 Anything to eat for 12 hours before arriving at the 
research centre.  
 Any sugary or milky drinks for 12 hours before your 
appointment. You can have plain water until 2 hours 
before the visit but nothing to drink after that. 
 Your Parkinson’s disease medication the morning of 
the visit. You can take your other medicines as usual. 
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During the test visit you will need to 
 Delay your Parkinson’s medications until around 
midday 
 Sit down or lie in bed in between meals. You will be 
able to get up to use the toilet.  
 
Some patients with Parkinson’s and memory problems may 
have trouble remembering everything they need to decide 
whether taking part is right for them. If this is the case for 
you we will go through the information with a friend or 
relative who can help you decide.  
Travel expenses 
We will arrange taxis to pick you up and take you home 
after each visit. If you would prefer to drive, or have a 
relative drive you, you will be able to use our car park for 
free. You will be able to claim back any travel expenses.  
What are the possible disadvantages or risks of taking 
part? 
Being in this study will not affect your health insurance but 
we may find a new health problem which could. You should 
think about this before deciding to take part. You may wish 
to talk to your insurer, carer or relative if you are not sure. 
You will need to come for the test visit without having had 
anything to eat or drink beforehand and without having your 
usual Parkinson’s disease medicines. Some people may 
find this uncomfortable.  
Some people might find it upsetting to talk about memory 
problems. We are very used to looking after people with 
Parkinson’s and memory problems and will be there to 
answer any questions you may have. 
Blood tests are sometimes uncomfortable. You might get a 
bruise from this. These usually disappear within a few days 
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What are the possible benefits of taking part? 
The benefit of taking part is to help us to understand if 
ghrelin is linked to weight loss in Parkinson’s and memory 
problems. Taking part in this study may not help you, but 
might help people in the future. 
What if relevant new information becomes available? 
Sometimes we find out things during a study which change 
the way it is carried out. If a change is made we will tell you 
about it. No changes will be made once you have started 
the study. 
What happens when the research study stops? 
When the study has finished we will send you a summary of 
the results through the post. 
What will happen if I don’t want to carry on with the 
study? 
You don’t have to take part and can stop the study any time 
without giving a reason. This will not affect your care now or 
in the future. 
Will my taking part in the study be kept confidential? 
Yes. If you decide to take part you will be given a unique 
code. We will record the information we collect from you in 
a computer system using this code. We will not record any 
information that could identify you such as your name, 
address or date of birth. The information will be stored in 
our computer system for a minimum of 5 years. 
We may find new information about your health during this 
study. If we do we will tell you straight away. We may also 
write to your GP but only with your permission. 
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What if there is a problem? 
Other than a slight delay in taking your tablets there will be 
no changes to your usual care. If any problems come to 
light during this study, for example if we diagnose a new 
medical condition, we will tell you straight away.  
Will my GP be told about the study? 
With your permission, we will write to your GP and let them 
know you are taking part. 
What will happen with any samples taken? 
Your blood samples will be labelled with the same code as 
your other study information. They will not have any 
information on them which could identify you. The samples 
will be sent to Swansea for testing. This might be done 
either during the study or in the future. The samples will be 
stored for 6 months after the study.  
What will happen with the results of the research 
study? 
The results will be analysed at Newcastle University. We 
want to present the results in scientific journals and at 
meetings. We want to use this study to design a larger 
study looking at ghrelin levels in Parkinson’s and memory 
problems  
Who is organising and funding the research? 
This study is organised by Newcastle upon Tyne Hospitals 
NHS Foundation Trust and Newcastle University. It is 
funded by the Newcastle NIHR Biomedical Research Unit in 
Lewy Body Dementia. 
Who has reviewed the study? 
This study has been reviewed and approved by the National 
Ethics Research Service.  
   
 oooo 
Who should I contact if I have any questions? 
Please telephone us if you would like to ask any questions. 
We are available Monday to Friday 9am-5pm and would be 
happy to hear from you. 
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What is the purpose of the study? 
Our study is looking into the differences between healthy older people 
(controls), people with Parkinson’s disease (PD) and people with Parkinson’s 
disease and memory problems.  Dementia is common in PD but not all sufferers 
develop memory problems. Those who lose weight are more likely to develop 
memory problems than others. The reasons behind this weight loss are not yet 
clear.  
One possibility is that hormones (chemical messengers) which act on the brain 
to both make people hungry and help with memory don’t work properly in some 
people with PD. One of these hormones is called ghrelin.  
We would like to find out if healthy older people have different ghrelin levels in 
their blood compared with people with Parkinson’s disease with normal memory 
and Parkinson’s disease and memory problems. We are interested in ghrelin 
because it has been shown to; 
 Improve memory when given to mice that have too much amyloid β in 
their brains- a protein that is thought to be important in Parkinson’s 
disease dementia.  
 improve the ability of brain cells (neurones) to make connections with 
each other- a process needed for learning and to make memories 
 Protect dopamine-containing neurones in mouse brains from poisons. 
These are the same cells damaged in Parkinson’s disease.  
This is a pilot study which means it is a small study designed to find out 
information to help us plan a bigger study in the future.  
We would also like to find out if; 
 people with low ghrelin levels feel fuller before eating, eat less food or 
choose different foods compared with people whose levels are normal 
 healthy older people, people with PD and PDD have different levels of 
hunger or food choices 
 a “bite-counter” gives a good measure of how much people eat. This is 
worn like a wrist watch and counts the movements your arm makes to 
your mouth when you eat.  
Why have I been chosen? 
You have been chosen because you are a friend, relative or carer of someone 
with Parkinson’s disease and memory problems and they have agreed to take 
part in this study. 
Do I have to take part? 
No. If you decide not to take part you do not need to give a reason. If you 
decide to take part but then change your mind you can stop anytime without 
giving a reason. Deciding not to take part will not affect the medical care of the 
participant now or in the future. 
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What will happen to me if I take part? 
We would be very grateful if you could accompany your friend/relative to two 
study visits. These will take place at the Clinical Ageing Research Unit (CARU) 
at Newcastle University. This is to make the visits as comfortable as possible for 
participants with dementia. It also helps us to have someone on hand who 
knows the participant if they become disorientated or need reassurance. You 
will not be asked to provide any care whilst they are at CARU.  
The first visit is called a screening visit and lasts about two hours.  
The second visit is called a test visit. This will last around 4 hours. Your friend or 
relative will be asked to come without having had anything to eat for 12 hours 
before the visit. We also ask that they don’t have any sugary or milky drinks for 
12 hours before the visit. They can drink plain water until 2 hours beforehand. 
They will be given breakfast and lunch with us and will have their medication at 
lunchtime. We will be able to provide you with tea and coffee and a light lunch. 
What will I have to do? 
We will ask you to join your friend or relative for visits at CARU. You will not 
need to provide any care whilst you are at CARU. 
Travel expenses: 
We will arrange taxis to pick you up and take you home after each visit. If you 
would prefer to drive, you will be able to use our car park for free. You will be 
able to claim back any travel expenses.  
What are the possible disadvantages or risks of taking part? 
There are no major disadvantages or risks in taking part in this study. In the 
event of something unexpected happening there will be someone available for 
advice at all times. We will also be happy to answer any questions you might 
have. 
What are the possible benefits of taking part? 
The benefit of taking part is to provide reassurance for your friend/relative and 
to make their visit more comfortable. Taking part in this study will not help you, 
but might help people with Parkinson’s disease in the future. 
What if relevant new information becomes available? 
Sometimes new scientific information may come to light during a study which 
will influence the way it is carried out. If a change is made you will be informed 
in writing and the new information will be discussed with you. No changes will 
be made once you have started the study. 
What happens when the research study stops? 
When the study has finished we will send you a summary of the results through 
the post. 
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What will happen if I don’t want to carry on with the study? 
You are under no obligation to take part and can withdraw from the study at any 
time and without giving a reason. 
Will my taking part in the study be kept confidential? 
Yes. We will store a copy of your consent form in the participant’s confidential 
medical notes and in a confidential site file. These are kept securely and access 
to them is restricted. 
What if there is a problem? 
We hope that problems will be rare. If unexpected issues do arise a member of 
staff will always be available during test visits. We are also very happy to be 
contacted by telephone to offer advice during the study.  
What will happen with the results of the research study? 
The results will be analysed by our research team at Newcastle University. We 
aim to distribute the results in scientific journals and at scientific meetings. 
Depending on the results we will use the study results to design a larger study 
looking at ghrelin levels in Parkinson’s disease and how it relates to dementia. 
Who is organising and funding the research? 
This study is organised by Newcastle upon Tyne Hospitals NHS Foundation 
Trust and Newcastle University. It is funded by the Newcastle NIHR Biomedical 
Research Unit in Lewy Body Dementia. 
Who has reviewed the study? 
This study has been reviewed and approved by the National Ethics Research 
Service.  
Who should I contact if I have any questions? 
If you would like to discuss this study further we would be happy to hear from 
you. We are available Monday to Friday 9am-5pm. 
Study Doctor 
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 Consent and consultee forms    
Centre Number:  
Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: Ghrelin and Dementia in Parkinson’s Disease 
Name of Researcher: Prof. David Burn 
Please initial 
all boxes  
1. I confirm that I have read and understand the 
information sheet dated ………………. (version …….) for 
the above study.  I have had the opportunity to 
consider the information, ask questions and have had 
these answered satisfactorily. 
2. I understand that my participation is voluntary and that 
I am free to withdraw at any time without giving any 
reason, without my medical care or legal rights being 
affected. 
3. I understand that relevant sections of my medical notes 
and data collected during the study, may be looked at 
by individuals from Newcastle University, from 
regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research.  I give 
permission for these individuals to have access to my 
records. 
4. I agree to my GP being informed of my participation in 
the study.    
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5. I agree to take part in the above study. 
 
            
Name of Participant   Date    Signature 
                                
 
            
Name of Person    Date    Signature  
taking consent.  
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Information for Consultees Ghrelin 
and Dementia in Parkinson’s 
Disease 
Your friend/relative has been invited to take part in a research study. They 
have given us permission to involve you, as someone they trust, to help them 
decide whether or not to take part. Some people with dementia can find it 
difficult to remember all of the information that they need to decide whether a 
study is right for them. This may not be the case for your friend/relative but, if 
it is, we would be grateful if you could act as a spokesperson for them. This 
would mean giving permission on their behalf if you think that;  
• taking part in this study is something is in keeping with your friend/ 
relative’s previous wishes   
• taking part will not be too difficult for them  
You are under no obligation to take on this responsibility.  
If you would like to act as a spokesperson or “consultee” please read the 
Participant Information Leaflet included to see if you think this study might be 
suitable for your friend or relative.  
Taking part in research is not for everybody. If you feel that this study will 
not suit your friend/ relative then please say NO on their behalf. This will 
not affect the care they receive in any way.  
If you or your friend/ relative change your mind about participating during the 
study you can withdraw at any time, without giving a reason and without 
affecting their care.  
The research team will also stop the study if your friend/ relative appears 
distressed or appears to object during the study.  
If you have any questions please don’t hesitate to contact us. We are 
available Monday to Friday 9am-5pm.  
   
 xxxx 
Study Doctor  
Dr. Fionnuala Johnston. Tel; 0191 208 1297/1250  
Study Nurse  
…………………………………… Tel; ………………………………  
Date of issue:     18.11.2013  
Version number: Version 1.1  2  
Author Dr. Fionnuala Johnston 
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 Power calculations 
E-mail from Dr. Shirley Coleman 
“Dear Fionnuala, 
I have written a response below for the ethics committee. I hope this is OK. Any 
queries, please email me.  
For Dr Fionnuala Johnston 
Statistical aspects of proposal entitled Plasma acyl-ghrelin: A biomarker for 
cognitive decline in Parkinson’s disease? 
The data analysis involves comparing the primary outcome of interest, fasting 
AG and UAG levels between PD, PDD and control groups.  
A secondary outcome measure is the bite rate (frequency and count) and ad 
libitum food intake in PDD, PD and controls and there will also be a comparison 
between the bite rate measured manually and using a bite counter. 
Sample sizes can be calculated using the mean ghrelin and standard deviation 
values found during previous studies (Unger et al., 2011). 
In Unger et al, 2011, the largest observed group mean differences were for the 
increase in ghrelin serum concentrations in the late postprandial phase 
calculated by the ratio of individual ghrelin serum concentrations at 300 minutes 
divided by the individual ghrelin serum concentrations at 60 minutes. The 
difference between controls and the combined PD group was 0.21 with a pooled 
standard deviation of approximately 0.22.  
The sample size in the proposed study needs to be large enough to detect a 
difference of this size at the 5% significance level with 80% power. Using 
standard methods, the sample size needs to be at least 19 in each of the 
control and PD groups to detect a difference of this size using t-tests. A sample 
size of at least 20 in each group is recommended. Assuming that the PDD 
group will be further from the control than the PD group, a sample size of 20 for 
the PDD group as well should be satisfactory to ensure that the difference 
between the largest and smallest values of the 3 groups will be detected as 
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significant at the 5% significance level with 80% power in an analysis of 
variance (ANOVA).  
As indicated in the proposal the analysis will involve comparing demographic 
and clinical data between all 3 groups. The mean ghrelin plasma concentrations 
will be plotted over time for each group and the area under the curves will be 
compared between groups. Data for all groups will be controlled for relevant 
covariates such as BMI, age and gender using analysis of covariance 
(ANCOVA). Bonferroni correction will be used where multiple tests are carried 
out to ensure statistical significance.  
Statistical support will be available throughout the study. A sample size of 20 in 
each of the control, PD and PDD groups is appropriate for the study. With this 
sample size, the study should be satisfactorily powered for the statistical 
analysis proposed. 
With kind regards, 
Shirley Coleman, 
Principal Statistician, 
ISRU, Newcastle University 
www.isru.ncl.ac.uk” 
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 Blood processing procedure 
 Blood collection protocol for subsequent ELISA quantification of hormone levels in 
human plasma 
Hormones to be measured by ELISA include total ghrelin, acyl-ghrelin, PYY leptin, insulin and 
IGF-1. 
The active ghrelin molecule is extremely unstable in plasma and should be rigorously protected 
during blood sample collection. For maximum protection, addition of AEBSF* should be 
performed on plasma samples that undergo total ghrelin, acyl-ghrelin and PYY ELISA. All 
samples should be processed as quickly as possible and kept on ice. 
Preparation and storage of AEBSF 
Product; AEBSF [4-(2-Aminoethyl)-benzenesulfonyl fluoride] (Cat no. A8456 Sigma), 500 mg 
vial.  
1. Keep the bottle of lyophilised AEBSF (A8456-500mg) desiccated at –20oC (should be 
stable for ~3 years). 
2. When ready to use, re-constitute AEBSF in 10mls sterile water. This will give you a 
clear colourless stock solution that is 50mg/ml (200mM). This stock solution will be 
stable for ~6 months if kept refrigerated (4oC). 
3. 80ul of AEBSF stock solution (50mg/ml, or 200mM) should be in 2ml of blood (to give a 
final concentration of 2mg/ml, or 8mM)* 
Sample preparation 
1. Prepare microfuge tubes for AG/UAG samples by pipetting 80ul of 50mg/ml AEBSF 
stock solution into a 2ml microfuge tube for each time point (7 samples). Store in the 
fridge. 
2. Make sure pre-treated microfuge tubes are clearly labelled. 
3. Collect whole blood into Vacutainer® K2EDTA-plasma tubes (#VT-6450; can collect up 
to 7 ml blood/tube).  
4. Gently rock the Lavender Vacutainer tubes several times immediately after collection of 
blood for anti-coagulation.   
5. Place on ice and take to the lab immediately.  
6. Immediately transfer 2 mls of the blood from the lavender vacutainer tubes to cold 
sterile centrifuge tubes containing AEBSF and gently rock several times to inhibit the 
activity of proteinases. (This fraction will be used for total ghrelin, acyl-ghrelin and PYY 
ELISA) 
7. Pipette 2mls each into to untreated microfuge tubes. One of these will be used for leptin 
and insulin; the other will be used for IGF-1 and GH. Make sure they are clearly 
labelled. 
8. Put the IGF-1  sample on ice. 
9. Promptly centrifuge the AESBF sample and the leptin/insulin sample together at 2,000 x 
g for 15 minutes at 4 ± 2oC. This will result in the formation of three layers. First, the 
uppermost plasma layer (yellow) (should be free of signs of hemolysis and lipemia). 
Second, a very thin white layer containing leukocytes and platelets (white). Finally the 
bottom layer containing red blood cells (red). 
10. Carefully transfer the supernatant (i.e uppermost layer of plasma) into separate sterile 
cryovial tubes (400ul aliquots). 
11. Centrifuge the IGF-1 samples at 1,000 xg for 10 mins 
12. Date and identify each sample. Clearly label samples that underwent AEBSF pre-
treatment). 
13. Store samples at -80oC for later use.  
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Note that blood collection time points are baseline, 5, 15, 30, 60, 120 and 180 minutes; making 
immediate processing of all samples difficult. Therefore IGF-1 samples can be left on ice until 
75 minutes to allow time for AG/UAG/PYY and leptin/insulin samples to be processed in a 
timely fashion. 
 Questionnaires 
Geriatric Depression Scale -15 (GDS) Scoring Instructions  
Instructions:  Score 1 point for each bolded answer.  A score of 5 or more  
 suggests depression.  
1. Are you basically satisfied with your life?     yes  no  
2. Have you dropped many of your activities and interests?   yes  no  
3. Do you feel that your life is empty?      yes  no  
4. Do you often get bored?        yes  no  
5. Are you in good spirits most of the time?     yes  no  
6. Are you afraid that something bad is going to happen to you?   yes  no  
7. Do you feel happy most of the time?      yes  no  
8. Do you often feel helpless?       yes  no  
9. Do you prefer to stay at home, rather than going out and doing things? yes  no  
10. Do you feel that you have more problems with memory than most?  yes  no  
11. Do you think it is wonderful to be alive now?     yes  no  
12. Do you feel worthless the way you are now?     yes  no  
13. Do you feel full of energy?       yes  no  
14. Do you feel that your situation is hopeless?     yes  no  
15. Do you think that most people are better off than  you are?   yes  no  
  A score of > 5 suggests depression  Total Score   
Ref. Yes average:  The use of Rating Depression Series in the Elderly, in Poon(ed.): Clinical Memory 
Assessment of Older Adults, American Psychological Association, 1986  
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Three Factor Eating Questionnaire  
1. When I smell a sizzling steak or see a juicy piece of meat, I find it very difficult to 
keep from eating, even if I have just finished a meal.  
TRUE   
FALSE   
2. I usually eat too much at social occasions, like parties and picnics.  TRUE   
FALSE   
3. I am usually so hungry that I eat more than three times a day.  TRUE   
FALSE   
4. When I have eaten my quota of calories, I am usually good about not eating anymore.  TRUE   
FALSE   
 5. Dieting is so hard for me because I just get too hungry.     TRUE   
FALSE   
6. I deliberately take small helpings as a means of controlling my weight.   TRUE   
FALSE   
7. Sometimes things just taste so good that I keep on eating even when I am no longer 
hungry.  
TRUE   
FALSE   
8. Since I am often hungry, I sometimes wish that while I am eating, an expert    
would tell me that I have had enough or that I can have something more to eat.  
TRUE   
FALSE   
9. When I feel anxious, I find myself eating.  TRUE   
FALSE   
 10. Life is too short to worry about dieting.     TRUE   
FALSE   
11. Since my weight goes up and down, I have gone on reducing diets more than once.  TRUE   
FALSE   
12. I often feel so hungry that I just have to eat something  TRUE   
FALSE   
13. When I am with someone who is overeating, I usually overeat too.  TRUE   
FALSE   
14. I have a pretty good idea of the number of calories in common food.  TRUE   
FALSE   
 15. Sometimes when I start eating, I just can’t seem to stop.     TRUE   
FALSE   
 16. It is not difficult for me to leave something on my plate.     TRUE   
FALSE   
17. At certain times of the day, I get hungry because I have gotten used to eating then.    
18. While on a diet, if I eat food that is not allowed, I consciously eat less for a period of 
time to make up for it.  
TRUE   
FALSE   
19. Being with someone who is eating often makes me hungry to eat also.    TRUE   
FALSE   
20. When I feel blue, I often overeat.  TRUE   
FALSE   
21. I enjoy eating too much to spoil it by counting calories or watching my weight.  TRUE   
FALSE   
22. When I see a real delicacy, I often get so hungry that I have to eat right away.  TRUE   
FALSE   
23. I often stop eating when I am not really full as a conscious means of limiting the 
amount I eat  
TRUE   
FALSE   
24. I get so hungry that my stomach often seems like a bottomless pit.  TRUE   
FALSE   
25. My weight has hardly changed at all in the last ten years.  TRUE   
FALSE   
26. I am always hungry so it is hard for me to stop eating before I finish the food on my 
plate.   
TRUE   
FALSE   
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 27. When I feel lonely, I console myself by eating.     TRUE   
FALSE   
28. I consciously hold back at meals in order not to gain weight.  TRUE   
FALSE   
29. I sometimes get very hungry late in the evening or at night.  TRUE   
FALSE   
 30. I eat anything I want, any time I want.     TRUE   
FALSE   
 31. Without even thinking about it, I take a long time to eat.     TRUE   
FALSE   
32. I count calories as a conscious means of controlling my weight.  TRUE   
FALSE   
33. I do not eat some foods because they make me fat.  TRUE   
FALSE   
34. I am always hungry enough to eat at any time.  TRUE   
FALSE   
35. I pay a great deal of attention to changes in my figure.  TRUE   
FALSE   
 
36. While on a diet, if I eat a food that is not allowed, I often splurge and eat 
other high calorie foods.  
TRUE   FALSE   
Please answer the following questions by filling in the circle on your answer sheet corresponding to 
the letter of the response that is appropriate to you.  
37. How often are you dieting in a conscious effort to control your weight?  
  
rarely    
sometimes  
usually    
always    
38. Would a weight fluctuation of 5 lbs. affect the way you live your life?  
  
rarely    
sometimes  
usually    
always    
39. How often do you feel hungry?  
  
rarely    
sometimes  
usually    
always    
40. Do your feelings of guilt about overeating help you to control your food 
intake?  
rarely    
sometimes  
usually    
always    
41. How difficult would it be for you to stop eating halfway through dinner 
and not eat for the next four hours?  
  
 easy          
slightly difficult                 
moderately difficult          
  
very difficult                     
  
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42. How conscious are you of what you are eating?  not at all                 
slightly                                
 
moderately                       
  
extremely                            
  
43. How frequently do you avoid “stocking up” on tempting foods?  
  
almost never                    
  
seldom                              
  
usually                             
  
almost always                   
  
44. How likely are you to shop for low calorie foods?  
  
unlikely                                
  
slightly likely    
moderately likely             
  
very likely                           
  
45. Do you eat sensibly in front of others and splurge alone?  
  
never                                  
  
rarely                                  
  
often                                
  always                                
  
46. How likely are you to consciously eat slowly in order to cut down on how 
much you eat?  
  
unlikely                   
slightly likely    
moderately likely              
  
very likely    
47. How frequently do you skip dessert because you are no longer hungry?  
  
almost never                    
  
seldom                                 
  
at least once a week        
  
almost every day               
48. How likely are you to consciously eat less than you want?  
  
unlikely                              
  
slightly likely    
moderately likely                
  
very likely                        
  
49. Do you go on eating binges though you are not hungry?  
  
never                                
  
rarely                                
  
sometimes                           
  
at least once a week           
  
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50. On a scale of 1 to 5, where 1 means no Restraint in eating (eating whatever you want, whenever you want it) 
and 5 means total Restraint (constantly limiting food intake and never “giving in”), what number would you 
give yourself?   
  
1) usually or always eat whatever you want, whenever you want it   
2) often eat whatever you want, whenever you want it      
3) often limit food intake, but often “give in”        
4) usually limit food intake, rarely “give in”          
5) constantly limiting food intake, never “giving in”       
51. To what extent does this statement describe your eating behavior? “I start dieting in the morning, but 
because of any number of things that happen during the day, by evening I have given up and eat what I want, 
promising myself to start dieting again tomorrow.”  
not like me     
little like me    
pretty good description of 
me   
describes me perfectly    
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Montreal Cognitive Assessment 
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Visual analogue scales 
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 Posters, presentations and publications 
Posters 
 Johnston F, Yarnall A, Davies J, Siervo M and Burn DJ.Pilot study 
protocol; Ghrelin and cognitive impairment in Parkinson’s. Presented at 
Parkinson’s UK conference 2014 
 Johnston F, Lawson R, Khoo T, Yarnall A, Duncan G, Coleman S, Burn 
DJ. Leptin and insulin; biomarkers for cognitive impairment in 
Parkinson’s disease? ICICLE-PD 36 month interim analysis. Presented 
19th at the International Congress International Congress of Parkinson’s 
Disease and Movement Disorders San Diego June 2015 
 Lawson RA, Yarnall AJ, Duncan GW, Johnston F, Khoo TK, Collerton 
D, Taylor JP, Brittain KR and Burn DJ. The impact of cognitive 
impairment in people with Parkinson’s disease and caregivers: a mixed 
methods study. Presented at the British Psychological Society Annual 
Conference, Nottingham, April 2016. 
 Sleeman IJ, Lawson RA, Yarnall AJ, Duncan GW, Johnston F, Khoo 
TK, Collerton D, Taylor JP and Burn DJ. Urate and homocysteine: 
Changes in motor and cognitive symptoms in newly diagnosed 
Parkinson’s disease. Presented at the 20th International Congress of 
Parkinson’s Disease and Movement Disorders, Berlin June 2016 
 Johnston F, Siervo M, Hornsby AKE, Davies JS, David J Burn DJ. 
Ghrelin and the IGF-1 axis in cognitive impairment in PD. Presented at 
the 21st International Congress of Parkinson’s Disease and Movement 
Disorders, Vancouver June 2017 
Presentations 
 “Ghrelin and Dementia” delivered to a local Dementias and 
Neurodegenerative Diseases (DemaNDs) Research Group meeting 2015 
 “Ghrelin and Parkinson’s disease” delivered to the local Parkinson’s 
Researchers Seminars series 2015 
 “Appetite and cognition in Parkinson’s Disease” delivered to the national 
British Geriatric Society Movement Disorder Section Meeting 2017 
Publications 
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 Lawson, R.A., Yarnall, A.J., Johnston, F., Duncan, G.W., Khoo, T.K., 
Collerton, D., Taylor, J.P. and Burn, D.J., 2016. Cognitive impairment in 
Parkinson's disease: impact on quality of life of carers. International 
journal of geriatric psychiatry 
 Under review by Journal of Neurology, Neurosurgery and 
Psychiatry.  Sleeman IJ, Lawson RA, Yarnall AJ, Duncan GW, 
Johnston F, Khoo TK, and Burn DJ. Urate and homocysteine: 
predicting changes in motor and cognitive symptoms in newly 
diagnosed Parkinson’s 
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 Supplementary data and analysis 
Histograms showing normality of key transformed variables  
All hormones measured in pg/ml 
 
Figure 56. MoCA 
 
 
Figure 57. Acyl-ghrelin 
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Figure 58. Total ghrelin 
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Figure 59. Leptin 
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Figure 60. Insulin 
Growth hormone analysis by group 
 
Table 22. GH AUC against age by group 
Group Age GH AUC 
Control age Pearson Correlation 1 .506* 
Sig. (2-tailed)  .023 
N 20 20 
GH AUC Pearson Correlation .506* 1 
Sig. (2-tailed) .023  
N 20 20 
PD age Pearson Correlation 1 .163 
Sig. (2-tailed)  .506 
N 19 19 
GH AUC Pearson Correlation .163 1 
Sig. (2-tailed) .506  
N 19 19 
PD-CI age Pearson Correlation 1 .203 
Sig. (2-tailed)  .452 
N 16 16 
GH AUC Pearson Correlation .203 1 
Sig. (2-tailed) .452  
N 16 16 
*. Correlation is significant at the 0.05 level (2-tailed). 
  




Figure 61. GH AUC against age by group 
 
Table 23. Fasting GH against age by group 
Group Age Fasting GH 
Control age Pearson Correlation 1 .452* 
Sig. (2-tailed)  .046 
N 20 20 
GH baseline Pearson Correlation .452* 1 
Sig. (2-tailed) .046  
N 20 20 
PD age Pearson Correlation 1 .113 
Sig. (2-tailed)  .646 
N 19 19 
GH baseline Pearson Correlation .113 1 
Sig. (2-tailed) .646  
N 19 19 
PD-CI age Pearson Correlation 1 -.009 
Sig. (2-tailed)  .973 
N 16 16 
GH baseline Pearson Correlation -.009 1 
Sig. (2-tailed) .973  
N 16 16 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Figure 62. Fasting GH against age by group 
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Exploratory Pearson correlations 
Table 24. Pearson correlations duration ad libitum meal 
  
Duration of ad 
libitum meal 
Ad libitum meal 
total energy intake 




PD Motor UPDRS 
LgMoCA=Log(31-
value) GDS 
Duration of ad libitum 
meal 
Pearson Correlation 1 .388** .672** .366** .421* .384** .417** 
Sig. (2-tailed)   .004 .000 .007 .015 .004 .002 
N 53 53 48 53 33 53 53 
Adlibitum meal total 
energy intake 
Pearson Correlation .388** 1 .706** -.092 .215 -.061 .013 
Sig. (2-tailed) .004   .000 .502 .214 .658 .923 
N 53 55 50 55 35 55 55 
Ad libitum meal bite 
counter count 
Pearson Correlation .672** .706** 1 .183 .208 .135 .305* 
Sig. (2-tailed) .000 .000   .204 .261 .349 .031 
N 48 50 50 50 31 50 50 
Duration of PD Pearson Correlation .366** -.092 .183 1 .300 .510** .621** 
Sig. (2-tailed) .007 .502 .204   .080 .000 .000 
N 53 55 50 55 35 55 55 
Motor UPDRS scores Pearson Correlation .421* .215 .208 .300 1 .559** .533** 
Sig. (2-tailed) .015 .214 .261 .080   .000 .001 
N 33 35 31 35 35 35 35 
LgMoCA=Log(31-
v26) 
Pearson Correlation .384** -.061 .135 .510** .559** 1 .681** 
Sig. (2-tailed) .004 .658 .349 .000 .000   .000 
N 53 55 50 55 35 55 55 
Geriatric depression 
scale 
Pearson Correlation .417** .013 .305* .621** .533** .681** 1 
Sig. (2-tailed) .002 .923 .031 .000 .001 .000   
N 53 55 50 55 35 55 55 
**. Correlation is significant at the 0.01 level (2-tailed). *. Correlation is significant at the 0.05 level (2-tailed). 




Table 25. Pearson correlation fasting variables 




















age Pearson Correlation 1 .066 .114 -.040 .046 .237 .196 .385* -.095 .055 .090 .015 -.047 .060 .305* .309* -.126 .017 -.225 
Sig. (2-tailed)   .631 .406 .772 .792 .082 .152 .004 .490 .692 .518 .914 .758 .720 .024 .026 .359 .899 .099 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
fat mass 
% 
Pearson Correlation .066 1 .518*
* 
-.254 -.042 -.264 -.240 .123 .056 .048 .652** .120 -.216 -.181 -.058 .033 -.190 -.306* .208 
Sig. (2-tailed) .631   .000 .061 .810 .051 .078 .381 .683 .733 .000 .382 .150 .275 .673 .816 .164 .023 .128 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
BMI Pearson Correlation .114 .518*
* 




.083 .445** .412** -.050 .108 -.075 .206 .173 -.099 .136 
Sig. (2-tailed) .406 .000   .063 .969 .081 .090 .037 .015 .550 .001 .002 .741 .517 .586 .143 .208 .471 .322 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
Duration 
of PD 
Pearson Correlation -.040 -.254 -.253 1 .300 .510** .621*
* 
-.093 -.039 .050 -.163 .060 .153 -.006 .092 -.023 -.092 -.129 .085 
Sig. (2-tailed) .772 .061 .063   .080 .000 .000 .509 .778 .720 .240 .664 .310 .970 .505 .873 .502 .348 .537 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
Motor 
UPDRS  
Pearson Correlation .046 -.042 -.007 .300 1 .559** .533*
* 
-.134 -.214 -.008 -.168 -.316 -.101 -.259 -.072 -.083 .215 -.174 .128 
Sig. (2-tailed) .792 .810 .969 .080   .000 .001 .442 .216 .966 .341 .064 .625 .257 .680 .642 .214 .318 .463 








.002 -.131 -.145 -.097 -.122 -.074 .077 -.005 -.061 -.101 .094 
Sig. (2-tailed) .082 .051 .081 .000 .000   .000 .011 .988 .344 .296 .481 .419 .660 .575 .970 .658 .463 .493 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
GDS Pearson Correlation .196 -.240 -.231 .621** .533** .681** 1 -
.299* 
-.143 .057 -.130 .053 .018 -.170 .051 -.046 .013 -.111 .102 
Sig. (2-tailed) .152 .078 .090 .000 .001 .000   .029 .297 .682 .349 .701 .904 .308 .713 .745 .923 .420 .460 












-.014 -.009 -.212 .015 -.115 .020 -.321* -.090 .017 .138 
Sig. (2-tailed) .004 .381 .037 .509 .442 .011 .029   .000 .919 .947 .127 .925 .504 .889 .022 .520 .905 .324 
N 53 53 53 53 35 53 53 53 53 52 52 53 44 36 53 51 53 53 53 
lg TG 
fasting 
Pearson Correlation -.095 .056 -
.325* 
-.039 -.214 .002 -.143 .727*
* 
1 -.076 -.055 -.201 .099 -.095 .178 -.278* -.212 .050 .207 
Sig. (2-tailed) .490 .683 .015 .778 .216 .988 .297 .000   .585 .692 .141 .512 .571 .193 .046 .120 .718 .129 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
lg PYY 
fasting 
Pearson Correlation .055 .048 .083 .050 -.008 -.131 .057 -.014 -.076 1 -.104 .046 .407** .451** .158 .002 -.235 -.226 .067 
Sig. (2-tailed) .692 .733 .550 .720 .966 .344 .682 .919 .585   .460 .739 .005 .005 .253 .991 .088 .101 .632 
N 54 54 54 54 34 54 54 52 54 54 53 54 45 37 54 51 54 54 54 
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-.163 -.168 -.145 -.130 -.009 -.055 -.104 1 .452** -.113 .062 -.156 .108 -.101 -.270* .009 
Sig. (2-tailed) .518 .000 .001 .240 .341 .296 .349 .947 .692 .460   .001 .461 .717 .261 .449 .466 .049 .950 
N 54 54 54 54 34 54 54 52 54 53 54 54 45 37 54 51 54 54 54 
Lg insulin 
fasting 
Pearson Correlation .015 .120 .412*
* 
.060 -.316 -.097 .053 -.212 -.201 .046 .452** 1 -.044 .211 -.130 .300* .012 -.043 .043 
Sig. (2-tailed) .914 .382 .002 .664 .064 .481 .701 .127 .141 .739 .001   .773 .203 .345 .031 .928 .753 .757 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
Lg GLP-1 
fasting 
Pearson Correlation -.047 -.216 -.050 .153 -.101 -.122 .018 .015 .099 .407** -.113 -.044 1 .262 -.212 -.126 -.128 -.095 -.001 
Sig. (2-tailed) .758 .150 .741 .310 .625 .419 .904 .925 .512 .005 .461 .773   .112 .157 .420 .397 .528 .995 
N 46 46 46 46 26 46 46 44 46 45 45 46 46 38 46 43 46 46 46 
lg IGF-1 
fasting 
Pearson Correlation .060 -.181 .108 -.006 -.259 -.074 -.170 -.115 -.095 .451** .062 .211 .262 1 .138 .135 .094 .037 -.230 
Sig. (2-tailed) .720 .275 .517 .970 .257 .660 .308 .504 .571 .005 .717 .203 .112   .408 .434 .575 .825 .166 
N 38 38 38 38 21 38 38 36 38 37 37 38 38 38 38 36 38 38 38 
lg GH 
fasting 
Pearson Correlation .305* -.058 -.075 .092 -.072 .077 .051 .020 .178 .158 -.156 -.130 -.212 .138 1 .103 .020 .183 -.175 
Sig. (2-tailed) .024 .673 .586 .505 .680 .575 .713 .889 .193 .253 .261 .345 .157 .408   .467 .887 .181 .200 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
lg glucose 
fasting 




.002 .108 .300* -.126 .135 .103 1 -.081 .304* -.022 
Sig. (2-tailed) .026 .816 .143 .873 .642 .970 .745 .022 .046 .991 .449 .031 .420 .434 .467   .567 .029 .876 
N 52 52 52 52 34 52 52 51 52 51 51 52 43 36 52 52 52 52 52 
Energy 
intake 
Pearson Correlation -.126 -.190 .173 -.092 .215 -.061 .013 -.090 -.212 -.235 -.101 .012 -.128 .094 .020 -.081 1 .341* -.283* 
Sig. (2-tailed) .359 .164 .208 .502 .214 .658 .923 .520 .120 .088 .466 .928 .397 .575 .887 .567   .011 .037 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
hunger 
baseline 
Pearson Correlation .017 -
.306* 
-.099 -.129 -.174 -.101 -.111 .017 .050 -.226 -.270* -.043 -.095 .037 .183 .304* .341* 1 -.204 
Sig. (2-tailed) .899 .023 .471 .348 .318 .463 .420 .905 .718 .101 .049 .753 .528 .825 .181 .029 .011   .135 
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
fullness 
baseline 
Pearson Correlation -.225 .208 .136 .085 .128 .094 .102 .138 .207 .067 .009 .043 -.001 -.230 -.175 -.022 -.283* -.204 1 
Sig. (2-tailed) .099 .128 .322 .537 .463 .493 .460 .324 .129 .632 .950 .757 .995 .166 .200 .876 .037 .135   
N 55 55 55 55 35 55 55 53 55 54 54 55 46 38 55 52 55 55 55 
 
  








Table 26. Correlations AUC values 






























intake hunger  
Full-
ness 
age Pearson Correlation 1 .066 .114 -.040 .046 .237 .196 -
.386** 
-.265 .065 .104 .021 .027 .107 .382** .138 .052 -.126 -.037 .058 
  Sig. (2-tailed)   .631 .406 .772 .792 .082 .152 .004 .051 .636 .454 .881 .849 .510 .004 .330 .721 .359 .787 .672 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
fat mass 
% 
Pearson Correlation .066 1 .518** -.254 -.042 -.264 -.240 .140 -.016 .103 .662** .279* .202 -.134 -.135 -.082 -.270 -.190 -.427** .328* 
  Sig. (2-tailed) .631   .000 .061 .810 .051 .078 .318 .909 .454 .000 .039 .156 .410 .324 .563 .058 .164 .001 .014 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
BMI Pearson Correlation .114 .518** 1 -.253 -.007 -.237 -.231 -.186 -
.395** 
.165 .419** .479** .262 .069 -.016 .163 -.021 .173 -.213 .040 
  Sig. (2-tailed) .406 .000   .063 .969 .081 .090 .183 .003 .230 .002 .000 .063 .674 .905 .248 .882 .208 .118 .772 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
Duration 
PD 
Pearson Correlation -.040 -.254 -.253 1 .300 .510** .621** -.107 -.063 -.048 -.154 -.014 -.014 -.096 .110 .048 .183 -.092 .125 -.035 
  Sig. (2-tailed) .772 .061 .063   .080 .000 .000 .447 .648 .726 .266 .921 .925 .555 .423 .736 .204 .502 .363 .798 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
Motor 
UPDRS  
Pearson Correlation .046 -.042 -.007 .300 1 .559** .533** -.091 -.137 -.047 -.160 -.358* -.137 -.357 .087 -.186 .208 .215 .203 -.276 
  Sig. (2-tailed) .792 .810 .969 .080   .000 .001 .604 .433 .787 .365 .035 .463 .094 .618 .291 .261 .214 .243 .108 




Pearson Correlation .237 -.264 -.237 .510** .559** 1 .681** -
.384** 
-.087 -.200 -.133 -.068 -.190 -.128 .206 .110 .135 -.061 -.058 -.018 
  Sig. (2-tailed) .082 .051 .081 .000 .000   .000 .005 .526 .142 .337 .623 .182 .429 .132 .439 .349 .658 .676 .897 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
GDS Pearson Correlation .196 -.240 -.231 .621** .533** .681** 1 -.304* -.193 .003 -.109 -.010 -.068 -.251 .119 .109 .305* .013 .183 -.198 
  Sig. (2-tailed) .152 .078 .090 .000 .001 .000   .027 .159 .985 .433 .943 .638 .118 .388 .442 .031 .923 .182 .147 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
Lg AG Pearson Correlation -
.386** 
.140 -.186 -.107 -.091 -.384** -.304* 1 .777** .004 -.055 -.171 .123 -.080 -.247 -.145 -.129 -.070 .146 .171 
  Sig. (2-tailed) .004 .318 .183 .447 .604 .005 .027   .000 .976 .696 .220 .400 .632 .074 .309 .380 .617 .296 .220 
  N 53 53 53 53 35 53 53 53 53 53 52 53 49 38 53 51 48 53 53 53 




-.063 -.137 -.087 -.193 .777** 1 -.230 -.132 -.242 .022 -.125 -.169 -.090 -.103 -.145 .056 .214 
  Sig. (2-tailed) .051 .909 .003 .648 .433 .526 .159 .000   .091 .343 .076 .877 .440 .218 .525 .475 .292 .687 .116 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
Lg PYY Pearson Correlation .065 .103 .165 -.048 -.047 -.200 .003 .004 -.230 1 -.043 .008 .462** .269 .035 .067 -.253 -.294* .036 -.058 
  Sig. (2-tailed) .636 .454 .230 .726 .787 .142 .985 .976 .091   .758 .957 .001 .093 .799 .635 .077 .029 .794 .672 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
                      







































intake hunger  
Full-
ness 
Lg Leptin Pearson Correlation .104 .662** .419** -.154 -.160 -.133 -.109 -.055 -.132 -.043 1 .503** .135 .202 .004 .170 -.080 -.136 -.379** .189 
  Sig. (2-tailed) .454 .000 .002 .266 .365 .337 .433 .696 .343 .758   .000 .351 .218 .976 .234 .587 .326 .005 .170 
  N 54 54 54 54 34 54 54 52 54 54 54 54 50 39 54 51 49 54 54 54 
Lg Insulin Pearson Correlation .021 .279* .479** -.014 -.358* -.068 -.010 -.171 -.242 .008 .503** 1 .087 .079 -.102 .461** -.034 -.028 -.211 .117 
  Sig. (2-tailed) .881 .039 .000 .921 .035 .623 .943 .220 .076 .957 .000   .545 .627 .458 .001 .816 .837 .123 .394 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
Lg GLP-1 Pearson Correlation .027 .202 .262 -.014 -.137 -.190 -.068 .123 .022 .462** .135 .087 1 .021 -.046 -.190 -.249 -.113 -.232 .237 
  Sig. (2-tailed) .849 .156 .063 .925 .463 .182 .638 .400 .877 .001 .351 .545   .898 .747 .196 .092 .432 .101 .094 
  N 51 51 51 51 31 51 51 49 51 51 50 51 51 40 51 48 47 51 51 51 
Lg IGF-1 Pearson Correlation .107 -.134 .069 -.096 -.357 -.128 -.251 -.080 -.125 .269 .202 .079 .021 1 .455** .264 .338* .134 .052 -.153 
  Sig. (2-tailed) .510 .410 .674 .555 .094 .429 .118 .632 .440 .093 .218 .627 .898   .003 .109 .044 .411 .750 .346 
  N 40 40 40 40 23 40 40 38 40 40 39 40 40 40 40 38 36 40 40 40 
Lg GH Pearson Correlation .382** -.135 -.016 .110 .087 .206 .119 -.247 -.169 .035 .004 -.102 -.046 .455** 1 .084 .170 .127 .021 -.111 
  Sig. (2-tailed) .004 .324 .905 .423 .618 .132 .388 .074 .218 .799 .976 .458 .747 .003   .553 .237 .355 .880 .421 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
Lg GLu Pearson Correlation .138 -.082 .163 .048 -.186 .110 .109 -.145 -.090 .067 .170 .461** -.190 .264 .084 1 -.069 -.060 .155 -.047 
  Sig. (2-tailed) .330 .563 .248 .736 .291 .439 .442 .309 .525 .635 .234 .001 .196 .109 .553   .645 .670 .274 .740 
  N 52 52 52 52 34 52 52 51 52 52 51 52 48 38 52 52 47 52 52 52 
Ad libitum  
bite count 
Pearson Correlation .052 -.270 -.021 .183 .208 .135 .305* -.129 -.103 -.253 -.080 -.034 -.249 .338* .170 -.069 1 .706** .476** -
.546**   Sig. (2-tailed) .721 .058 .882 .204 .261 .349 .031 .380 .475 .077 .587 .816 .092 .044 .237 .645   .000 .000 .000 
  N 50 50 50 50 31 50 50 48 50 50 49 50 47 36 50 47 50 50 50 50 
Energy 
intake 
Pearson Correlation -.126 -.190 .173 -.092 .215 -.061 .013 -.070 -.145 -.294* -.136 -.028 -.113 .134 .127 -.060 .706** 1 .441** -
.546**   Sig. (2-tailed) .359 .164 .208 .502 .214 .658 .923 .617 .292 .029 .326 .837 .432 .411 .355 .670 .000   .001 .000 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
hunger 
AUC 
Pearson Correlation -.037 -
.427** 
-.213 .125 .203 -.058 .183 .146 .056 .036 -
.379** 
-.211 -.232 .052 .021 .155 .476** .441** 1 -
.623**   Sig. (2-tailed) .787 .001 .118 .363 .243 .676 .182 .296 .687 .794 .005 .123 .101 .750 .880 .274 .000 .001   .000 
  N 55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
fullness 
AUC 
Pearson Correlation .058 .328* .040 -.035 -.276 -.018 -.198 .171 .214 -.058 .189 .117 .237 -.153 -.111 -.047 -
.546** 
-.546** -.623** 1 
  Sig. (2-tailed) 
.672 .014 .772 .798 .108 .897 .147 .220 .116 .672 .170 .394 .094 .346 .421 .740 .000 .000 .000   
  N 
55 55 55 55 35 55 55 53 55 55 54 55 51 40 55 52 50 55 55 55 
**. Correlation is significant at the 0.01 level (2-tailed). 
                
*. Correlation is significant at the 0.05 level (2-tailed). 
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